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Abstract 
 
The development of vaccines against serogroup B Neisseria meningitidis to reduce 
the morbidity and mortality of meningococcal disease is a major public health priority. 
We developed a novel genetic screen for immunogens present on the bacterial surface 
using human immune sera with bactericidal activity. We found that two mutants 
lacking nmb1467 survived in high concentrations of sera from two patients, while the 
wild-type strain was killed. Biochemical assays using purified recombinant 
NMB1467 indicated that nmb1467 encodes an exopolyphosphatase (PPX) with the 
ability to hydrolyse inorganic polyphosphate (poly P). In addition, we demonstrated 
that the ∆ppx mutant has at least 2-fold more poly P than the wild-type strain. 
Therefore, we designated NMB1467 as PPX. We showed that N. meningitidis mutant 
lacking the ppx had an increased resistance against normal human complement 
system. Substitution of the glutamic acid at residue 147 of PPX with an alanine 
significantly reduced the enzymatic activity in vitro, and contributed to increased 
level of poly P in N. meningitidis and the resistance of bacteria against the 
complement-mediated killing. Levels of polysaccharide capsule and 
lipopolysaccharide (LPS) sialylation, two important virulence factors, were not 
affected by the loss of ppx in N. meningitidis. Using flow cytometry, we 
demonstrated that binding of factor H (fH), the negative regulator of the alternative 
pathway of complement activation, to the bacterial surface was increased in the strain 
lacking PPX. By Western blot analysis, we did not detect a significant change in the 
expression of the fH receptor, indicting another mechanism is involved in the fH 
binding to the bacterial surface and resistance of bacteria against complement-
mediated killing.  
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Introduction 
 
1.1 History 
Neisseria meningitidis is an aerobic and Gram-negative diplococcal bacterium that is 
a leading cause of bacterial meningitis. In 1805, Vieusseux documented 33 deaths 
from a “spotted fever” with symptoms of violent headache, fever and meningitis in 
Switzerland (Vieusseux, 1806). This is widely accepted as the first description of 
meningococcal disease. In 1887, Weichselbaum first isolated an organism from 
cerebrospinal fluid (CSF) from six of eight fatal cases with meningococcal disease 
and named the bacterium “Diplococcus intracellularis meningitidis” (Weichselbaum, 
1887). The organism was renamed Neisseria meningitidis after Albert Neisser’s 
discovery of Neisseria gonorrhoeae (Kampmeier, 1978). So far, N. meningitidis has 
only been isolated from humans.  
 
In the pre-antibiotic era, the mortality rate of meningococcal disease was more than 
70% (Cartwright, 1995). In the early 20
th
 century, the German researcher Jochmamn 
first raised antisera in rabbits and horses, which proved to be protective in a porcine 
model of disease (Kolle and Wasserman, 1906). By 1908, anti-meningococcal sera 
were used for intrathecal treatment in Europe and the USA with a dramatic 
improvement in the outcome (Kolle and Jobling, 1908). However, toxicity resulting 
from the administration of foreign proteins and cases of secondary meningitis were 
often associated with serum therapy, so it was abandoned when antibiotics became 
available (Cartwright, 1995). In 1937, sulfanilamide was reported to be the first 
specific and highly effective treatment for meningococcal infection (Schwentker, 
1937).  
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The first attempts to develop a vaccine were made by Sophian and Black in the USA 
using heat-killed bacteria (Sophian and Black, 1912). Until 1991, strain-specific outer 
membrane vesicles had been used to reduce local outbreaks of serogroup B disease 
(Bjune et al., 1991b; Sierra et al., 1991). In 1999, a protein/polysaccharide conjugate 
serogroup C vaccine was introduced in UK and the disease was rapidly controlled 
(Ramsay et al., 2001). Despite the availability of antibiotics and the introduction of 
vaccines, the case fatality from meningococcal disease remains 5-10% and up to 25% 
of survivors are left with permanent sequelae such as sensorineural hearing defects 
and/or loss of limbs (Tzeng and Stephens, 2000).  
 
 
1.2 Classification of N. meningitidis  
1.2.1. Serological typing of N. meningitidis 
A variety of immunological and genetic methods has been developed to categorise 
strains of N. meningitidis for epidemiological surveillance and the management of 
meningococcal disease. Serological typing has been traditionally used to identify 
surface expressed antigens including the polysaccharide capsule, lipopolysaccharide 
(LPS) and outer membrane proteins (OMPs). 
 
Based on the structural and immunological differences of the polysaccharide capsule, 
meningococci are currently divided into 13 serogroups (A, B, C, D, X, Y, Z, E, W-
135, H, I, K and L), with six serogroups (A, B, C, W-135 Y and X) commonly 
associated with meningococcal disease (Jodar et al., 2002; Stephens et al., 2007). 
Characterisation of the serogroup of case isolates is crucial to prevent further cases in 
close contacts, as most vaccines are serogroup specific (Harrison, 2006). A number of 
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commercial agglutination kits are available to distinguish individual serogroups 
directly using live bacteria recovered from the CSF or blood, or indirectly with dead 
bacteria. Antibodies recognising different serogroups have also been applied in 
enzyme linked immunosorbent assays (ELISAs) to screen large numbers of samples 
(Rosenqvist et al., 1990). However, a proportion of carriage isolates do not express a 
capsule, and therefore cannot be grouped according to this typing method 
(Yazdankhah and Caugant, 2004).  
 
N. meningitidis can be classified into at least 20 serotypes on the basis of the class 2/3 
OMP PorB, and into at least 10 serosubtypes based on the class 1 OMP PorA, 
depending on the reactivity of these porins to type-specific antibodies (Hansman and 
Ashton, 1994). The type specific epitopes are restricted to variable regions in the 
surface exposed loops of these proteins (Minetti et al., 1998; Russell et al., 2004; 
Sacchi et al., 1998). Serotyping and serosubtyping are usually performed with 
suspensions of heat-killed meningococci as antigens in whole-cell or dot-blot ELISAs 
(Wedege et al., 1990). However, the emergence of multiple antigenic variants of 
PorA and PorB which are not recognised by available antibodies has limited the 
utility of these forms of typing (Russell et al., 2004; van der Ende et al., 2003).  
 
Differences in LPS allow N. meningitidis to be divided into 12 immunotypes 
(Scholten et al., 1994). Most meningococcal isolates express more than one 
immunotype of LPS. Immunotype L3,7,9 is the most prevalent in serogroup B and C 
meningococci, followed by immunotypes L2 and L1,8 (Jennings et al., 1999). 
Immunotypes L10 and L11 are uniquely associated with and prevalent in serogroup A 
isolates (Scholten et al., 1994). An example of this serological typing is 
 16 
B:4:P1.4:L3,7,9 indicating the serogroup (B), serotype (4), serosubtype (P1.4) and 
immunotype (L3,7,9) (Tzeng and Stephens, 2000). 
 
Serological typing has been important for public health decisions and vaccine 
development, but is less suitable for detailed epidemiological studies for the 
following reasons. Firstly, N. meningitidis is naturally competent for DNA uptake and 
capable of exchanging genetic information encoding surface antigens (Alexander et 
al., 2004). For example, capsule switching from serogroup B to C, following the 
acquisition of the gene siaD, provides one mechanism by which closely related 
virulent meningococcal clones may not be recognised by traditional serogroup-based 
methods (Swartley et al., 1997). In addition, surface expressed immunogenic antigens 
used for serological typing are likely to be under selective pressure, and therefore 
variants may arise rapidly in populations of N. meningitidis (Hammerschmidt et al., 
1996; Jennings et al., 1999; Johansson et al., 2005; Swartley et al., 1997). Low level 
expression of capsule or other antigens used for serotyping or serosubtyping of strains 
recovered from carriers also limits the use of serological typing methods. Thus, since 
the late 1990s molecular typing techniques have been increasingly applied to 
understand the epidemiology and evolution of N. meningitidis.  
 
1.2.2 Molecular characterisation of N. meningitidis 
Multilocus enzyme electrophoresis (MLEE) is a method that identifies phylogenetic 
relationships in bacterial species by measuring allelic variation in metabolic enzymes 
based on the electrophoretic mobility of twenty-five housekeeping enzymes (Selander 
et al., 1986). Each novel combination of allelic variants is referred to as an 
electrophoretic type (ET), and strains possessing similar ETs are grouped into clonal 
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complexes (Caugant et al., 1987b). Investigation of global meningococcal 
epidemiology by MLEE reveals that the ET-5 and ET-37 complexes, which include 
serogroup B, C and W135 strains, have been associated with several outbreaks and 
most sporadic meningococcal disease in Europe and the USA (Raymond et al., 1997; 
Swartley et al., 1997; Taha et al., 2000). However, as this method requires calibration 
with standard strains and is technically demanding, MLEE has been less often used in 
reference laboratories since the advent of multilocus sequence typing (MLST) 
(Maiden et al., 1998). 
 
MLST is a DNA sequence-based version of MLEE, recording variations in the 
nucleotide sequence of housekeeping genes distributed around the genome (Spratt, 
1999). MLST categorises bacteria according to the nucleotide sequence of fragments 
of approximately 433-501 bp in length from seven housekeeping genes: abcZ, adk, 
aroE, fumC, gdh, pdhC and pgm. As these genes are dispersed across the genome, 
alleles are unlikely to be co-inherited through a single recombination event. In 
addition, the housekeeping genes are also generally not in close proximity to genes 
that are under strong selective pressure and therefore can be used to assess the genetic 
background of N. meningitidis (Maiden et al., 1998). Every unique sequence at each 
locus is assigned an allele number, and every unique combination of alleles is 
assigned a sequence type (ST). Highly prevalent STs usually have the highest number 
of related STs that differ at only one or two loci, and genetically related STs 
surrounding a central genotype are grouped into clonal complexes (Feavers et al., 
1999). MLST provides unambiguous and portable results that can be compared 
between different laboratories on a central database (http://pubmlst.org/neisseria) via 
the internet (Jolley et al., 2004). However, MLST might not be sufficient for outbreak 
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investigations, thus combinations of MLST with other approaches, such as pulsed-
field gel electrophoresis, sequencing of 16S rRNA genes, multilocus variable-number 
tandem repeats analysis and sequencing of genes encoding outer membrane proteins, 
have been used (Popovic et al., 2001; Sacchi et al., 2002; Yazdankhah et al., 2005).  
 
Amplification and sequencing the capsule biosynthesis genes has been used to 
determine the serogroup of isolates, even in the absence of capsule expression 
(Lansac et al., 2000; Porritt et al., 2000). It can also be directly applied to clinical 
samples without culture (Abdel-Salam, 1999). Similarly, amplification of porA and 
porB by PCR, and querying the PorA and PorB variable region sequence database 
(http://neisseria.org/nm/typing/pora/ and http://neisseria.org/nm/typing/porb/) have 
been used to characterise strains (Jelfs et al., 2000). Recently, more surface antigens 
have been employed as epidemiological markers. For example, FetA is found to be 
conserved within hyper-invasive lineages, and a database of the sequence of the 
variable region in fetA (http://neisseria.org/nm/typing/feta) is available for classifying 
strains (Thompson et al., 2003).  
 
 
1.3. Meningococcal carriage  
N. meningitidis is an obligate commensal in humans, and it can colonise the 
nasopharynx without causing the disease, a phenomenon known as carriage 
(Yazdankhah and Caugant, 2004). The carriage rate ranges between 5-28% in healthy 
individuals (Stephens et al., 2007), and very high carriage rates (> 90%) have been 
were reported among military recruits during serogroup A epidemics (Caugant et al., 
1992).  
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A number of factors are associated with meningococcal carriage. The carriage rate is 
age-dependent; it is less than 3% in children who are less than 4 years old, then 
increases to between 24-37% in the 15-24 year age group, and declines to about 10% 
in the elderly (Cartwright et al., 1987; Caugant et al., 1994). Carriage rates are higher 
in closed populations, such as military recruits, university students, and household 
contacts of cases (Cartwright et al., 1991; Caugant et al., 1992; Imrey et al., 1995). 
Individuals with upper respiratory tract damage caused by microbial infection or 
smoking are at higher risk of being carriers (Artenstein et al., 1967; Blackwell et al., 
1990; Moore et al., 1990). Males have more often been reported to be carriers than 
females for unknown reasons (Cartwright et al., 1987; Caugant et al., 1994). A one 
year post-vaccination survey in the UK showed that introduction of meningococcal 
serogroup C conjugate vaccine reduced the carriage of serogroup C meningococci in 
young adults aged 15-17 years by 66%, but had no impact on the carriage of other 
serogroups strains (Maiden and Stuart, 2002).  
 
Culturing bacteria following nasopharyngeal swabbing is the conventional method of 
studying N. meningitidis carriage. However, carriage rates obtained by this method 
depend on the number of swabs taken, the site swabbed and the sensitivity of 
nasopharyngeal culture (Broome, 1986). A recent study suggests that nasopharyngeal 
swabbing may underestimate the carriage rate, with carriage detected in only in 10% 
patients undergoing tonsillectomy, compared to carriage of 45% identified by 
immunohistochemistry analysis of tonsillar tissue (Sim et al., 2000; Yazdankhah and 
Caugant, 2004). 
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1.4 Epidemiology 
Meningococcal infection is spread by direct contact with infectious respiratory 
secretions and by droplet transmission. The incidence of meningococcal disease 
varies from 1 case per 100,000 population per year to over 1,000 cases per 100,000 
population per year (Tzeng and Stephens, 2000).  
 
Serogroup A meningococcal strains are prevalent in developing countries and are the 
main cause of both endemic and epidemic meningococcal disease in Africa. In a 
region of sub-Saharan Africa extending from Senegal to Ethiopia (referred to as the 
meningitis belt), sporadic infections occur in seasonal annual cycles, while large-scale 
epidemics happen at greater intervals with an irregular pattern (Greenwood et al., 
1885; World Health Organisation 2005). During a major outbreak in 1996, the 
number of cases reached 150,000 with 20,000 deaths, and molecular and genetic 
analysis revealed that most the strains belonged to the ST-7 or ST-5 complexes 
(Tzeng and Stephens, 2000). Recently, attack rates of meningococcal disease have 
also increased in non-meningitis-belt countries in Africa. The emergence of the ST-7 
complex was first reported in China in the early 1990s, and this ST complex then 
spread to Russia in 1996 (Girard et al., 2006; Yang et al., 2007).  
 
Serogroup B and C meningococcal strains are associated with endemic disease in 
developed countries. They account for 80% of cases in certain European countries, 
such as the UK and Spain, and are responsible for 30-40% of cases in North America 
(Cartwright et al., 2001). Endemic infection, with incidences ranging from 1 to 10 per 
100,000 population, often occur in annual cycles with a peak incidence in the first 
quarter of the year (Ramsay et al., 1997). Epidemics of serogroup B disease have 
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been reported in Cuba, Chile, Norway and New Zealand (Bovre et al., 1977; Caugant 
et al., 1987a; Oster et al., 2005; Sierra et al., 1991). The global incidence of 
serogroup B disease is about 20,000 to 80,000 cases per year, with a mortality rate of 
approximately 10%. Genotypic analysis suggests that most strains are ET-5/ST-32 
and ET-37/ST-11 (Vogel et al., 2000). 
 
Serogroup W-135 (ET-37/ST11) has caused worldwide outbreaks associated with the 
Hajj pilgrimage and also disease in African meningitis belt countries such as Burkina 
Faso (Aguilera et al., 2002; Decosas and Koama, 2002; Lingappa et al., 2003). 
Disease resulting from serogroup Y (ET-501/ST-23) has been increasing in the USA 
since 1990 (Rosenstein et al., 2001), and has also been reported in Israel and Sweden 
(Memish, 2002). Serogroup X has been identified as the cause of local outbreaks in 
parts of sub-Saharan Africa such as in Niger (Nathan et al., 2005).  
 
Many factors have been associated with an increased susceptibility to disease, of 
which the most important is the degree of host immunity. In England and Wales, the 
peak incidence of serogroup B and C disease occurs at 6 months of age when 
maternal bactericidal antibodies have largely disappeared and before active immunity 
has developed (Ramsay et al., 2003). The relatively low case incidence compared 
with carriage in military recruits is related to the level of serum bactericidal 
antibodies induced by nasopharyngeal carriage (Almeida-Gonzalez et al., 2004; 
Goldschneider et al., 1969b; Orren et al., 1987). Individuals with complement 
deficiencies are highly susceptible to meningococcal disease, and are likely to 
experience recurrent attacks (Figueroa et al., 1993; Orren et al., 1987; Vega and 
Quinby, 1994). In addition, fully functional opsonisation and phagocytosis are also 
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necessary for the protection of the host against meningococcal disease (Sparling, 
2002). 
 
 
1.5 N. meningitidis virulence determinants  
1.5.1 Polysaccharide capsule  
The polysaccharide capsule is the outermost layer of meningococcus and interacts 
with the external environment, mediating a variety of biological processes relevant to 
pathogenesis. Based on its biochemical and physical properties, the meningococcal 
capsule is similar to the capsule from Escherichia coli K1 and Haemophilus 
influenzae, and is categorised as a group II capsule (Frosch et al., 1989; Frosch et al., 
1991). N-acetyl neuraminic acid (NANA, sialic acid) is a crucial component of the 
polysaccharide capsule of disease-associated serogroups B, C, W135 and Y. The 
serogroup B capsule is composed of α(2-8)-linked sialic acid that is also present as a 
modification of the mammalian neural cell adhesion molecule (NCAM), while, the 
serogroup C capsule is composed of α(2-9)-linked sialic acid (Kabat et al., 1986; Liu 
et al., 1971a). Serogroups Y and W135 capsules contain alternating units of sialic 
acid with D-glucose or D-galactose, respectively (Bhattacharjee et al., 1976). As the 
exception, the serogroup A capsule does not contain sialic acid, and instead it is 
composed of α(1-6) linked N-acetyl-D-mannosamine-1-phosphate (Liu et al., 1971b).  
 
Genes involved in meningococcal capsule biosynthesis are clustered at a 
chromosomal locus, which is termed the capsule biosynthesis locus (cps). The cps is 
about 24 kb length and divided into five distinct regions: E, C, A, D and B (Frosch et 
al., 1989). Region A encodes enzymes for the biosynthesis of the capsular 
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polysaccharide, while regions B and C are involved in the translocation of the 
polysaccharides to the cell surface. The capsule biosynthesis genes in region A (siaA, 
siaB, siaC, siaD) are transcribed co-ordinately as a single operon (Swartley et al., 
1996). The siaA, siaB, siaC genes are highly conserved in different serogroups, 
whereas, siaD gene sequence is specific for different serogroups (Claus et al., 1997).  
 
Despite the distinct chemical composition of the capsule based on genes in region A, 
the genes in regions B and C share a high degree of homology among all serogroups, 
and even in the genomes of other bacterial species expressing group II capsules 
(Claus et al., 1997). Genes in region C (ctrA, ctrB, ctrC, ctrD) share a divergently 
transcribed promoter region with genes in region A (Swartley et al., 1996). CtrABCD 
together with an ATP-binding cassette (ABC) transport system participate in the 
transport of the polysaccharide chains to the cell surface (Frosch et al., 1992). Genes 
in region B (lipA, lipB), which is separate from the sia and ctr operons, are 
responsible for the phospholipid substitutions at the reducing end of polysaccharide 
chains (Frosch and Muller, 1993).  
 
Encapsulation is a pre-requisite for meningococci to survive in the systemic 
circulation of host and cause disease. Epidemiologic studies of an outbreak of ET-5 in 
Washington revealed that expression of capsule was higher in invasive isolates 
recovered from the blood and CSF in comparison to strains present in the 
nasopharynx (Tzeng and Stephens, 2000). Similarly, the genotype and phenotype of 
isolates recovered from carriers were the same as the outbreak strains, with the 
exception that they lacked capsule, during the Stonehouse outbreak of serogroup B 
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meningococcal disease in England (Cartwright et al., 1987; Hammerschmidt et al., 
1996).  
 
The importance of the polysaccharide capsule in meningococcal pathogenesis is not 
only demonstrated by epidemiological and clinical studies, but also by clear 
experimental evidence. Encapsulation is crucial for bacteria to avoid complement-
mediated bacteriolysis during systemic infection. The sialic acid capsule of serogroup 
B strains is indispensable for systemic infection in the infant rat and murine models 
(Mackinnon et al., 1993; Vogel et al., 1996). Interruption of siaD leads to loss of 
capsule expression, and resultant mutants are highly sensitive to complement-
mediated killing compared to the parental strains (Frosch et al., 1990). It is suggested 
that the capsule can down-regulate the alternative complement pathway and/or 
prevent the insertion of the Membrane Attack Complex (MAC) into the bacterial 
outer membrane (Jarvis and Vedros, 1987; Ram et al., 1999).  
 
In addition, the polysaccharide capsule inhibits phagocytosis of N. meningitidis by 
macrophages, with decreased rates of incorporation of the major lysosomal integral 
membrane protein (LAMP-1) into the phagosome (Read et al., 1996). This 
antiphagocytic property was further confirmed by the observation that expression of a 
serogroup A, B, or C capsule dramatically decreased the adherence of bacteria to 
dendritic cells (DC) and phagocytosis (Unkmeir et al., 2002). Furthermore, the 
capsule protects bacteria against cationic antimicrobial peptides (CAMPs), such as 
polymyxin B, defensins and protegrin PG-1, enabling bacteria to survive and replicate 
within epithelial or endothelial cells (Spinosa et al., 2007). The expression of siaD 
and lipA, required for the capsular polysaccharide biosynthesis and translocation 
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respectively, are up-regulated when bacteria were recovered from eukaryotic cells in 
comparison with bacteria cultured in medium alone (Spinosa et al., 2007). 
 
1.5.2 Lipopolysaccharide  
Lipopolysaccharide (LPS) is the most abundant antigenic component in the N. 
meningitidis cell envelope, and is a key virulence factor involved in the pathogenesis 
of meningococcal sepsis and meningitis (Brandtzaeg et al., 2001; Verheul et al., 
1993). 
 
LPS is an amphipathic glycolipid with a molecular mass of about 4.8 kDa. It consists 
of the hydrophobic lipid A domain embedded in the outer membrane, joined by the 
inner core carbohydrates to two short chains of oligosaccharides (Jennings et al., 
1980). Meningococcal LPS lacks the repeating O-antigen found in enteric pathogens, 
and only has a few sugar residues linked to the inner core, and thus is often referred to 
as lipooligosaccharide (LOS) (Jennings et al., 1987). The lipid A backbone, also 
called endotoxin, is the main toxic component of LPS that induces inflammatory 
responses (Brandtzaeg et al., 2001). The inner core region is composed of 3-deoxy-D-
manno-2-octulosonic acid (KDO) and heptose (Hep) attached to lipid A. The variable 
side chains (α-, β-) are attached to the KDO and Hep residues (Kahler et al., 1998). 
The carbohydrate moieties are highly diverse in the α-chain, and the biochemical and 
immunogenic differences in α-chain are the basis of the different immunotypes 
(Kurzai et al., 2005).  
 
LPS is essential for adhesion to and colonisation of host cells by N. meningitidis. 
Inactivation of lpxA, encoding the enzyme responsible for the first step of lipid A 
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biosynthesis, severely reduces bacterial adhesion to and invasion of epithelial cells 
(Gorter et al., 2003). A pgm mutant, which is unable to express the α-chain of LPS, 
invades epithelial cells much more slowly than the wild-type strain, and has a 
significant defect for survival in the murine bloodstream (Plant et al., 2006). The 
important role of LPS in early infection is further supported by the finding that a 
mutant without LPS is unable to persist in the lung and invade the blood in a murine 
model (Zarantonelli et al., 2006). 
 
LPS is important for N. meningitidis to escape killing by the immune system. Full 
length LPS is required for bacteria to avoid complement-mediated lysis, regardless of 
the expression of capsule (Hammerschmidt et al., 1994; Kahler et al., 1998). A lacto-
N-neotetraose (LNnT) moiety in the α-chain of LPS is identical to a human blood 
group antigen, and is an excellent example of molecular mimicry used by N. 
meningitidis to subvert the immune system (Mandrell et al., 1988). The LNnT epitope 
present in LPS can be sialylated exogenously in the presence of 5’-monophosphate-
N-acetyl-neuraminic acid (CMP-NANA) or endogenously via the sialic acid 
biosynthesis pathway in serogroup B, C, W-135 and Y strains (Hammerschmidt et al., 
1994; Mandrell et al., 1991). Strains with full length and sialylated L3,7,9 LPS are 
more frequently associated with invasive disease, whereas, L8 immunotypes 
predominant in carriage isolates (Jones et al., 1992). Sialylation has been shown to 
contribute to bacteraemia in the infant rat model (Vogel et al., 1996). However, the 
contribution of LPS sialylation to meningococcal serum resistance is controversial 
(Ram et al., 1999; Smith et al., 1995). Some but not all of ∆lst mutants of serogroup 
B N. meningitidis strains have increased sensitivity to complement-mediated killing 
in the presence of high concentrations of serum only (Vogel et al., 1999). By masking 
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the surface molecules Opa or Opc, sialylation of the LNnT epitope renders bacteria 
resistant against opsonophagocytosis by human neutrophils and phagocytosis by DCs 
(Unkmeir et al., 2002).  
 
LPS is released from N. meningitidis in membrane blebs. The level of LPS in the 
plasma and CSF is correlated with the level of inflammatory mediators, clinical 
severity and the outcome from disease (Brandtzaeg et al., 2001). Patients with 
persistent septic shock, multiple organ failure, and severe coagulopathy have 
extraordinarily high levels of LPS in plasma. Mortality related to shock increases 10-
fold with an increase of plasma LPS from 10 to 100 endotoxin units/ml (Brandtzaeg 
et al., 2001). Meningococcal LPS binds to the CD-14 receptor and Toll-like receptor-
4 (TLR-4) with its co-factor, myeloid differentiation protein-2 (MD2), on 
macrophages, granulocytes and endothelial cells (Ingalls et al., 2000). This triggers 
the activation of nuclear factor κB (NFκB) and other cytokine pathways, leading to 
increased production of tumour necrosis factor (Stephens et al., 2007; Westendorp et 
al., 1995). 
 
1.5.3 Pili 
Pili are filamentous, hair-like outer membrane protein organelles that extend beyond 
the bacterial surface (Devoe and Gilchrist, 1974). Type IV pili (Tfp) have several 
remarkable functions in many Gram-negative bacteria, including bacterial motility, 
adhesion to host cells, aggregation, biofilm formation, natural transformation and 
immune escape (Merz and So, 2000; Nassif et al., 1997; Rudel et al., 1995). The 
importance of pili to the pathogenesis of N. meningitidis has been demonstrated by 
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the findings that pili are ubiquitously expressed by clinical isolates from patients with 
meningococcal sepsis (Stephens and McGee, 1981). 
 
Expression of Tfp facilitates N. meningitidis adhesion to epithelial cells during 
colonisation of the mucosal surface, and to endothelial cells while crossing the blood-
brain barrier (Nassif et al., 1997). Mutants lacking piliation adhere to both epithelial 
and endothelial cells several orders of magnitude less than piliated meningococci 
(Stephens and McGee, 1981; Stephens et al., 1983; Virji et al., 1991). Meningococcal 
pili are mainly composed of thousands of copies of the pilin protein, PilE (Potts and 
Saunders, 1988). N. meningitidis can express Class-I or Class II pili, with the former 
recognised by the monoclonal antibody, SM1 (Virji et al., 1989). Biogenesis of Tfp 
includes the assembly of fibres in the periplasm, stabilisation and secretion to the 
bacterial surface, and requires at least 15 genes (Craig et al., 2006; Tonjum and 
Koomey, 1997). For example, PilD, PilF and PilG are involved in fibre assembly, 
while PilQ contributes to the secretion and translocation of fibres to the bacterial 
surface (Tonjum et al., 1995). In addition to proteins required for pili expression, PilT, 
PilU, PilC, PilX and PilW contribute to pilus function. For instance, PilX mediates 
bacterial aggregation but not adhesion during early interactions between N. 
meningitidis and human cells (Carbonnelle et al., 2005). PilT is required for bacterial 
competence and twitching motility, and plays a key role in interactions with the host 
cells by up-regulating the expression of PilC and by mediating pilus retraction (Pujol 
et al., 1999; Wolfgang et al., 1998; Yasukawa et al., 2006).  
 
PilC alleles (PilC1 and PilC2) are required for fibre stabilisation and adhesion, as a 
double pilC knock-out mutant is non-piliated (Nassif et al., 1997). Encapsulated 
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pilC2
+
/pilC1
-
 strains are piliated but not adhesive, indicating that adhesion is 
mediated by the expression of PilC1 but not PilC2. This could be explained by the 
presence of a putative cell binding domain in the PilC1 but not in PilC2 (Nassif et al., 
1997). The adhesiveness of bacteria is correlated with the expression of PilC1, the 
transcription of which is modulated by pilA and pilT (Taha et al., 1998).  
 
In addition to the expression of PilC, sequencing of pilE reveals that high level of 
adhesiveness is associated with pilin antigenic variation. For example, in the 
hypervariable region of PilE, an aspartic acid (Asp) residue is present at amino acid 
140 in low adhesive strains, whereas a lysine (Lys) is found in highly adhesive 
isolates (Nassif et al., 1997). The pili of highly adhesive variants mediate aggregation 
and the formation of large bundles, and strains grow as colonies on infected 
monolayers of human cells. This enhanced adhesiveness could be due to increased 
bacteria-bacteria interactions allowing a high density of adhesins interacting with 
eukaryotic receptors (Marceau et al., 1995).  
 
The proposed receptor for the Tfp is CD46, which is expressed in almost all human 
cells, apart from erythrocytes. Purified pili can bind to a protein of the size of CD46, 
and adhesion of N. meningitidis to cells is blocked by anti-CD46 antibodies 
(Kallstrom et al., 1997). Furthermore, transgenic mice expressing human CD46 are 
susceptible to meningococcal disease (Johansson et al., 2005). The initial attachment 
of gonococci to host epithelial cells results in phosphorylation of tyrosine at 354 
amino acid on the intracellular domain of CD46 by Src-family kinase. Inhibition of 
these tyrosine kinases results in a significant reduction in the adhesion of the 
gonococcus to the epithelium (Lee et al., 2002). However, the recent finding that 
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down-regulation of CD46 by RNA interference has no effect on the binding 
efficiency of piliated gonococci or purified PilC2 protein calls into questions the role 
of CD46 as a receptor in N. meningitidis infection (Kirchner et al., 2005) 
 
1.5.4 Outer membrane proteins 
As a Gram-negative bacterium, N. meningitidis has an outer membrane (OM) 
containing numbers of proteins in addition to lipids and LPS. The major outer 
membrane proteins are categorised into five classes based on their different mobility 
on sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (Tsai 
et al., 1981). Studies identified that class 2 and class 3 proteins are encoded by two 
different alleles of a single gene, porB, and demonstrated class 1, 4 and 5 proteins are 
PorA, Rmp and Opa/Opc, respectively (Aho et al., 1991; Blake et al., 1989; Olyhoek 
et al., 1991; Tsai et al., 1981).  
 
The class 1 PorA and class 2/3 PorB are porins. PorA forms cation-selective pores in 
the OM, while, PorB forms anion-selective channels, which allow ion exchange 
between the inside of bacteria and the external environment (Tommassen et al., 1990). 
The molecular mass of PorA varies between 44 and 47 kDa in different strains, 
whereas PorB is present as one of two mutually exclusive forms. Structural analysis 
predicts that PorA and PorB have eight surface exposed hydrophilic loops with 
variation between strains (van der Ley et al., 1991). The predicted surface loops I and 
IV are designated as variable regions 1 and 2 (VR1 and VR2), respectively, while 
loops V and VI are designated as semi-variable regions (SR1 and SR2) (Sacchi et al., 
1998). The immunological properties of the VRs are responsible for serosubtype 
classification, while nucleotide sequence analysis of VRs has been be used for 
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epidemiological studies (Devoy et al., 2005; Feavers et al., 1999). As an abundant 
surface protein, PorA is frequently recognised by bactericidal antibodies. Monoclonal 
antibodies directed against PorA can activate complement-mediated killing of 
meningococci, and have been shown to be effective in preventing infection in an 
infant rat model of meningococcal infection (Saukkonen et al., 1987). Serum from 
individuals immunised with outer membrane vesicle (OMV) vaccines revealed a 
correlation between protection and the presence of antibodies against PorA 
(Guttormsen et al., 1994; Milagres et al., 1994). The adjuvant property of 
recombinant PorA has been demonstrated by its ability to activate monocyte-derived 
DCs, and influence T-helper immune responses (Al-Bader et al., 2004). In contrast, 
PorB can stimulate B lymphocyte proliferation and Ig secretion, by binding to TLR-2 
(Wetzler et al., 1996). PorB is also capable of inserting into the membrane of host 
cells and facilitating bacterial attachment by forming functional channels and 
interfering with Ca
2+
 signalling (Muller et al., 1999). The interaction of PorB with 
mitochondria of host cells blocks the activation of caspase-9, caspase-3 and DNA 
degradation, thus preventing cell apoptosis (Massari et al., 2003; Plummer et al., 
1993). 
 
The class 4 protein (33-34 kDa) was designated reduction-modifiable protein M 
(RmpM), as its electrophoretic mobility is influenced by the presence of reducing 
reagents. RmpM of meningococci shares 94.2% homology with protein III of N. 
gonorrhoeae and limited homology with the C-terminus of E. coli OmpA (Klugman 
et al., 1989). Rmp is found in close association both with porins, PorA and PorB, and 
iron-regulated outer membrane proteins, LbpA, TbpA and FrpB (Jansen et al., 2000; 
Prinz and Tommassen, 2000). Antibodies against RmpM fail to promote 
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complement-mediated bactericidal killing of meningococci, and some anti-protein III 
mAbs have been shown to inhibits the killing of meningococci by blocking the 
bactericidal antibodies against proteins and LPS (Plummer et al., 1993; Virji and 
Heckels, 1988). However, later studies showed that purified anti-RmpM antibodies 
have no blocking effect on the bactericidal activity induced by PorA (Rosenqvist et 
al., 1999).  
 
The Class 5 proteins, Opa and Opc, are opacity-associated (Opa) proteins. Opa is a 
highly variable protein and encoded by up to four genes (Aho et al., 1991), whereas 
Opc is relatively conserved and encoded by a single gene (Olyhoek et al., 1991). Opa 
proteins are subject to antigenic and phase variation, the latter is mediated by multiple 
CTCTT repeats upstream of the opa open reading frame (ORF) (Belland et al., 1997). 
Opa and Opc bind to the human CD66 and heparin sulphate proteoglycan receptors, 
respectively, and are important for intimate adhesion of N. meningitidis to host cells 
following initial attachment mediated by pili (de Vries et al., 1998; Virji et al., 1993; 
Virji et al., 1996b). However, the interaction between bacterial Opa and Opc with 
host cells is often masked by the polysaccharide capsule and sialylated LPS (Unkmeir 
et al., 2002). The Opa proteins may also act as immunomodulators, interacting with 
macrophages, neutrophils, and CD4
+
 T cells, by binding to members of the 
carcinoembryonic antigen cell adhesion molecule
 
(CEACAM) family of proteins 
(Boulton and Gray-Owen, 2002; Gray-Owen et al., 1997). 
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1.6 Phase variation  
Pathogenic bacteria have evolved sophisticated strategies to adapt to the highly 
selective environments they encounter within their hosts. Phase variation enables N. 
meningitidis to produce multiple combinations of phenotypes, some of which may 
have increased fitness in specific niches, enhancing virulence during systemic 
infection (Henderson et al., 1999; Moxon et al., 1994) 
 
Morphologic changes of N. gonorrhoeae colonies in their colour, opacity and size 
were first reported by Kellogg (Kellogg et al., 1963), and similar findings for N. 
meningitidis were observed by Blake (Blake et al., 1989). These phenotypic 
variations are linked to changes in the expression of surface phase variable structures, 
such as the polysaccharide capsule (Hammerschmidt et al., 1996), pili (Seifert, 1996), 
LPS (de Vries et al., 1996), PorA (van der Ende et al., 2003) and Opa proteins (van 
der Ende et al., 2003).  
 
Phase variation is the reversible on-off switching of gene expression in cells of a 
clonal population (van der Woude and Baumler, 2004). The variation is heritable 
between generations and can affect more than 60 N. meningitidis genes (Alexander et 
al., 2004; Snyder et al., 2001). The genome of N. meningitidis is relatively small (~ 2 
Mb) and has a limited number of classic regulatory mechanisms compared to E. coli, 
such as sigma factors and two-component systems (Jolley et al., 2005). However, it 
has a number of mechanisms to promote gene variation through mutation (Jolley et 
al., 2005).  
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Repetitive DNA sequences are highly prevalent in the genome of N. meningitidis. 
Most phase variation events are based on the loss or gain of repetitive DNA 
sequences during DNA replication or repair (Stern and Meyer, 1987). Typically, loss 
or gain of repeat sequences in an ORF can result in frameshift mutants and or 
translation of non-functional proteins (Chen et al., 1998). Changes in repetitive 
sequence located in promoters can alter the transcriptional activity of genes. For 
example, the presence of TAAA repeats within the promoter of nadA mediates phase 
variation by altering interactions with the transcription factor IHF and its DNA 
binding site (Martin et al., 2003). In addition to repetitive DNA, insertion elements 
and atypical recombination are also responsible for phase variation of N. meningitidis. 
For example, insertion of IS1301 within siaA mediates phase variation of this gene 
and abolishes capsule expression (Hammerschmidt et al., 1996). Homologous 
recombination between pilE encoding subunits of pili and copies of the silent gene 
leads to the on/off expression of pili (Virji et al., 1992; Virji et al., 1993) 
 
Several environmental factors affect the frequency of phase variation, such as the 
level of available iron (Schryvers and Stojiljkovic, 1999). Iron starvation is associated 
with increased DNA recombination and repair, and elevated rates of phase variation 
of pili in N. gonorrhoeae (Sechman et al., 2005; Serkin and Seifert, 2000). 
Transformation of N. meningitidis with donor DNA from heterologous strains can 
also increase the rate of phase variation up to 73-fold (Alexander et al., 2004). 
Adherence to host cells has similar effect on the up-regulation of the rate of phase 
variation (Morelle et al., 2005). The length or number of repetitive sequences can also 
affect the phase variation rate. For instance, increased numbers of G residues in the 
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poly G tract of the hmbR gene results in an increase in the rate of phase variation 
(Tapsall et al., 2001).  
 
Antigenic variation refers to the expression of functionally conserved moieties within 
a clonal population that are antigenically distinct (Davidsen and Tonjum, 2006; van 
der Woude and Baumler, 2004). The genetic information for producing a family of 
antigenic variants can be available within the bacterium, with only one variant 
expressed at a given time (van der Woude and Baumler, 2004). In N. meningitidis, 
type IV pili and Opa proteins are typical structures that vary through intragenomic 
recombination (Nassif et al., 1993). Alternatively, antigenic variation can arise by 
spontaneous mutation or by transformation (Koomey et al., 1987; Seifert et al., 1988).  
 
 
1.7 Competence of N. meningitidis  
Transformation is the one of the major routes for bacteria to obtain novel genetic 
information. Transformation consists of binding of exogenous DNA, transport 
through the membranes surrounding the bacteria, and incorporation of the DNA into 
the chromosome (Chen et al., 1998). Neisseria spp. are naturally competent for 
transformation throughout their whole life cycle (Lorenz and Wackernagel, 1994).  
 
Experiments performed on the closely related species N. gonorrhoeae indicated that a 
10-bp DNA uptake sequence (5’-GCCGTCTGAA-3’, DUS) in the incoming DNA 
enhances the frequency of transformation (Graves et al., 1982). DUS is the most 
frequent repetitive sequence element in the meningococcal genome and is present in 
approximately 1,900 copies (Alexander et al., 2004). The requirement of DUS for 
 36 
Neisseria transformation was first described in 1988 when DNA segments from N. 
gonorrhoeae were used for transformation (Goodman and Scocca, 1988). Further 
experiments showed that N. gonorrhoeae exhibited preferential uptake of DNA 
containing DUS when incubated with homologous and foreign DNA (Hamilton and 
Dillard, 2006). In addition to the presence of PilE on the bacterial surface, PilQ and 
PilP, which form a channel for the transport of incoming DNA (Collins et al., 2005), 
and PilT, which mediates pilus retraction, are essential for DNA uptake (Wolfgang et 
al., 1998). Once the incoming DNA passes through the outer membrane, ComE in the 
periplasm is required for DNA uptake by an unknown mechanism (Chen et al., 1998). 
ComA, an inner membrane protein, is crucial for DNA transport into the cytosol 
(Rudel et al., 1995). Integration of the homologous incoming DNA into the 
chromosome is RecA-dependent, and also partially requires RecBCD, RecN, RecX 
(Mehr and Seifert, 1998; Stohl et al., 2002).  
 
 
1.8 Complement system  
1.8.1 Complement pathway 
Complement was first identified as a heat-labile activity in serum that “complemented” 
antibodies in the killing of bacteria (Bordet, 1895). The complement system consists 
of more than 30 fluid phase proteins circulating in the plasma, and several membrane-
associated complement-receptor proteins and regulators. Activation of the 
complement system can be achieved through three different pathways, the classical 
(CP), alternative (AP) and lectin (LP) pathways (Ikeda et al., 1987; Ingwer et al., 
1978) (Figure 1.1). The importance of complement in the immune system has been 
well established (Walport, 2001). First, it defends the host against micro-organisms 
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through opsonisation, lysis of bacteria and chemotaxis and activation of leukocytes. 
Secondly, it can bridge innate immunity with adaptive immunity, by inducing 
antibody responses and immunologic memory, or attracting leukocytes to the site of 
infection (Nielsen and Leslie, 2002). For example, C5a, the cleavage product of C5 
can recruit phagocytic cells, and C3a can regulate the inflammatory response by 
triggering the release of lysosomal enzymes, histamine secretion from mast cells 
(Fretland et al., 1991). Thirdly, complement is involved in the elimination of immune 
complexes and the clearance of apoptotic cells (Walport, 2001).  
 
The CP is mainly initiated by binding of antibodies to antigens. Binding of C1q of the 
C1 complex (which consists of C1q, C1s and C1r) to the heavy chain of IgM or IgG 
leads to the activation of C1s (Loos, 1982; Ziccardi, 1983). Activated C1s first 
cleaves C4 into C4a and C4b, and then separates C2 into C2a and C2b. Binding of 
C4b to C2a forms C4b2a, which is the C3 convertase of the CP. This C3 convertase 
cleaves C3 into active C3b, which then binds to an activator surface (Walport, 2001). 
Initiation of AP occurs by spontaneous low-rate hydrolysis of the thioester bond in 
C3 and formation of C3(H2O) in plasma (Pangburn, 1983). C3(H2O) binds to factor B 
(fB), and factor D (fD) can cleave fB in the complex, resulting the C3(H2O)Bb. 
C3(H2O)Bb is the fluid-phase C3 convertase and can cleave C3 into C3a and C3b. 
C3b on the bacterial surface can then bind to fB and form C3bBb in the presence of 
fD (Pangburn et al., 1983). Binding to properdin stabilises the activity of C3bBb, 
which is C3 convertase of the AP. C3bBb can cleave further C3 molecules, and this 
amplification loop is a key feature of the AP (Fishelson et al., 1983). C3b is also able 
to bind to C3bBb to form C3bBb3b, a C5 convertase capable of cleaving C5 into C5a 
and C5b (DiScipio et al., 1983). 
 38 
 
The LP is activated when mannose-binding lectin (MBL) or ficolins bind to 
carbohydrates or other ligands on a micro-organism in a calcium-dependent manner 
(Fujita et al., 2004). MBL is associated with three MBL-associated serine proteases 
(MASPs), MASP-1, MASP-2 and MASP-3. The MBL-MASP-2 complex is able to 
cleave C4 and C2, forming C4b2a, the C3 convertase that splits C3 into C3a and C3b 
(Sim and Laich, 2000). In addition to activating complement, binding of MBL to 
some carbohydrate structures on the microbial surface can enhance phagocytosis via 
complement receptor 1 (CR1/CD35) (Ghiran et al., 2000). 
 
C3 plays a pivotal role in complement activation as the three complement pathways 
converge at this complement component (Daha et al., 1976). Binding of C3b to C3 
convertase (C4b2a or C3bBb) forms the C5 convertase that cleaves C5 into C5a and 
C5b (DiScipio et al., 1983). C5a is an inflammatory mediator that activates a variety 
of cells through G protein-linked receptors (Pellas and Wennogle, 1999). C5b binds 
to C6, and the resulting complex binds to C7. The C5b67 complex is hydrophobic 
and preferentially inserts into membrane lipid bilayers initiating the formation of the 
membrane attack complex (MAC). C8 binds to C5b67 at C5b and forms small 
transmembrane channels, and acts as the receptor for the polymerisation of C9, which 
completes the MAC transmembrane channel, leading to osmotic lysis of cells 
(Podack and Tschopp, 1982). 
 
In addition to complement-mediated lysis, C3 has an important role in phagocytosis 
(Griffin and Mullinax, 1985). C3b functions as an opsonin, mediating uptake of 
coated particles by phagocytic cells through complement receptor 3 (CR3) 
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(Ehlenberger and Nussenzweig, 1977). A breakdown product of C3b, iC3b, can itself 
function as an opsonin leading to complement receptor 3- and 4-mediated uptake 
(Winkelstein et al., 1975).  
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Figure 1.1 The three complement activation pathways. The classical pathway (CP) 
and the lectin pathway (LP) use C2 and C4 to generate C4b2a as a C3 convertase, while the 
alternative pathway forms C3bBb as a C3 convertase. Cleavage of C3 by a C3 convertase 
(C4b2a or C3bBb, in yellow) results in C3b, and then forms C5 convertase (C4b2a3b or 
C3bBbC3b, in green). The C5 convertase splits C5 into C5a and C5b, and C5b binds to C6, 
C7, C8 and C9 to form the membrane attack complex (MAC). The MAC inserts into the 
membrane of bacteria and causes cell lysis. A few of negative regulators of complement 
pathways are indicated in pink. 
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1.8.2 Regulation of the complement cascade 
Inappropriate and uncontrolled activation of complement could potentially damage 
host cells, and therefore the complement system is tightly regulated, with activation 
confined to foreign particles and damaged tissue (Haupt and Fischer, 1962; 
Humphrey, 1971). Regulation of the complement system occurs at different stages of 
the cascade, from the initial recognition of activator molecules to the formation of the 
MAC. The soluble protein C1-inhibitor inhibits the activation of the C1 complex in 
the initial stages of the CP (Yonemasu, 1988). C4bp is a co-factor in the factor I-
mediated cleavage of C4b and participates in the dissociation of C4b2a, the C3 
convertase of the CP and the LP (Nagasawa and Stroud, 1977; Ruddy and Austen, 
1971). Binding of C4bp to the surface of N. meningitidis confers protection of the 
bacterium against the CP activation (Jarva et al., 2005). The analogous regulator of 
the AP is factor H, a co-factor in the factor I-mediated cleavage and inactivation of 
C3b. fH also contributes to the dissociation of C3bBb, and thus has decay-
accelerating activity for the AP (Zipfel et al., 1999). Recruitment of fH to the surface 
of N. meningitidis contributes to avoidance of complement-mediated killing 
(Schneider et al., 2006). It has been found that S-protein can block the formation of 
MAC (C5b-9) by preventing C9 polymerisation, and blocking the attachment of the 
C5b67 to the cell surface (Hetland et al., 1987). In addition to these soluble proteins, 
several membrane-associated proteins, such as complement receptors (CRs) and 
homologous restriction factor (CD55), take part in complement regulation. For 
example, CD59 can inhibit the formation of the MAC by binding to C8 and/ or C9, 
and contribute the survival of the Helicobacter pylori on the gastric mucosa 
(Rautemaa et al., 2001).  
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1.8.3 Complement deficiencies and meningococcal infection 
The importance of the complement system for host defence against meningococcal 
infection is illustrated by the fact that individuals with complement deficiencies are 
highly susceptible to meningococcal disease (Ellison et al., 1983). Individuals with 
deficiencies of the terminal complement components (C5-C9) have a 5-10,000 fold 
greater risk of developing meningococcal disease than the normal population, and 
half of them experience recurrent attacks (Pollard and Scheifele, 2001). In addition, 
infection with W-135, Y and other rare serogroups are found more often in people 
with terminal complement deficiencies (Sjoholm et al., 2006).  
 
Meningococcal infections have also been associated with defects in the AP and the 
LP. Individuals with either properdin or factor D deficiency have a 250-fold increased 
susceptibility to meningococcal infection especially with serogroup Y and W-135 
strains (Figueroa and Densen, 1991), and have higher mortality rates than normal 
individuals (Sjoholm et al., 2006). Polymorphisms of major complement regulatory 
proteins of the AP have also been associated with meningococcal infection. For 
example, a genetic susceptibility study showed that individuals possessing fH (C-
496T C/C) genotype have a higher risk of N. meningitidis infection, due to increased 
serum fH level and reduced bactericidal activity of the serum (Haralambous et al., 
2006). A large study in children with meningococcal disease revealed that low 
concentration or decreased biological activity of mannose-binding lectin is also 
associated with higher incidence of bacterial infections during childhood (Bathum et 
al., 2006). 
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1.9 Pathogenesis of meningococcal infection  
The development of meningococcal disease requires exposure of a susceptible host to 
pathogenic meningococci, colonisation and penetration of bacteria of the 
nasopharyngeal mucosa and survival of the bacterium in the bloodstream.  
 
Meningococci are transferred in droplets from a carrier to a new host and the 
transmission rate of virulent strains is higher than for non-pathogenic isolates (van 
Deuren et al., 2000). Acquisition of a virulent isolate can lead to meningococcal 
disease within one week, but most individuals carry the bacterium asymptomatically. 
For instance, a study in Norway suggested that in endemic situations, only 1% of 
people harbouring ET-5 and ET-37 isolates become ill (Caugant et al., 1994).  
 
N. meningitidis colonises selectively the microvilli of non-ciliated epithelial cells in 
the mucosa of the human nasopharynx (Stephens et al., 1983). Electron microscopic 
studies using human nasopharyngeal tissue as a model distinguished two steps in the 
adhesion of N. meningitidis. The initial attachment is characterised by dispersed 
microcolonies of 10-100 meningococci on the surface of epithelial cells, which is 
mediated primarily by Tfp (Nassif et al., 1997; Stephens et al., 1983). Binding of Tfp 
to its putative receptor CD46 can trigger an increase in cytosolic calcium and induce 
signal transduction pathways in host cells (Kallstrom et al., 1998). After initial 
attachment, the microvilli of these nonciliated cells elongate and surround the 
organisms. Eight to sixteen hours post-infection, bacteria disperse from the 
microcolonies, which is mediated by PilT and down-regulation of pilus expression 
(Pujol et al., 1999; Yasukawa et al., 2006). Individual diplococci become intimately 
attached to the cell surface by binding of Opa/Opc proteins to their receptors (Virji et 
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al., 1993; Virji et al., 1996a). This process is promoted by down-regulation of capsule, 
which is mediated by a negative transcription regulator CrgA (Deghmane et al., 2002).  
 
The nasopharyngeal epithelium has barrier functions, mediated by tight junctions 
between cells (Pujol et al., 1997). Traversal of the epithelial layer by meningococci is 
not well understood. Encapsulated meningococci are transported through the cell in 
large membrane-bound phagocytic vacuoles, whereas non-capsulated strains traverse 
the cytoplasm without vacuoles (Stephens et al., 1993). Six to twelve hours after 
infection, endocytic vacuoles containing meningococci can be observed in the apical 
portion of some non-ciliated columnar cells (Stephens et al., 1983). Expression of 
polysaccharide capsule hinders invasion and is down-regulated during this stage (de 
Vries et al., 1996). Expression of the surface antigen NadA promotes bacterial 
adhesion and invasion in a capsule-negative background (Capecchi et al., 2005). 
During invasion, translocation of PorB into target cells membranes affects the 
maturation of nascent phagolysosomes (Muller et al., 1999). IgA1 protease, produced 
by N. meningitidis but not by non-pathogenic bacteria such as N. lactamica, can 
inactivate specific IgA1 (Mulks and Plaut, 1978; Vitovski et al., 1999). Accelerated 
degradation of LAMP-1, resulting from infection with meningococci, can promote the 
survival of N. meningitidis in epithelial cells (Ayala et al., 1998). Within twenty-four 
hours, meningococci are observed in the submucosa in close proximity to local 
immune cells and blood vessels (Stephens et al., 1993). 
 
After mucosal penetration, bacteria gain access to the circulation. Expression of the 
polysaccharide capsule, which protects bacteria against complement-mediated killing 
and phagocytosis, is an essential bacterial virulence factor for survival in the 
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bloodstream (Mackinnon et al., 1993; Vogel et al., 1996). PorA can inhibit the 
phagocytic capacity of human neutrophils by down-regulation of the Fcγ receptor, 
and C1 and C3 receptors (Bjerknes et al., 1995). In addition to the properties of the 
meningococcus, the host immune system is important for bacteria to survive in 
bloodstream. As the production of antibodies takes at least one week after acquisition 
of the bacterium, the innate immune response is indispensable. For example, X-linked 
properdin deficiency involved in the AP may lead to overwhelming invasive disease 
(Fijen et al., 1995). Once viable meningococci reach the bloodstream, different 
disease manifestations can develop.  
 
Following dissemination in the vascular system, circulating N. meningitidis is capable 
of crossing the blood-brain barrier (BBB) to cause meningitis. The BBB is made of 
two different structures. One structure consists of the endothelium of brain capillaries 
with tight junctions limiting paracellular flux. The second structure is the choroid 
plexus, which is the major site of CSF synthesis and is located in the ventricles 
(Rubin et al., 1991). Meningococci adhere to the endothelial cells of both the choroid 
plexus and the meninges. Expression of PilC was much higher in bacteria isolated 
from the CSF in comparison to expression from isolates obtained from the systemic 
circulation (Pron et al., 1997). The mechanism by which meningococci invade the 
meninges and cross the BBB is not fully understood. Once in the subarachnoid space, 
where the principal humoral and cellular host defence mechanisms are absent, N. 
meningitidis proliferate in an uncontrolled fashion (Brandtzaeg et al., 1989; 
Simberkoff et al., 1980; van Deuren et al., 2000). 
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1.10 Clinical manifestations 
The initial clinical manifestations of meningococcal disease are similar to a viral 
infection, which makes early diagnosis difficult. The number of bacteria and the level 
of circulating LPS are associated with different clinical presentations and outcomes 
(Stephens et al., 2007). 
 
Bacterial meningitis, resulting from hematogenous dissemination, is the most 
common clinical manifestation of meningococcal disease, and observed in about 50% 
of patients (Manchanda et al., 2006; van Deuren et al., 2000). Most patients 
experience a rapid onset of high fever, headache and neck stiffness. Some patients 
also have nausea, vomiting and mental confusion. In infants, headache and nuchal 
rigidity are not typical, while a swollen fontanelle, irritability and poor feeding are 
more typical (Welch and Nadel, 2003). The application of quantitative real-time PCR 
reveals that patients with meningitis usually have low concentrations of meningococci 
(<10
3 
CFU/ml) and endotoxin (<3 EU/ml) in plasma, but high concentrations in the 
CSF (Ovstebo et al., 2004) 
 
Meningococcal septicaemia (meningococcaemia), with rapid proliferation of N. 
meningitidis in the circulation, occurs in approximately 5-15% of cases of 
meningococcal disease and has a high mortality (van Deuren et al., 2000). It is 
characterised by the abrupt onset of fever, prostration and often a petechial rash, and 
may progress to purpura and/or fulminant septicaemia (van Deuren et al., 2000). 
Patients who develop septicaemia are hypotensive, and may have acute adrenal 
hemorrhage (Waterhouse-Friderichsen syndrome) with multiple organ failure 
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(Stephens et al., 2007). The concentration of bacteria is about 10
5–108 CFU/mL with 
10
1–103 EU/ml of endotoxin in plasma (Brandtzaeg et al., 1989; Hackett et al., 2002).  
 
Chronic meningococcaemia is a rare form of meningococcal disease. Patients 
normally have intermittent fever, lasting from a few days to weeks, and a non-specific 
maculopapular rash (Hansen et al., 2003). Pneumonia has been found in 5-15% of 
patients with this syndrome; other manifestations of N. meningitidis infection include 
septic arthritis, urethritis and pericarditis (Stephens et al., 2007). 
 
 
1.11 Diagnosis  
The gold standard for the diagnosis of meningococcal disease is the isolation of N. 
meningitidis from a normally sterile body site (Rosenstein et al., 2001). As the 
meningococcus is a fastidious organism, samples should be cultured as soon as they 
are collected, ideally within one hour (Manchanda et al., 2006). Even so, the 
sensitivity of diagnosis by bacterial culture is not very high, especially when prior 
antibiotic treatment has been administered. Gram staining of CSF is another 
important method for the rapid detection of N. meningitidis. However, the definitive 
diagnosis of meningococcal disease relies on bacteriologic culture (Dunbar et al., 
1998). 
 
Molecular methods, which do not require recovery of viable bacteria, are less 
compromised by antibiotic treatment. These methods reduce the time for 
identification and increase the sensitivity of the diagnosis (Abdel-Salam, 1999; 
Fontanals et al., 1996; Newcombe et al., 1996). For instance, PCR is used to amplify 
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either conserved genes encoding 16S rRNA or species-specific targets such as porA 
or ctrA (Atobe et al., 2000; Jordens and Heckels, 2005; Whiley et al., 2003). The 
sensitivity of PCR is highest within the first 24 hours after antibiotic treatment. In the 
UK, more than half of cases are now diagnosed by PCR without culture (Atobe et al., 
2000; Gray et al., 2006). 
 
Additionally, molecular methods are essential for the identification of the serogroup 
of N. meningitidis and bacterial susceptibility to antibiotics. Serogroups B, C, Y and 
W135 can be detected by amplification of their different alleles of siaD (Borrow et al., 
1997; Borrow et al., 1998). Serogroup A strains can be identified by amplifying the 
mynB/sacC gene (Taha et al., 2005). Agglutination is widely used to detect capsular 
antigen of serogroups A, B, C, Y and W-135 in clinical samples (Martynov Iu et al., 
1990). False negatives are more common in cases of serogroup B disease and in non-
encapsulated strains. Antibiotic resistance of N. meningitidis has been increasingly 
observed in recent years. Modifications of the penA gene, encoding penicillin binding 
protein 2 (PBP2), is responsible for most reduced susceptibility to penicillin. PCR can 
be used to characterise this alteration and is increasingly used in reference 
laboratories (Taha et al., 2006).  
 
 
1.12 Treatment 
As meningococcal disease can be fatal within a few hours of onset, admission to 
hospital or a health centre is necessary. Early recognition of disease prompts initial 
antibiotic treatment and intensive monitoring, which reduces the rate of 
meningococcal sepsis and fatality (Gardner, 2006). Effective antibiotic treatment 
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rapidly halts the proliferation of bacteria in the CSF and vascular system. Within 3-4 
hours of the administration of antibiotics, all meningococci in the CSF are killed and 
the concentration of endotoxin in plasma falls by approximately 50% (Brandtzaeg et 
al., 1989; Kanegaye et al., 2001; Ovstebo et al., 2004). The concentration of key 
cytokines and chemokines falls in parallel (Moller et al., 2005; van Deuren et al., 
1995). In general, antibiotics are given by the parenteral route. In developed countries, 
benzylpenicillin alone or a third generation cephalosporin remains the treatment of 
choice (Stephens et al., 2007). For patients who are allergic to penicillin, intravenous 
chloramphenicol can be given (Feldman and Zweighaft, 1979). The duration of 
treatment varies. A recent study of patients with serogroup B disease in New Zealand 
showed that a three-day treatment course with intravenous benzylpenicillin was 
sufficient and not associated with relapse (Ellis-Pegler et al., 2003; Latorre et al., 
2000). The resistance of meningococci against penicillin has been increasing 
worldwide since the late 1980s (Latorre et al., 2000). However, there is no evidence 
of any association between a poor clinical outcome and reduced susceptibility to 
penicillin. In developing countries, a single dose of ceftriaxone or chloramphenicol 
can be sufficient for the treatment of patients with meningococcal meningitis (Nathan 
et al., 2005). 
 
Treatments to increase the circulating blood volume, decrease blood coagulation or 
haemorrhage are given to patient to reduce mortality (Welch and Nadel, 2003). 
Attempts to inactivate meningococcal LPS and thereby block the inflammatory 
cascade have not been shown to significantly improve survival (Derkx et al., 1999; 
Levin et al., 2000). 
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1.13 Vaccines against serogroup A, C, Y and W135 meningococcal disease 
Over the past 80 years there have been many attempts to develop effective vaccines 
against the meningococcus, including the use of purified capsular polysaccharide, 
protein polysaccharide conjugates, outer membrane proteins, and reverse vaccinology 
(Girard et al., 2006; Harrison, 2006). Immunological correlates of protection, which 
can consistently predict immunity, are essential for evaluating the efficacy of 
vaccines. In studies conducted in US military recruits in 1969, Goldschneider showed 
that the presence or absence of serum bactericidal antibodies (SBA) against serogroup 
C N. meningitidis predicted the risk of subsequent disease in individuals, which 
established the SBA titre as a surrogate measure of immunity (Goldschneider et al., 
1969b). Subsequent studies revealed that the percentage of individuals with an SBA 
titre of ≥ 4 had an inverse relationship with the incidence of serogroup C disease 
(Goldschneider et al., 1969a). Commercially available baby rabbit complement is 
now recommended for standard bactericidal assays (SBAs) in evaluating the efficacy 
of vaccines. A SBA titre of ≥ 8 is accepted as a correlation of protection against 
meningococcal serogroup C strains (Borrow et al., 2001) .  
 
1.13.1 Polysaccharide vaccines 
The bactericidal activity of serum from healthy volunteers was abolished when 
antibodies against the capsular polysaccharide were removed by adsorbing serum 
with purified capsule. This result suggested that immune responses against the 
polysaccharide capsule were responsible for protection (Gotschlich et al., 1969). Thus, 
high molecular weight capsular polysaccharide was purified and used as a vaccine.  
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A serogroup C capsular polysaccharide vaccine proved effective in preventing 
serogroup C disease in military recruits in the USA, and in the 2-29 year age group 
during an outbreak in Texas (Artenstein et al., 1970; Rosenstein et al., 1998). 
Similarly, the efficacy of a serogroup A capsular polysaccharide vaccine in school-
aged children was about 89% during a serogroup A outbreak in Europe in 1970s 
(Wahdan et al., 1977). In the following decades, bivalent (A, C), and tetravalent (A, 
C, W-135, Y) combinations of purified capsular polysaccharides have been widely 
used to control outbreaks of meningococcal disease (Vodopija et al., 1983). More 
recently, a trivalent (A, C, W-135) vaccine was licensed against the emergent W-135 
serogroup of N. meningitidis, which causes epidemics in the countries of the 
meningitis belt (Sacchi et al., 2002).  
 
However, there are several limitations of polysaccharide vaccines. Firstly, capsular 
vaccines are poorly immunogenic in children less than 2 years old, who are most at 
risk of meningococcal disease. Secondly, waning levels of antibody are age-
dependent, with lower persistence and protective immunity in the younger age group. 
In addition, polysaccharide vaccines induce T-cell independent immune responses, 
and therefore fail to induce immunological memory. Finally, polysaccharide vaccines 
have limited effects on carriage rates (Girard et al., 2006). 
 
1.13.2 Polysaccharide/Protein conjugate vaccines 
The shortcomings of capsular polysaccharide vaccines are largely attributable to a 
lack of T cell-dependent responses, and can be overcome by incorporating a T cell-
dependent antigen into the polysaccharide. The introduction of the H. influenzae type 
b glycoconjugate vaccine successfully eradicated this disease in developed countries 
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(Robbins et al., 1996), and led to the application of the same strategy to 
meningococcal capsular polysaccharides. The carrier proteins used for meningococcal 
conjugate vaccines include tetanus toxoid proteins, diphtheria toxoid, and diphtheria 
cross-reactive material (CRM197) (Girard et al., 2006).  
 
Commercial meningococcal serogroup C conjugate vaccines, consisting of 
fractionated capsular polysaccharide linked to tetanus toxoid or CRM197, were 
introduced into the UK routine immunisation programme in 1999. These vaccines 
proved highly effective against serogroup C disease, with a 90% decrease in 
incidence across all age groups, and a 66% decrease in carriage (Balmer et al., 2002; 
Ramsay et al., 2003). In addition to the protection reported in the vaccinated 
population, the conjugate vaccine also reduces the incidence of disease in non-
vaccinated people by 67% through herd immunity (Ramsay et al., 2003). In recent 
years, serogroup C conjugate vaccines were licensed in Australia, Canada and in 
other European countries such as Spain (Welte et al., 2005). 
 
A tetravalent conjugate vaccine (MCV4) incorporating the polysaccharide capsule 
from serogroups A, C, Y and W-135 linked to diphtheria toxoid was licensed in the 
USA for people between 11-55 years of age in 2005 (Bilukha and Rosenstein, 2005). 
However, it is not recommended to routinely immunise children aged from 2-10 years 
of age unless the child is at increased risk for disease (2008).  
 
Currently, the World Health Organisation (WHO) and Meningitis Vaccine Project 
(MVP) are working to develop cheaper and cost-effective serogroup A conjugate 
vaccines to prevent epidemic disease in the African meningitis belt (Jodar et al., 
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2003). They are aiming to license the monovalent A conjugate vaccine for use in 
single-dose mass vaccination campaigns in approximately 400-500 million people 
aged 1 to 29, hopefully starting in 2008-2009 (Girard et al., 2006).  
 
 
1.14 Serogroup B vaccines  
There is no effective polysaccharide vaccine against serogroup B strains, as the 
serogroup B capsule is poorly immunogenic and has structural similarity to a 
polysialylated form of a neural cell adhesion molecule, NCAM-1 (Finne et al., 1983; 
Finne et al., 1987). Attempts have been made to replace the N-acetyl sialic acid 
residues of the serogroup B capsular polysaccharide with N-propionylated (NPR) 
groups in a conjugate vaccine, but no serum bactericidal activity was induced in 
human volunteers (Bruge et al., 2004; Pon et al., 1997). Consequently, vaccine 
research against serogroup B meningococci has focused on OMVs and OMPs.  
 
1.14.1 Outer membrane vesicles and proteins  
OMVs have been used to control prolonged serogroup B outbreaks, which tend to be 
caused by a single clone. The efficacy of OMV vaccines was first evaluated in the 
late 1970s using aggregated OMPs from OMVs, from which LPS had been depleted 
by treatment with detergents. Despite promising results in animal studies, this vaccine 
failed to induce bactericidal antibodies in either adults or children, which was 
probably due to the altered conformation of OMPs (Zollinger et al., 1978). Thus, a 
soluble OMV vaccine, in which the native conformation of OMPs was retained, was 
prepared by purifying OMVs from bacteria during growth and selectively removing 
LPS. Modest increases in SBA titres were found after immunisation of adults with 
 54 
this vaccine (Frasch and Peppler, 1982). Significantly increased immunogenicity was 
found by incorporating serogroup B polysaccharide into soluble OMVs (Yang et al., 
2007). In addition, a further increase in bactericidal titres resulted from the addition 
of aluminium hydroxide as an adjuvant (Frasch et al., 1988).  
 
A number of efficacy trials with serogroup B OMV vaccines have been conducted, 
with the two most extensively studies developed in Cuba and Norway. The B+C 
meningococcal vaccine licensed in Cuba in 1989 (commercially marketed as VA-
MENGOC-BC® by the Finlay Institute and GSK) consists of LPS-depleted OMVs 
from a B:4:P1.19,15 strain with serogroup C capsular polysaccharide in a high 
molecular weight complex, all adsorbed onto aluminium hydroxide. The vaccine was 
administered in two doses, and approximately 83% efficacy was observed. However, 
the efficacy of the vaccine is dependent on age, with very low protection in children 
less than 4 years old (de Moraes et al., 1992). A Norwegian serogroup B vaccine 
containing LPS-depleted OMVs from a serogroup B:15:P1.7,16 strain, adsorbed onto 
aluminium hydroxide, showed an efficacy of 57% in an trial conduced in secondary 
school children in Norway (Bjune et al., 1991a). In New Zealand, an OMV vaccine 
containing PorA, PorB and LPS from the New Zealand serogroup B strain (B:4:P1.7b, 
4) was licensed in 2004 for use in a national campaign immunisation (O'Hallahan et 
al., 2004). This vaccine successfully reduced the incidence of disease and raised 
bactericidal antibodies in 70% of children from 6 month of age in 90% of teenagers 
(Oster et al., 2005). 
 
PorA is the most abundant OMP in OMVs and sufficient to induce bactericidal 
antibodies following nasopharyngeal carriage, invasive meningococcal infection, and 
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immunisation with serogroup B OMVs (Idanpaan-Heikkila et al., 1995; Jones et al., 
1998; Rosenqvist et al., 1995). However, anti-PorA bactericidal antibodies are 
directed against the two longest external variable loops of the protein, and the 
protective immune response is serosubtype-specific (Idanpaan-Heikkila et al., 1995; 
van der Ley et al., 1991). Thus, single-strain based PorA vaccines are only able to 
prevent clonal disease outbreaks and not sporadic disease. To overcome this problem, 
an OMV vaccine containing PorA from six different prevalent serogroup B isolates 
was developed by the Rijksinstituut voor Volksgezondheid en Milieu (RIVM) in the 
Netherlands to cover 80% of disease-causing strains in the UK (Cartwright et al., 
1999). This hexavalent PorA-OMV vaccine is able to increase SBA titres by at least 
4-fold after a fourth doses of immunisation and elicit memory responses in 78-95% of 
children (Longworth et al., 2002). However, the effectiveness of a PorA-based 
vaccine is likely to be limited by the rapid evolution of antigenic variation of PorA in 
the meningococcal population under selective pressure and by the emergence of 
PorA-deficient meningococcal strains (Cartwright et al., 1999; van der Ende et al., 
2003).  
 
In addition to porins, a number of other OMPs are under investigation for their 
vaccine potential, such as class 5 proteins, Neisserial surface protein A (NspA), the 
iron regulated protein (FrpB) and transferrin binding proteins B (TbpB) (Ala'Aldeen 
et al., 1994; Martin et al., 1997; Rokbi et al., 1997). Immunisation with recombinant 
NspA was able to elicit bactericidal antibodies against serogroup B N. meningitidis, 
but it only killed about 50% of genetically diverse strains (Moe et al., 2001). Anti-
TbpB bactericidal antibodies have been found in sera from carriers and patients with 
meningococcal disease, but not from healthy individuals (Filatova and Gamzulina, 
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2000). Immunisation with affinity-purified Tbps from N. meningitidis was able to 
elicit bactericidal antibodies and to induce protection against challenge in mice 
(Ala'Aldeen and Borriello, 1996; Danve et al., 1993). However, a recent Phase I 
study showed that adults sera raised by recombinant TbpB purified from E. coli were 
not active in killing serogroup B strains (Danve et al., 1998). Furthermore, an OMP-
based vaccine with six PorA and five FrpB sequence variants could induce a 
protective immune response against most circulating Neisseria isolates (Urwin et al., 
2004).  
 
1.14.2 N. lactamica  
The cross-reactivity of immune responses between non-pathogenic Neisseria spp. and 
N. meningitidis provides another approach for vaccine development (Cann and 
Rogers, 1989; Kim et al., 1989; Troncoso et al., 2000). The carriage of N. lactamica 
often occurs in infants and young children, and the carriage rate declines with 
increasing age, which is in contrast to the age-specific carriage rate of N. meningitidis 
(Gold et al., 1978). Thus, carriage of N. lactamica is often thought to be important for 
the development of natural immunity (Troncoso et al., 2002). Immunisation with live 
N. lactamica elicits high titres of bactericidal antibodies and protects mice against 
challenge with live N. meningitidis (Li et al., 2006). Differences were found between 
different N. lactamica strains in their ability to induce protective immune responses, 
indicating the need to identify specific surface antigens responsible for cross-
reactivity.  
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1.14.3 Reverse vaccinology  
With the availability of the complete genome sequence, all proteins can be tested as 
vaccines without any prior selection based on their in vivo expression or role in 
virulence (Tettelin et al., 2000). This method of identification of vaccine candidates 
based on whole genome sequence has been termed “reverse vaccinology” (Pizza et al., 
2000; Rappuoli, 2001). There are approximately 2,158 ORFs in N. meningitidis 
serogroup B strain MC58 predicted by algorithms and whole-genome homology 
searches. Based on bioinformatic analysis, 570 ORFs were predicted to encode 
surface-exposed or secreted proteins, which are potential immunological targets 
because of their accessibility to antibodies. Taking advantage of recombinant DNA 
technology, genes encoding 334 candidates were successfully cloned in E. coli, 
expressed and purified as soluble recombinant proteins, and used to immunise mice 
(Pizza et al., 2000). Using assays including immunoblot, ELISA and fluorescence-
activated cell sorting (FACS), 91 novel surface-expressed proteins were identified. 
All sera were analysed for complement-mediated bactericidal activity, and 28 
recombinant proteins were identified as able to induce a protective immune response. 
The most promising antigens which elicited the highest bactericidal titres were 
evaluated for their sequence conservation in a large number of N. meningitidis strains 
of genetic and geographic diversity (Tettelin et al., 2000).  
 
One of these novel surface antigens, referred to as Genome-derived Neisserial 
Antigen (GNA), is lipoprotein GNA1870. GNA1870 has a predicted molecular mass 
of 27 kDa, and three variants have been identified based on the sequence of the gene 
in 71 strains (Masignani et al., 2003). Conservation within each variant ranges 
between 91.6% and 100%, while conservation between the variants can be as low as 
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62.8% (Jacobsson et al., 2006). The bactericidal activity against GNA1870 is variant-
specific, as serum raised against a recombinant form of one variant of the protein is 
effective in killing strains carrying the same variant but not strains carrying other 
variants (Welsch et al., 2004). A recent study showed that using OMVs prepared 
from a N. meningitidis strain over-expressing GNA1870 could elicit greater 
bactericidal antibodies than that induced by either GNA1870 or OMV alone (Hou et 
al., 2005). Recombinant lipoprotein rLP2086, a homologue of GNA1870 from a 
serogroup A strain Z2491, has similar effect to the rGNA1870 in its capacity to 
induce bactericidal antibodies against many serogroup B isolates (Fletcher et al., 
2004).  
 
Several other genome-derived antigens have been under investigation for their 
vaccine potential such as GNA2132 and GNA33. Immunisation of mice with 
recombinant GNA2132 failed to elicit bactericidal antibodies, but was able to protect 
sinfant rats against meningococcal bacteraemia after challenge with serogroup strain 
NZ394/98 (Welsch et al., 2003). Immunisation with GNA33 was able to elicit 
bactericidal antibodies against serotype P1.2 serogroup B strains, as a result of cross-
reaction with an epitope on loop IV of PorA, indicating that molecular mimetics have 
potential as meningococcal vaccine candidates (Granoff et al., 2001) 
 
1.14.4 Genetic Screening for Immunogens  
Based on the availability of the whole genome sequence of serogroup B N. 
meningitidis MC58 and in vitro mutagenesis technology, our group developed a new 
approach (Genetic Screening for Immunogens, GSI) to identify genes that encode 
surface expressed antigens that could be potential used as vaccine candidate (more 
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details are provided in the Chapter 3). Two independent mutants were identified with 
Tn5 transposon in ORF of nnmb1467. According to bioinformatic analysis, 
NMB1467 is a homologue to Escherichia coli exopolyphosphatase, an enzyme 
involved in cleavage single phosphate (Pi) from Inorganic polyphosphate (poly P).  
 
 
1.15 Inorganic polyphosphate  
Inorganic polyphosphate (poly P) is a linear chain composed of tens or many 
hundreds of orthophosphate (Pi) residues linked by high-energy phosphor-anhydride 
bonds (Figure 1.2) (Kornberg, 1999). Poly P was first isolated from yeast and 
subsequently found in all living cells including bacteria, fungi, protozoans, plants and 
animals (Wood and Clark, 1988). It has been found on the surface of cells, in the 
cytoplasm, and in the periplasm of microbes (Glonek et al., 1971). Various biological 
functions are associated with the presence of poly P, depending on its location and the 
bacterial species. For instance, poly P can act as a reservoir of energy and phosphate, 
as a chelator of metal ions (e.g., Mn
2+
 and Ca
2+
), as a buffer against alkali, as a 
regulator of gene expression and can promote competence for bacterial DNA uptake 
(Kornberg, 1999).  
 
 
Figure 1.2 Inorganic polyphosphate (Kornberg, 1999) 
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Poly P was first observed using light microscopy as metachromatic granules, when it 
stained pink by basic blue dyes (Kornberg, 1999). Poly P appears highly refractive 
and quickly vanishes under an electron beam (Ogawa and Amano, 1987). Nuclear 
magnetic resonance (NMR) analysis is also able to detect highly concentrated poly P, 
but not in aggregated forms or in metal complexes (Deslauriers et al., 1980).  
 
As a polyanion, poly P is able to bind to basic dyes, such as toluidine blue, and shift 
its absorption to a shorter wavelength (Kornberg, 1999). Similar to nucleic acids 
which are also polyanions, poly P can nonspecifically bind to basic proteins, such as 
histones and basic domains of proteins (Kornberg, 1999; Stros et al., 1984). Recently, 
it has been reported that poly P can specifically bind to the ATP-dependent protease 
Lon, which promotes the degradation of most ribosomal proteins and competence 
with DNA binding (Kuroda et al., 2001; Nomura et al., 2004).  
 
Polyphosphate kinase (PPK) was first enzyme purified to homogeneity from E. coli 
that catalyses the reversible conversion of terminal(γ) phosphate of ATP to poly P 
(Poly Pn + ATP ↔ poly Pn+1 + ADP) (Kornberg et al., 1956; Ahn and Kornberg, 
1990). This membrane protein is mainly responsible for the synthesis of longer chains 
of poly P, but in an excess of ADP, this enzyme can convert poly P to ATP (Ahn and 
Kornberg, 1990). PPK is highly conserved in most bacterial species including 
pathogens, but no PPK activity has been found in yeast or mammalian cells (Ault-
Riche et al., 1998). Recently, an actin-related protein complex was identified in 
mammalian cells, which synthesise poly P from GTP or ATP, and is called 
polyphosphate kinase 2 (PPK2) (Ishige et al., 2002; Zhang et al., 2002).  
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Aside from PPK, there are several enzymes involved in the utilisation of poly P (list 
in Table 1.1). For example, exopolyphosphatase (PPX) splits the terminal phosphate 
until only pyrophosphate (PPi) is left (poly Pn+ (n-2) H2O → (n-2) Pi + PPi) (Akiyama 
et al., 1993). Endopolyphosphatase (PPN) cleaves poly P internally to generate 
shorter chains of poly P and tripolyP (Kowalczyk and Phillips, 1993). 
Pyrophosphatase (PPA), which is traditionally considered to be responsible for the 
hydrolysis of pyrophosphate (PPi), has been recently shown to be able to catalyse the 
breakdown of poly P in Trypanosoma brucei (Lemercier et al., 2004).  
 
The importance of poly P in bacterial pathogens has been illustrated mainly in 
experiments with ppk mutants, which have decreased levels of cellular poly P. In E. 
coli, a ppk mutant has a defect in long term survival during stationary phase and is 
more sensitive to oxidative, osmotic and heat stresses (Rao and Kornberg, 1996). All 
the defects appear to be related to a decreased expression of rpoS, which encodes a 
sigma factor that controls the expression of more than 50 genes responsible for 
adaptation to stress and the survival in the stationary phase (Shiba et al., 1997). Poly 
P is also required for motility of bacterial pathogens such as Salmonella spp., 
Pseudomonas aeruginosa, Vibrio cholerae (Rashid et al., 2000). In addition, P. 
aeruginosa, poly P is necessary for swarming motility, twitching motility, quorum 
sensing and the development of biofilms (Rashid and Kornberg, 2000).  
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Table 1.1 Enzymes involved in inorganic polyphosphate metabolism 
Enzymes  Functions 
Polyphosphate kinase (PPK) Poly Pn + ATP ↔ poly Pn+1 + ADP 
Poly Pn + GDP → poly Pn-1 + GTP 
Poly Pn + GDP → poly Pn-2 + ppppG 
Polyphosphate kinase 2 (PPK2) Poly Pn + ATP ↔ poly Pn+1 + ADP  
Poly Pn +GTP ↔ poly Pn+1 + GDP 
AMP-phosphotransferase Poly Pn + AMP → poly Pn-1 + ADP 
Glucokinase  Poly Pn + glucose → poly Pn-1 + glucose-6-P  
Exopolyphosphtase (PPX) Poly Pn + (n-2) H2O → poly Pn-2 + PPi 
Endopolyphosphtase (PPN) Poly P750 + H2O → n poly P60 + 3n P3 
Pyrophosphatase (PPA) PPi→Pi + Pi 
Poly Pn + H2O → poly Pn-x + Px 
 
 
Due to its co-transcription with ppk, a mutant lacking only ppx has not been 
constructed in E. coli (Rao and Kornberg, 1996). In Bacillus cereus, a ppx mutant, 
which accumulates 1000-fold more of poly P than the wild-type, has defects in 
motility, biofilm formation and sporulation (Shi et al., 2004). However, in 
Saccharomyces cerevisiae, a mutant harbouring an inactivation of the gene encoding 
a major exopolyphosphatase (PPX1) has similar levels poly P as the wild-type strain 
(Lichko et al., 2002).  
 
The membrane localization of PPK in bacteria suggests that poly P might be made 
and localized at that site (Kornberg, 1999). In S. cerevisiae, poly P is found in nucleus, 
mitochondria, vacuole (lysosome), and cytosol (Lichko et al., 2006). In N. 
gonorrhoeae, more than 10% of cellular phosphate is present in the form of poly P 
and at least half of poly P is loosely associated with the cell surface and can be easily 
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washed off (Noegel and Gotschlich, 1983). The presence of cell surface poly P in 
addition to its polyanionic character suggests that it may form a protective layer 
around the cell, such as observed around N. gonorrhoeae as a pseudo-capsule (James 
and Swanson, 1977; Noegel and Gotschlich, 1983).  
 
According to the whole genome sequence of N. meningitidis serogroup B MC58 and 
protein blast, nmb0641 nmb1467 and nmb1900 encode PPA, PPX and PPK, respectively, 
which are enzymes involved in the metabolism of poly P (Tettelin et al., 2000). A ppk-
mutant of serogroup B N. meningitidis strain M1080, with reduced total poly P, was more 
sensitive to complement-mediated killing through unknown mechanisms (Tinsley et al., 
1993; Tinsley and Gotschlich, 1995), suggesting  a capsule-like function of poly P in N. 
meningitidis. 
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Aim of the thesis 
 
The function of nmb1467, loss of which renders serogroup B N. meningitidis MC58 
resistant against complement-mediated killing, has not been reported before. The 
aims of this study were to:  
1) identify meningococcal factors involved in interactions with the complement 
system by GSI, 
2) assess the vaccine potential role of NMB1467, 
3) investigate the biochemical function of this protein,  
4) understand the mechanisms of serum resistance of the ∆nmb1467 mutant. 
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Chapter 2 Materials and Methods 
 
2.1 Bacterial strains and growth conditions 
All N. meningitidis and E. coli strains used in this study are listed in Table 2.1. For 
overnight culture, N. meningitidis was grown on the Brain Heart Infusion (BHI) agar 
plates with Levanthal’s supplement in the presence of 5% CO2 at 37°C. To prepare 
Levanthal’s supplement base, 37 g of BHI broth (Oxoid) and 500 ml of horse blood 
(Oxoid) were dissolved in 1 litre H2O and autoclaved, and the supernatant was 
collected after centrifugation at 6000 xg at 4°C for 30 minutes. Aliquots were stored 
at -20°C. To make BHI agar plates, 37 g of BHI broth (Oxoid), 1 g of soluble starch 
and 15 g of bacteriological agar (1.5% wt/vol final concentration, Oxoid) were 
dissolved in 1 litre of H2O, autoclaved, and 50 ml of Levanthal’s base was added.  
 
E. coli was either grown in LB (20 g of Lennox L Broth base in 1 litre H2O, 
Invitrogen) liquid medium with shaking at 200 r.p.m or on LB agar plates (1.5% agar 
wt/vol) without shaking at 37°C. To make frozen stocks, bacteria were suspended in 
liquid medium used for growth with 15% glycerol, and stored at -80°C.  
 
 
Table 2.1 Bacterial strains and plasmids used in this study 
Strains/Plasmid  Genotype/Description   Reference 
N. meningitidis      
MC58  Wild-type serogroup B   (Tettelin et al., 
2000) 
Δnmb1467 (Δppx)  Insertional inactivation of nmb1467; 
kanamycin resistant  
 This study 
ΔsiaD  Insertional inactivation of siaD; 
erythromycin resistant  
 (Exley et al., 2005) 
 66 
ΔsiaD:ppx  Insertional inactivation of siaD and 
ppx 
 This study 
Δlst  Insertional inactivation of lst; 
tetracycline resistant  
 (Exley et al., 2005) 
Δlst:ppx  Insertional inactivation of lst and 
ppx 
 This study 
Δnmb1467com 
(Δppxcom) 
 Complemented Δnmb1467 with ppx  This study 
ΔppxE147A  Complemented Δppx with 
nmb1467
E147A
 
 This study 
Δppk  Insertional inactivation of ppk; 
tetracycline resistant 
 This study 
Δgna1870  Insertional inactivation of gna1870; 
tetracycline resistant 
 This study 
Δgna1870:ppx  Insertional inactivation of lst and 
nmb1467 
 This study 
E. coli      
TOP10   F
-
 mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX74 recA1 
araD139 ∆(araleu) 7697 galU galK 
rpsL (Str
R
) endA1 nupG  
 Invitrogen 
BL21(DE3)pLysE  F
-
 ompT hsdSB (rB
-
mB
-
) gal dcm 
(DE3) pLysE (Cam
R
) 
 Invitrogen 
TT24554  E. coli Top10/pHIS-ppk   (Price-Carter et al., 
2005) 
Plasmids     
pCR
®
2.1-TOPO
®
  Cloning vector   Invitrogen 
pET-15b  Vector for protein expression   Novagen 
pYHS25  Vector for complementation   (Winzer et al., 
2002) 
pnmb1467-pET-15b   pET-15b containing nmb1467  This study  
pnmb1467
E147A
-pET-
15b 
 pET-15b containing nmb1467 with 
modification at 147 residue  
 This study 
pnmb1467-pYSH25  pYSH25 containing nmb1467  This study 
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2.2 Antibiotics 
Antibiotics were used at following concentrations: for E. coli strains, 50 µg/ml of 
kanamycin, 50 µg/ml of ampicillin, 200 µg/ml of erythromycin and 15 µg/ml of 
tetracycline; for Neisseria strains, 100 µg/ml of kanamycin, 2.5 µg/ml of tetracycline 
and 2.5 µg/ml of erythromycin. To make stocks of higher concentrations, all the 
antibiotics were dissolved in H2O, with the exceptions of tetracycline that was 
dissolved in 70% ethanol, and erythromycin which was dissolved in 100% ethanol, 
filter sterilised, and aliquots kept at -80°C. 
 
 
2.3 Isolation of genomic DNA from N. meningitidis  
Between one quarter to one half loop (10 µl loop) of bacteria was harvested after 
overnight growth on solid media, and re-suspended in 567 µl of TE buffer (10 mM 
Tris, pH 7.6, 1 mM EDTA), 30 l of 10% SDS and 3 l of proteinase K (> 600 
mAU/ml, Qiagen). After a 1 hour incubation at 37°C, 100 l of 5 M NaCl and 80 l 
of cetyl-trimethyl-ammonium bromide (CTAB)/NaCl (10% CTAB, 0.7 M NaCl) 
were added to the mixture, and incubated at 65°C for 10 minutes. An equal volume of 
phenol was added to the mixture, which was mixed by inverting the tube several 
times, and centrifuged at 16,000 xg for 10 minutes. The aqueous layer was transferred 
to a clean tube, mixed with an equal volume of chloroform by inverting the tube, and 
centrifuged at 16,000 xg for 10 minutes. The top layer containing DNA was 
transferred to another clean tube, and the DNA was precipitated by adding 0.7 
volumes of isopropanol and centrifuged at 16,000 xg for 10 minutes. The DNA pellet 
was washed with 70% ethanol, and dried using DNA speed Vacuum DNA110 
(Savant, ThermoQuest). The DNA was re-suspended in distilled H2O. For Southern 
 68 
blot analysis, the DNA was further treated with 2 mg/ml RNAse A (100 mg/ml, 
Qiagen).  
 
To isolate plasmid DNA, the QIAprep Spin Miniprep Kit (Qiagen) was used 
following the protocol provided by the manufacturer. 
 
 
2.4 Restriction endonuclease digestion of DNA 
Restriction enzymes and buffers were either purchased from New England Biolabs or 
Invitrogen. Digestion of DNA was completed by mixing 1x restriction endonuclease 
buffer, 0.5 U/µl of restriction endonuclease and target DNA, and incubating the 
reaction mixture at the recommended temperature (in general, 37°C) for at least 1 
hour. For certain enzymes from New England Biolabs, 100 µg/ml of bovine serum 
albumin (BSA) was added to the reaction. 
 
 
2.5 Gel electrophoresis and purification of DNA from agarose gels 
Purified DNA was normally analysed by agarose gel electrophoresis. DNA samples 
were mixed with a 1/6 volume of 6x loading buffer (0.25% bromophenol blue, 30% 
glycerol, 0.25% xylene cyanol), and separated on 0.8% agarose gels in 1x Tris-
Acetate-EDTA (TAE) buffer (40 mM Tris, 20 mM acetic acid and 2 mM Na2-EDTA). 
The DNA was either stained with 0.1% ethidium bromide or 0.1% SYBR Green I 
(Invitrogen). The stained DNA was visualised under UV illumination and images 
were taken using the Gene Flash Bio Imaging System (Syngene, UK). 
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To recover DNA samples from agarose gels, the QIAEX II Gel Extraction Kit 
(Qiagen) was used following the protocol provided by the supplier. This kit was also 
used to clean DNA fragments from enzymatic reactions.  
 
 
2.6 Ligation of DNA 
Ligation of DNA fragments was performed in two different ways depending on the 
nature of the inserts and vectors. PCR products synthesised by Taq polymerase with a 
single 3’-A overhang were ligated to the TA cloning vector pCR®2.1-TOPO® 
(Invitrogen) directly according to manufacturer’s protocol. For other ligations, T4 
DNA ligase was required. Purified DNA fragments (1-10 µg/ml in total) with ratio of 
insert to vector ranging from 2:1 to 6:1 were incubated with a 1/20 volume of T4 
DNA ligase and ligase buffer. Using T4 ligase (5 U/µl, Invitrogen), the incubation 
was performed at 16°C from 1 hour to overnight, whereas, using Quick-Stick Ligase 
(10 U/µl, Bioline), the ligation was incubated for 5 minutes at room temperature.  
 
 
2.7 Transformation 
Chemically competent cells One Shot
®
 Top10 and One Shot
®
 BL21 (DE3) pLysE E. 
coli strains were purchased from Invitrogen for transformations. Ligation products or 
plasmids (5-10 µl) were added to competent cells, and the mixture incubated on ice 
for 15-30 minutes. After a brief heat-shock for 45 second at 42°C, the mixture was 
placed on ice immediately for 2 minutes. The cells were then incubated with 250 µl 
of rich medium SOC (Invitrogen) at 37°C with shaking at 200 r.p.m for 60 minutes. 
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Bacteria were plated on appropriate selective solid medium and incubated at 37°C 
overnight without shaking.  
To transform N. meningitidis, strains were grown on BHI agar plates overnight, and 
re-suspended in phosphate buffered saline (PBS). A small portion of the bacterial 
suspension (10 µl) was spotted on a BHI agar plate, and after 5-10 minutes, 5 µl of 
DNA was added and allowed to dry. Plates were next incubated at 37°C in the 
presence of 5% CO2. After 4-5 hours incubation, bacteria were re-streaked on BHI 
plates containing appropriate antibiotics, and incubated overnight at 37°C in the 
presence of 5% CO2. 
 
 
2.8 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) was used to amplify target genes from either 
genomic or plasmid DNA. PCRs containing 0.2 µM of each primer (listed in Table 
2.2), 200 µM dNTPs, a 0.1 volume of 10x PCR buffer, 2-50 ng of template DNA and 
2 U of Taq DNA polymerase (Sigma) were performed in a Perkin Elmer GeneAmp
®
 
System 9700 thermal cycler (Applied Biosystems, UK). Expand High Fidelity PCR 
System (Roche) was used to amplify DNA fragments for complementation or protein 
expression, and a long template PCR system (Roche) was used for products with size 
larger than 3 kb. Colony PCR was used for rapid screening of bacterial colonies. E. 
coli colonies were picked with sterile toothpicks, dabbed into the PCR mixture and 
directly used as the DNA template. N. meningitidis colonies were boiled in 50 µl of 
distilled H2O for 10 minutes, and the supernatant was used as the DNA template. 
Typical PCR conditions started with an initial step of denaturation at 95°C for 5 
minutes and followed by 30 cycles each of 30 seconds of denaturation at 95°C, 30 
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seconds of annealing at 55°C and 2 minutes of extension at 72°C (for fragments 
larger than 3 kb, 1 minute per 1 kb incubation at 68°C was used). The reaction ended 
with 7 minutes of extension at 72°C (or 68°C for if PCR product was larger than 3 
kb). PCR products were stored at 4°C overnight, or at -20°C for longer periods. 
 
Tables 2.2 Primers used in this study  
Name Sequence 
NG551 GCGCTAGCTGCCGTCGGCAACATCCGTGG  
(with a NheI site at the 5’ end) 
NG552 GCGGATCCTCAGACGGCCTCGACTTTGAACG  
(with a BamHI site at the 5’ end) 
NG559  GCCATATGACCACCACCCCCGCAAAC 
(with a NdeI site at the 5’ end)  
NG591 
 
GCGGATCCTCAGCCTCCGAGCAGTGT 
(with a BamHI site at the 5’ end) 
NG607 GGCGGTTCGACAGCATTTGTCATCGGCTCGACG  
NG608 CGTCGAGCCGATGACAAATGCTGTCGAACCGCC 
NG663 
 
GCCATATGCCGTCTGAAACCGGCGCA  
(with a NdeI site at the 5’ end) 
NG1153 GCGGATCCATGCCGTCTGAAACC 
(with a BamHI site at the 5’ end) 
NG1157 GCAAGCTTTATTTCGAGGGTAACAT 
(with a HindIII site at the 5’ end) 
NG1347 GGATCCATGCCGTCTGAACC 
(with a BamHI site at the 5’ end) 
NG1348 GAATTCGAACTCTCCACTCTCCAA 
(with a EcoRI site at the 5’ end) 
NG1349 GAATTCCAAGTATACAAACAAAGCC 
(with a EcoRI site at the 5’ end) 
NG1350 TTCGAATTATTGCTTGGCGGCAAG 
(with a BstBI site at the 5’ end) 
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2.9 Southern analysis  
RNA-free genomic DNA was digested with ClaI and DraI separately at 37°C. The 
digested DNA was separated overnight by agarose gel electrophoresis at 15 V with 
DNA ladders on both sides of the digested samples. The gel was washed in H2O and 
equilibrated in depurination buffer (0.25 M HCl) by slow shaking for 12 minutes. 
After rinsing in H2O briefly, the gel was immersed in denaturing buffer (0.5 M NaOH, 
1.5 M NaCl) for 15-18 minutes, then equilibrated in neutralising solution (1 M Tris, 3 
M NaCl) for 15-18 minutes. A nitrocellulose membrane (10 cm x 15 cm, Hybond N+, 
Amersham) was pre-wetted in H2O for 30 seconds, soaked into 20x SSC (3 M NaCl, 
0.3 M C6H8NaO7, pH 7.0). The DNA gel was covered with the membrane without 
any air bubbles. Three pieces of Whatman paper (Fisher) pre-soaked in 20x SSC were 
placed on top of the membranes followed by three pieces of dry Whatman paper. 
Transfer of DNA from the gel to the membrane was completed in 4 hours, and the 
DNA was fixed by exposing membranes to UV light for 30 seconds. The membrane 
was soaked in 2x SSC buffer for a few seconds and washed in a hybridisation tube 
with solution containing 0.5% SDS and 0.1x SSC for 20 minutes at 65ºC. Alkphos 
Direct Labelling (Amersham) was used to label DNA probes following the 
instructions provided by the manufacturer. DNA probes (10 ng/µl) were denatured by 
heating at 100°C for 5 minutes, and then placed on ice immediately. The probes were 
mixed gently with 10 µl of reaction buffer, 2 µl of labelling reagent, and 10 µl of 
cross linker (diluted 1:5 in H2O), spun briefly, and incubated at 37°C for 30 minutes. 
The labelled DNA probes could be used immediately or kept on ice for up to 2 hours. 
When the probe was ready, the membrane was pre-incubated with hybridisation 
buffer (0.5 M NaCl, 4% blocking reagent, Amersham) at 55°C for at least 15 minutes, 
then hybridised with labelled probes (5-10 ng/ml) at 55°C overnight in a 
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hybridisation oven. The membrane was carefully transferred to another clean 
hybridisation bottle and washed with pre-heated buffer (0.2 M urea, 0.1% SDS, 0.05 
M sodium phosphate pH 7.0, 1 mM MgCl2, 0.2% blocking reagent) at 55°C for 10 
minutes. The membrane was washed twice with buffer (1 M Tris-HCl, pH 10, 2 M 
NaCl) at room temperature, and then placed in an X-ray film cassette. Signals on 
Southern blots were visualised on Hyperfilm film by autoradiography (Amersham). 
 
 
2.10 DNA sequencing 
DNA samples were mixed with 3.2 pmol of primer and diluted with H2O to a final 
volume of 10 µl and sent to sequencing service centre at Imperial College London. 
 
 
2.11 Real time-PCR 
Bacteria were grown in 10 ml of liquid BHI with shaking at 150 r.p.m for 4 hours to 
mid-logarithmic phase, and were harvested by centrifugation at 15,000 xg for 5 
minutes. Total RNA was extracted using the RNeasy Mini
®
 Kit (Qiagen), and cDNA 
was synthesised from RNA using QuantiTec Rev Transcription Kit (Qiagen). 
Transcription levels were measured by qrtRT-PCR using QuantiTect SYBR Green 
PCR Kit (Qiagen) on a thermal cycler (Rotor-Gene 3000; Corbett Research).
 
Data 
were analysed using the comparative quantitation method
 
by Rotor-Gene software 
(version 6.0; Corbett Research). Controls
 
included reactions with no template and 
samples of RNA that
 
had not been treated with RT. qrtRT-PCRs were performed in 
triplicate
 
on cDNA samples derived from three independent cultures.
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2.12 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Polyacrylamide gels were prepared using a Mini-
Protean II gel apparatus (Bio-Rad) and were run in SDS-PAGE buffer (200 mM 
glycine, 248 mM Tris, 34 mM SDS) at 120 V for 1-2 hours. Reagents used to make a 
12% polyacrylamide gel are listed in the following table.  
 
Table 2.3 Reagents for 12% polyacrylamide gel  
 Separating buffer (5ml) Stacking buffer (1.5ml) 
30% Acrylamide (Bio-Rad)  2 ml 225 µl 
1.5 M Tris-HCl  1.25 ml, pH 8.8 125 µl, pH 6.8 
10% SDS 375 µl 11.25 µl 
dH2O 1.75 ml 1.125 ml 
10% APS 16 µl 15 µl 
TEMED 3.5 µl 1.5 µl 
 
 
2.13 Staining and de-staining of polyacrylamide gel 
Polyacrylamide gels were immersed in Coomassie blue staining buffer (0.2% 
Coomassie blue R-250, 40% ethanol, 10% glacial acetic acid) with slow shaking at 
room temperature for at least 10 minutes. De-staining of gels was completed by 
incubation in de-staining buffer I (40% methanol, 10% glacial acetic acid) for 10 
minutes and with de-stain buffer II (10% glacial acetic acid, 4% glycerol) overnight.  
 
 
2.14 Preparation of whole cell lysates of N. meningitidis  
N. meningitidis strains were harvested after overnight growth on BHI agar plates and 
re-suspended in PBS. The concentration of the bacterial suspension was determined 
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by measuring the optical density (O.D.) of a mixture containing 20 µl of the bacterial 
suspension and 980 µl of lysis buffer (1 M NaOH, 1% SDS) at 260 nm using a UV-
VIS specphotometer (Shimadzu UK). The bacterial suspension was adjusted to 10 x 
10
9
 CFU/ml, mixed with an equal volume of 2x SDS-PAGE loading buffer (100 mM 
Tris-HCl pH 6.8, 20 µM β-mercaptoethanol, 4% SDS, 0.2% bromophenol blue, 20% 
glycerol), and boiled for 10 minutes. The samples were centrifuged at 16,000 xg for 
20 seconds, and 10 or 20µl of samples was analysed by SDS-PAGE.  
 
 
2.15 Western blot analysis 
When proteins were separated on 12% polyacrylamide gel, one piece of 7cm x 9 cm 
Immobilon Polyvinylidene Fluoride (PVDF) membrane (Millipore) pre-wetted with 
methanol, and two fibre pads (Bio-Rad) and two pieces of Whatman paper (VWR) 
were soaked in cold wet blot transfer buffer (48 mM Tris, 39 mM glycine, pH 8.3) 
before use. To transfer proteins from gels to PVDF membranes, one pad and one 
piece of wet Whatman paper were put on the dark side of the gel transfer holder 
cassette. Then the polyacrylamide gel and PVDF membrane, wet Whatman paper and 
a fibre pad were placed on top of each other in that sequence. Transfer of proteins 
was performed at 70 V for 1 hour using a Mini Trans-Blot Cell (Bio-Rad). The PVDF 
membrane was blocked in PBS with 5% milk at room temperature for 1 hour or at 
4°C overnight. Next, the membrane was rinsed with PBS and incubated with the 
primary antibody diluted in PBS containing 1% milk with slow shaking. The 
concentration of and incubation time of primary antibodies were optimised for each 
antibody. After incubation with the primary antibody, membranes were washed three 
times in PBS containing 0.1% Tween-20 (PBS-T) for 10 minutes at room temperature. 
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Membranes were incubated with 1:1,000 diluted anti-mouse, anti-goat, or anti-human 
horseradish peroxidase conjugated immunoglobulin G (DakoCytomation, UK) for 1 
hour at room temperature with shaking. After another three washes with PBS-T, 
membranes were incubated with ECL Western blot detection reagent (Amersham) for 
1 minute at room temperature. After removing excess detection reagent, membranes 
were wrapped in SaranWarp, placed in an X-ray film cassette, and exposed to an 
autoradiography Hyperfilm film (Amersham). 
 
 
2.16 Flow cytometry analysis (FACS) 
N. meningitidis was harvested after overnight growth on BHI plates, and 2 x 10
7
 CFU 
bacteria were fixed with 3% paraformaldehyde (PFA) at room temperature for 20 
minutes. The fixed bacteria were washed three times with PBS-T and incubated with 
50 µl PBS containing the primary antibody at 37°C for 30 minutes. After three 
washes with PBS-T, bacteria were incubated with a secondary, FITC-conjugated 
antibody that was 1:100 diluted in PBS at 4°C for 30 minutes in the dark. After three 
washes, bacteria were re-suspended in 500 µl of PBS. Binding of the secondary 
antibody to meningococci was detected by flow cytometry using FACSCalibur 
machine (Becton Dickinson). 
 
 
2.17 Whole cell enzyme linked immunosorbent assay (ELISA)  
N. meningitidis was harvested after overnight growth on solid medium, re-suspended 
in PBS, and killed by heating at 56°C for 1 hour. Bacteria were re-suspended in 
ELISA coating buffer (Sigma), and 100 µl of bacterial suspension (10
8
 CFU) were 
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coated onto each well of ELISA plates (Maxisorb, NuncTM) at 4°C overnight. The 
wells were washed three times with 200 l of PBS-T, and incubated with 100 µl of 
PBS containing different concentrations of the primary antibody at 37°C for 1 hour. 
The unbound primary antibody was removed by three washes with PBS-T, and the 
wells were incubated with the HRP-conjugated, secondary antibody diluted 1:100 in 
PBS at 37°C for 1 hour. After three washes, 100 µl of substrate (0.4 mg/ml o-
phenylenediamine dihydrochloride, 0.4 mg/ml urea hydrogen peroxide and 0.05 M 
phosphate-citrate, pH 5.0) was added to each well, and incubated at room temperature 
for 10-15 minutes. Reactions were stopped by the addition of 100 µl of 3 M HCl, and 
absorbance was read at 492 nm.  
 
 
2.18 Over-expression of recombinant NMB1467 in E. coli  
For protein expression, E. coli BL21 cells carrying the pnmb1467-pET-15b were 
grown overnight in the LB liquid medium with 50 µg/ml ampicillin at 37°C with 
shaking. Bacteria were sub-cultured into fresh LB culture to give an initial O.D. A600 
of 0.1. After 1.5-2 hours incubation at 37°C with shaking, the O.D. A600 of cultures 
reached approximately 0.6, and isopropyl-D-thiogalactoside (IPTG) was added to a 
final concentration of 1 mM. Protein samples from bacteria were separated by SDS-
PAGE, and the over-expression of recombinant protein was analysed by Coomassie 
blue staining and Western blot analysis using a HRP-conjugated anti-His monoclonal 
antibody (Qiagen).  
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2.19 Antibodies 
A list of antibodies used in this work is shown in Table 2.4. 
Table 2.4 Antibodies used in this work 
Antibody Isotype Reference 
Anti-penta His HRP conjugate Mouse, monoclonal  Qiagen 
Anti-meningococcal serogroup B Mouse, monoclonal NIBSC 
Anti-meningococcal immunotype L3,7,9  Mouse, monoclonal  NIBSC 
3F11 Mouse, monoclonal  Gift (M. Apicella) 
FITC-conjugated goat anti-C3 polyclonal EMD 
Anti-human C5b-9 Rabbit, polyclonal Calbiochem 
Anti-human factor H Goat, polyclonal Calibochem 
Anti-RecA Rabbit, polyclonal Gift (D. Holden) 
Anti-rNMB1467 Mouse, serum This study 
Anti-rGNA1870 Mouse, serum Gift (YW. Li) 
 
 
2.20 Purification of recombinant NMB1467 
After 3-4 hours incubation with 1 mM IPTG, bacteria over-expressing recombinant 
protein were harvested by centrifugation at 4,000 xg at 4°C for 30 minutes. The 
bacterial pellet was either directly used for protein purification or stored at -80°C 
until use. Bacteria were re-suspended in 10 ml of washing/equilibration buffer (500 
mM sodium phosphate, pH 7.0, 300 mM NaCl), and lysed in a French press (three 
times at 1,500 p.s.i). Intact cells and the insoluble fraction were removed by 
centrifugation at 17,000 xg at 4°C for 1 hour. The supernatant was filtered using a 0.4 
µm pore and applied to a 1 ml volume of Nickel-Sepharose High performance pre-
packed HisTrap™ column (GE healthcare), pre-equilibrated with 
washing/equilibration buffer. The column was washed with 15 ml of 
washing/equilibration buffer to remove non-specifically bound proteins. The over-
expressed rNMB1467 with His-tag was eluted with washing/equilibration containing 
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200 mM imidazole. Samples collected from different steps were analysed by SDS-
PAGE followed by Coomassie blue staining and Western blot analysis using anti-
penta His HRP conjugated mAb.  
 
 
2.21 Estimation of protein concentration  
Protein concentrations were determined using the Bradford reagent (Sigma) following 
the manufacturer’s protocol. For purified recombinant, BSA (New England Biolab) 
diluted in washing/equilibration buffer with 200 mM imidazole was used as a 
standard. 
 
 
2.22 Construction of nmb1467
E147A
 
The point mutation in nmb1467 was constructed using Quick Change Site-Direct 
Mutagenesis Kit (Stratagene). The gene encoding NMB1467
E147A
 was amplified by 
PCR using pnmb1467-pET-15b as DNA template, PfuTurbo DNA polymerase and 
primers NG607 and NG608. The PCR product was digested with 1 U/µl of DpnI at 
37°C overnight, and transformed into TOP10 cells. The mutated gene was verified by 
DNA sequencing, and then the corresponding plasmids were transformed in to BL21 
cell for protein over-expression and purification as described above.  
 
To construct complemented Δnmb1467E147A strain, plasmid pnmb1467
E147A
-pET-15b 
was digested SmaI and BamHI sequentially. The DNA fragment containing 
nmb1467
E147A 
point mutation was recovered from an agarose gel, and ligated into 
pnmb1467-YHS25 digested with the same enzymes. The ligation product was 
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transformed into TOP10 competent cells, and plasmids were analysed. The mutation 
was verified by DNA sequencing, and pnmb146
E147A
-pYSH25 was used for 
transformation of N. meningitidis.  
 
 
2.23 Generation of polyclonal anti-serum against recombinant NMB1467 
The immunisation of mice to generate polyclonal anti-serum against rNMB1467 was 
performed by Dr. YW Li. Six- to eight-week-old BALB/c mice (Harlan, UK) were 
immunised by subcutaneous inject with 20 µg of rNMB1467 in 100 µl of PBS mixed 
with 100 µl of Freund’s incomplete adjuvant. Booster doses were given on days 21 
and 28 post-immunisation. On day 35, blood was obtained by cardiac puncture under 
terminal anaesthesia, and sera were collected by centrifugation at 2,000 xg at 4°C for 
20 minutes. Sera containing antibody were aliquoted and kept at -80°C. 
 
 
2.24 Extraction of LPS from N. meningitidis  
N. meningitidis strains were harvested after overnight growth on BHI agar plates and 
re-suspended in PBS. Bacterial suspensions were adjusted to 6 x 10
9
 CFU/ml and 
mixed with an equal volume of 2x LPS loading buffer (100 mM Tris-HCl, pH 8.0, 6% 
β-mercaptoethanol, 6% SDS, 0.2% bromophenol blue, 46% glycerol, 10 mM 
dithiothreitol), and boiled for 10 minutes. Proteins in the mixture were digested with 
0.1 mg/ml proteinase K at 37°C overnight. Prior to loading, the samples were boiled 
for 10 minutes and treated with 0.1 mg/ml proteinase K at 56°C for another 3 hours.  
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2.25 Electrophoresis and staining of LPS 
Tricine sodium dodecyl sulphate-polyacrylamide gel electrophoresis (TSDS-PAGE) 
was used to obtain high resolution separation of LPS. The reagents used to make the 
16% of separating gel and the stacking gel are listed in Table 2.5. Electrophoresis of 
LPS was the same as SDS-PAGE except for the running buffers and voltage. The 
anode buffer (0.2M Tris-HCl, pH 8.9) was filled carefully into the inner chamber of a 
Mini-PROTEAN 3 cell (Bio-Rad) and the cathode buffer (0.1 M Tris-HCl, pH 8.25, 
0.1 M Tricine, 0.1% SDS) was added to the rest of the tank. Samples were run in the 
stacking gel at 15 V, then separated in the separating gel at 90-150 V. LPS were 
visualised using a Silver Staining Kit (GE Healthcare).  
 
Table 2.5 Reagents for 12% Tricine-SDS polyacrylamide gel 
 Separating buffer (5ml) Stacking buffer (1.5ml) 
30% Acrylamide (Bio-Rad)  2 .67ml 225 µl 
1.5 M Tris-HCl  1.25 ml, pH 8.8 125 µl, pH 6.8 
10% SDS 375 µl 11.25 µl 
Urea 1.2 g - 
dH2O To make up to 5 ml 1.125 ml 
10% APS 16 µl 15 µl 
TEMED 3.5 µl 1.5 µl 
 
 
2.26 Bacterial growth curves 
N. meningitidis strains were harvested after overnight growth on BHI agar plates and 
re-suspended in PBS. The suspension was centrifuged at 1,000 xg for 2 minutes and 
the supernatant was transferred to a new tube. The concentration of bacteria was 
determined by measuring the O.D. at 600 nm. The suspension was diluted to a O.D. 
A600 of 0.1 in 10 ml of BHI liquid, and the culture was incubated at 37ºC with 150 
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r.p.m. Bacterial samples were taken every hour to measure the O.D. at 600 nm, and 
the number of CFU was determined by plating the aliquots of the culture to solid 
media and counting the number of colonies after overnight incubation. 
 
 
2.27 Serum bactericidal activity assay (SBA) 
N. meningitidis strains were harvested after overnight growth on BHI agar plates and 
re-suspended in PBS. The suspension was centrifuged at 1,000 xg for 2 minutes, and 
the supernatant transferred to a new tube. The concentration of bacteria was 
determined by measuring the O.D. at 260 nm of the mixture of the bacterial 
suspension in lysis buffer as above. The bacterial suspension was diluted in SBA 
buffer (PBS with 0.1% glucose) to a final concentration of 2 x 10
4
 CFU/ml and 
incubated with an equal volume (12.5 µl per well in a 96-well plates) of baby rabbit 
complement (Pelfreeze, US) diluted 1:4 in SBA buffer, and 25 µl of serial dilutions of 
sera in SBA buffer at 37°C for 1 hour in the absence of CO2. The number of 
surviving bacteria was determined by plating 10 µl of each well onto solid medium 
and counting the colonies after overnight incubation. The bactericidal activity was 
expressed as the reciprocal of the dilution of sera required to kill more than 50% of 
bacteria. 
 
 
2.28 Human serum sensitivity assay  
Bacterial strains were grown on BHI agar plates overnight and re-suspended in PBS. 
After centrifugation at 1,000 xg for 2 minutes, the bacterial suspension was 
transferred to a new tube. Bacteria were diluted to a final concentration of 1 x 10
5 
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CFU/ml in DMEM-glutaMAX
TM
 medium (Invitrogen), and incubated with different 
concentrations of normal human sera (NHS) at 37°C in the presence of CO2 for 1 
hour. Serum was heated at 56°C for 30 minutes to inactivate complement as required. 
The survival of bacteria in the presence of sera was determined by plating aliquots 
onto BHI plates and counting the number of colonies after overnight incubation.  
 
 
2.29 Quantification of poly P 
The concentration of poly P was quantified by two different methods based on the 
metachromatic reaction with toluidine blue (Mullan et al., 2002) and the activity of 
PPK (Ault-Riche et al., 1998).  
 
Method 1: Samples (10 µl) were added to 990 µl of 6 mg/L toluidine blue in 40 mM 
acetic acid. The O.D. of the mixture was read at 530 and 630 nm.  
 
Method 2: Samples were converted to ATP by incubation with 50 mM Tris-HCl, pH 
7.4, 40 mM ammonium sulphate, 4 mM MgCl2, 5 μM ADP and 24,000 U of PPK in a 
100 µl ATP reaction at 37°C for 40 minutes, and then at 90°C for 2 minutes. The 
concentration of resulting ATP was quantified by mixing an equal volume of the ATP 
reaction with CellTiter-Glo
®
 Reagent (Promega), and measuring the luminescence 
using a luminometer (Turner Designs). The concentration of poly P is given in terms 
of Pi residues.  
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2.30 Exopolyphosphatase activity assay 
The activity of purified recombinant NMB1467 was measured by the loss of standard 
poly P75 by the toluidine blue assay. A 100 µl reaction containing 50 mM 
Tricine/KOH (pH 8.0), 175 mM KCl, 15 mM poly P75, 1 mM MgCl2 and 
recombinant rNMB1467 was incubated at 37°C for 30 minutes. The concentration of 
poly P75 was determined using the toluidine blue assay. To determine the kinetics of 
rNMB1467 activity, different concentrations of protein were added to the reaction 
buffer.   
 
 
2.31 Polyphosphate kinase activity  
Purified protein was assayed in a 250 μl reaction volume consisting of 50 mM Tris–
HCl buffer, pH 7.0, 40 mM glycylglycine-KCl, 10 mM potassium phosphate (pH 7.0), 
10 mM MgCl2, 15% (v/v) glycerol, 2.5 mM ATP and 3 mM poly P75. To avoid 
inhibition of PPK by ADP formed during the reaction, 6 mM of phosphoenolpyruvate 
and 10 U of pyruvate kinase were also added to the assay mixture to permit the 
regeneration of ATP. The increased poly P concentration was subsequently 
determined using the toluidine blue assay. 
 
 
2.32 Extraction of poly P from N. meningitidis 
Poly P was extracted from N. meningitidis by two different methods according to 
reports by Tinsley (Tinsley et al., 1993) and Ault-Riché (Ault-Riche et al., 1998).  
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Method 1: N. meningitidis strains were harvested in PBS from BHI plates after 
overnight incubation. Bacteria were centrifuged at 16,000 xg for 5 minutes, and the 
pellet was re-suspended in 5.4% sodium hypochloride solution (7.5 ml/g of cells) 
with stirring at room temperature for 45 minutes. The cell debris containing poly P 
was collected after centrifugation at 16,000 xg for 30 minutes, and washed twice with 
ice-cold 1.5 M NaCl with 1 mM EDTA. Poly P was extracted twice with cold water 
with an equal volume sodium hypochlorite, poly P then precipitated by the addition 
of a 1/50 volume of 5 M sodium chloride, washed with 70% ethanol, and finally re-
suspended in 100 µl of 10 mM Tris-HCl, pH 7.5.  
 
Method 2: N. meningitidis strains were harvested into PBS from BHI plates after an 
overnight incubation. Bacteria (2 x 10
9
 CFU) were re-suspended in 0.5 ml of GITC 
lysis buffer (4 M guanidine isothiocyanate, 50 mM Tris-HCl, pH 7.0, pre-warmed to 
95°C), vortexed briefly and incubated in a heat block at 95°C for 5 minutes. The 
bacterial suspension was sonicated for 30 seconds at 12 W (Bandelin Sonoplus), and 
added with 30 μl of 10% SDS, 0.5 ml of 95% ethanol and 5 μl of Glassmilk (Sigma). 
The mixture was vortexed briefly and centrifuged at 16,000 xg for 2 minutes. The 
pellet was washed twice with 0.5 ml of cold New Wash buffer (5 mM Tris-HCl, pH 
7.5, 50 mM NaCl, 5 mM EDTA, 50% ethanol) by sonication. The washed pellet was 
then re-suspended in 100 μl of 50 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 20 μg/ml 
DNase and RNase, and incubated at 37°C for 10 minutes. After centrifugation, the 
pellet was washed with 150 μl of 4 M GITC lysis buffer and 150 μl of 95% ethanol 
once and New Wash buffer twice. Poly P was eluted from the pellet with 50 μl of 50 
mM Tris-HCl, pH 8.0, at 95°C for 2 minutes; recovery of poly P was completed by 
two additional elutions. 
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2.33 Crystallisation of native rNMB1467 
Following purification, rNMB1467 was dialysed against buffer containing 20 mM 
Tri-HCl, pH 8.0, 200 mM NaCl, 5 mM DTT and 5 mM pentasodium triphosphate 
using a Slide-A-Lyzer 10 MWCO Dialysis Cassettes (Pierce) at 4°C overnight. The 
dialysed protein was concentrated to 10 mg/ml using an Amicon
®
 Ultra10K 
Centrifugal Filter devices (Millipore) at 4°C, and used for a broad search of 
crystallisation conditions.  
 
The crystallisation of all PPX structures was carried out using the sitting drop vapour 
diffusion methods (Chayen, 1998). The initial crystallisation screen was performed 
using commercial available plates (Table 2.6).  
 
After optimisation, the diffraction of PPX crystals were tested on the Rigaku RU-
H3RHB model X-ray generator in Imperial College, a rotating anode technique based 
generator, prior to data collection at the SRS synchrotron in Daresbury, UK.  
 
          Table 2.6        Plates with buffers used for the initial crystallisation screen 
Plate ID Screen Company 
ICL1 Crystal Screen 1 & 2 Hampton Research 
ICL2 Wizard Screen 1 & 2 Emerald BioSystems 
ICL3 PEG/Ion & Natrix Hampton Research 
ICL4 Index Hampton Research 
ICL5 SaltRX Hampton Research 
ICL6 Mem-Start & Mem-Sys Molecular Dimensions Ltd 
ICL7 PACT Molecular Dimensions Ltd 
ICL8 JCSG+ Molecular Dimensions Ltd 
ICL9 MemGold Molecular Dimensions Ltd 
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2.34 Crystal mounting and freezing techniques 
To reduce radiation damage, X-ray data collection was carried out at cryogenic 
temperature, which allowed data to be collected from a singe crystal. This effect is 
due to the fact that by lowering the temperature to about 100K, diffusional processes 
and therefore propagation of highly reactive agents within crystals are slowed down 
or virtually eliminated.  
 
Nylon loops (0.2-0.4 mm, Hampton Research) were attached to CrystalCap Copper 
Magnetic bases (Hampton Research) using adhesive. A single crystal was fished out 
from the well using loops, briefly dipped into a drop appropriate cryo-protectant 
(mother liquor containing 15% glycerol) on a small cover slip. The CrystalCap was 
then transferred onto the goniometer, which is mounted onto the X-ray generator, and 
crystal is rapidly frozen in a gaseous stream of nitrogen (100K).  
 
 
2.35 Statistics 
Data were compared by the Student’s t test. Differences with p values of < 0.05 were 
considered significant. 
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Chapter 3 Identification and evaluation of rNMB1467 as a vaccine 
candidate 
 
3.1 Strategy of GSI 
Meningococcal disease remains a leading cause of childhood mortality and morbidity 
(Rosenstein et al., 2001; Stephens et al., 2007). In addition to antibiotic treatment, 
vaccination would provide an alternative and effective approach to combat 
meningococcal infection (Jodar et al., 2002). Unlike the polysaccharide capsules of 
serogroup A, C, W-135 and Y N. meningitidis, which have been successfully 
included in conjugate vaccines to reduce the global disease burden, the capsule of 
serogroup B shares antigenic similarities with neural tissue and is a poor immunogen 
in humans (Balmer et al., 2002; Bilukha and Rosenstein, 2005; Finne et al., 1987). 
The use of vaccines based on the PorA is effective in diminishing disease caused by 
strains with the corresponding serosubtypes, but is hindered by the genetic diversity 
of PorA (Idanpaan-Heikkila et al., 1995). Reverse vaccinology is based on bacterial 
genome sequencing and computer algorithms but is totally reliant on murine immune 
responses (Pizza et al., 2000; Rappuoli, 2001).  
 
Therefore, the production of a universal and safe vaccine against serogroup B N. 
meningitidis remains a challenge. An alternative strategy named GSI was developed 
by our group to identify the targets of bactericidal antibodies, which can be used as 
vaccine candidates, and to further understand the interaction between the 
meningococcus and the complement system.  
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In GSI, a library of insertional mutants of N. meningitidis was constructed and then 
screened for strains which are less susceptible to killing by bactericidal antibodies in 
human immune serum. It was anticipated that insertional inactivation of genes 
encoding important antigens recognised by antibodies in immune sera would at a 
selective advantage compared with the wild-type parental strain in the presence of 
bactericidal antibodies. Therefore, this approach should identify bacterial factors 
which modulate resistance against complement and/or might isolate important 
antigens on the bacterial surface (Figure 3.1A). Due to the availability of its complete 
genome sequence, MC58, a serogroup B ET-5 isolate of N. meningitidis, was used as 
the parental strain in these experiments (Tettelin et al., 2000). A library containing 
40,000 mutants was generated by in vitro mutagenesis with Tn5 (Sun et al., 2000). 
The diversity of transposon insertions in mutants was confirmed by performing 
Southern analysis on 30 mutants selected at random from the library. Genomic DNA 
was prepared from the mutants and digested with ClaI or DraI. The DNA fragments 
were transferred to membranes that were then probed with the kanamycin resistance 
cassette. As there is ClaI recognition site within the kanamycin cassette, two bands 
are recognised in DNA digested with this enzyme. The 30 mutants all had distinct 
fragments recognised by Southern analysis, demonstrating that in vitro mutagenesis 
with Tn5 generates a wide diversity of insertions in N. meningitidis (Figure 3.1B).  
 
To avoid PorA-mediated immune responses, acute and convalescent sera were 
obtained from patients who had been infected with N. meningitidis isolates expressing 
different serosubtypes from MC58 (B:15:P1.7,16b) and vaccinees given outer 
membrane vesicles prepared from N. meningitidis isolate H44/76 (B:15:P1.7,16) 
(Moe et al., 2002; Sorhouet Pereira et al., 2008). All the selected sera were tested 
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against MC58, and proved to have bactericidal antibodies with SBAs of > 1:64 when 
using a 1:4 dilution of baby rabbit complement (data not shown).  
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Figure 3.1 Strategy of GSI  
(A) GSI. Bacteria express targets (blue triangles) of bactericidal antibodies (blue inverted Y) 
on their surface. In a library of mutants, the transposon (red cross) may insert in the gene 
(blue box) encoding an important surface antigen. Loss of this target may enable bacteria to 
escape recognition of corresponding bactericidal antibodies and subsequent bacterial lysis. 
(B) Southern blot analysis of the diversity of mutants generated by Tn5 mutagenesis. 
Genomic DNA was extracted from 30 mutants selected at random from library, digested with 
ClaI or DraI and probed with the kanamycin resistance cassette. The sizes of DNA makers 
are shown in kb.  
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3.2 Identification of Δnmb1467 mutants 
Preliminary experiments were performed to establish conditions in which mutants 
that are resistant against complement-mediated killing would be selected from the 
library of mutants. As the library contained around 40,000 mutants, sufficient 
numbers of bacteria had to be included in assays. Furthermore, there was only limited 
amount of human immune serum. Initial assays were performed with wild-type 
MC58, with dilutions of heat-treated sera from patients and baby rabbit complement. 
Different total volumes (100 µl to 2 ml), number of bacteria (10
4
 to 10
7
 CFU), 
concentrations of human sera (1:64 to 1:1,024) and complement (1:2 or 1:4) were 
used to determine the maximum number of CFU that could be included in assays with 
the lowest concentrations of serum that gave killing of all wild-type bacteria. 
 
To screen for mutants with enhanced survival, the mutant library (10
5
 CFU) was 
incubated with baby rabbit complement (1:4) and with serial dilutions of human 
immune serum in a 2 ml volume for 1 hour. Bacteria were recovered at the end of this 
time by plating to solid medium. The wild-type isolate MC58 was screened in parallel 
with the mutant library on each occasion. Using sera from patient H, there were no 
colonies recovered when MC58 was inoculated in assays in the presence of a 1:1,024 
dilution of serum. In contrast, a few colonies (5-10) were recovered when the mutant 
library was screened under identical conditions. To confirm the enhanced resistance 
of these colonies was due to the transposon insertion, the mutations were re-
introduced into the parental strain from the mutants. The newly constructed mutants 
were then tested individually for resistance against complement-mediated killing in 
standard SBAs. Only mutants exhibiting consistently increased serum resistance were 
analysed for further detail. 
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To determine the transposon insertion sites, genomic DNA was extracted from the 
mutants, and digested with EcoRV and DraI, which do not recognise sites within the 
transposon. After self-ligation, the DNA was transformed into E. coli. Only cells 
containing the transposon, which harbours a functional origin of replication in E. coli, 
were recovered. Plasmids were extracted from these colonies, and the sequences 
flanking the transposon were determined by DNA sequencing using primers that are 
complementary to each end of the transposon. Interestingly, mutants with Tn5 
insertions were found in the gene nmb1467 in independent screens with sera from 
different individuals. In the mutant HT1024 L14, Tn5 is located 165 bp downstream 
of the first ATG of the predicted ORF of nmb1467, and in another mutant, T1024 L4, 
the insertion is 187 bp downstream of the first ATG (Figure 3.2A). 
 
As these two mutants exhibited very similar enhanced resistance against serum killing 
in preliminary experiments (data not shown), one of the mutants was used in 
subsequent analysis and was designated MC58Δnmb1467. To confirm the increased 
resistance resulted from mutation of nmb1467, the recovery of the Δnmb1467 mutant 
and MC58 was examined in standard SBAs using convalescent serum from patient H 
and serum from mice immunised with the attenuated serogroup B N. meningitidis 
strain 23A10 (Li et al., 2004). The SBA titre of patient H’ serum against the 
Δnmb1467 mutant was 1024, which was two-fold less than that against MC58 (Figure 
3.2B). The killing of both MC58 and Δnmb1467 by the α-23A10 serum was more 
efficient than the serum from patient H. However, the survival of the Δnmb1467 
mutant was increased compared with MC58 in the presence of 1:8,192 or 1:16,384 
diluted α-23A10 serum (Figure 3.2C).  
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The protein product of nmb1467 had not been characterised previously. Insertion in 
genes encoding structural components of the cell wall or regulators could affect 
expression of a number of surface antigens. Therefore, to determine whether mutation 
of nmb1467 led to pleiotropic effects, whole cell extracts were obtained from the 
Δnmb1467 mutant and MC58, and subjected to Western blot analysis using the serum 
from mice immunised with the attenuated N. meningitidis strain 23A10 (Li et al., 
2004). There was no significant difference in the binding of antibodies to proteins 
from the mutant compared with MC58, suggesting that loss of NMB1467 does not 
have multiple effects on the cell surface (data not shown).  
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Figure 3.2 Δnmb1467 mutants are relatively resistant to killing mediated by 
bactericidal antibodies 
(A) Schematic representation of open reading frames around nmb1467 and the locations of 
Tn5 insertions in mutants, HT1204 L14 and HT1024 L4. The size of 1 kb is indicated. 
NMB1466 and NMB1468 encode proteins of unknown function. 
(B) and (C) Increased resistance of the Δnmb1467 mutant in patient’s and murine immune 
serum, respectively. SBAs were performed using sera from patient H (B) and mice 
immunised with N. meningitidis 23A10 (C).  
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3.3 Enhanced resistance of the Δnmb1467 mutant in normal human serum 
After the relatively enhanced resistance of the Δnmb1467 mutant was confirmed in 
the patient H’s serum and α-23A10 serum with baby rabbit complement, the survival 
of the Δnmb1467 was examined in the presence of human complement using normal 
human serum (NHS). Analysis of the orientation of ORFs around nmb1467 
demonstrated that the transposon insertion is unlikely to have polar effects on 
downstream genes (Figure 3.3A). However, to exclude this possibility the Δnmb1467 
mutant was complemented by introducing a single wild-type copy of the gene at an 
ectopic chromosomal location. To construct the complemented strain Δnmb1467com, 
nmb1467 and its own promoter were amplified from MC58 by PCR using primers 
NG551 and NG552, and inserted into the complementation vector pYHS25 in E. coli 
(Winzer et al., 2002). After transformation of N. meningitidis, integration of the 
vector by double crossover leads to a single chromosomal copy of the complementing 
gene in the intergenic region between nmb102 and nmb103, which are ORFs 
orientated in a tail-to-tail fashion (Figure 3.3A). The complemented strain 
MC58Δnmb1467com was verified by PCR and Southern blot analysis (data not shown). 
 
To examine the contribution of nmb1467 to bacterial survival in the presence of 
human complement, the recovery of MC58, the Δnmb1467 mutant and the 
complemented strain Δnmb1467com was determined after a 1 hour incubation in NHS. 
In the presence of a 1:8 dilution of NHS, the number of colonies recovered from the 
Δnmb1467 mutant was about twice that of the wide-type strain; the relatively 
increased resistance of the mutant was abolished in the complemented strain, 
Δnmb1467com (Figure 3.3B). In contrast, when bacteria were incubated with serum 
which had been incubated at 55°C for 30 minutes to inactivate the complement 
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system, there was no significant difference in the survival of the strains (Figure 3.3C). 
Taken together, the results demonstrate that insertion of Tn5 in nmb1467 results in 
relatively increased resistance against complement-mediated killing, and inactivation 
of nmb1467 is solely responsible for this enhanced resistance. 
  
 98 
 
 
 
Figure 3.3 Loss of NMB1467 leads to increased survival in normal human serum 
(A) Schematic representation of the construction of the complemented strain, Δnmb1467com. 
nmb1467 was inserted with an erythromycin resistance gene into the intergenic region 
between nmb102 and nmb103, as a single copy in the genome.  
(B) Increased resistance of MC58Δnmb1467 against NHS. The survival of the Δnmb1467 
mutant was significantly greater than the wild-type strain after incubation with 1:8 diluted 
NHS for 1 hour (p < 0.05). The increased resistance was abolished in the complemented 
strain Δnmb1467com. The figure shows representative results of three independent 
experiments performed in triplicate, and error bars show the SEM of assays performed in 
triplicate.  
(C) Similar survival of MC58, the Δnmb1467 mutant and MC58Δnmb1467com in heat-
inactivated serum. Data represent the average of three independent experiments performed 
in triplicate, and error bars represent the SEM.  
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3.4 Over-expression and purification of recombinant NMB1467 in E. coli. 
To allow assessment of NMB1467 as a vaccine candidate, the protein was over-
expressed and purified in E. coli as a recombinant protein. The whole ORF of 
nmb1467 was amplified from MC58 by PCR using primes NG552 and NG559, and 
initially cloned into the expression vector pET15-b. The resulting plasmid was 
transformed into TOP 10 competent cells, which do not express T7 RNA polymerase. 
Once the sequence of nmb1467 in pET15-b was verified, the plasmid pnmb1467-
pET15-b was transferred into the expression host BL21, which contains T7 RNA 
polymerase under the control of lac operator. To investigate the effect of over-
expression of rNMB1467 on cell growth and to determine the optimal induction 
strategy for expression of NMB1467, the protein profile of small scale cultures (20 
ml) was examined. Bacteria were grown overnight in liquid culture, and sub-cultured 
to fresh LB to an O.D. A600 of 0.1. Strains were grown to an O.D. A600 of 0.6, with 
IPTG added to a final concentration of 1 mM. The growth of bacteria in the presence 
and absence of IPTG was monitored by measuring O.D. A600 every 30 minutes, and 
aliquots of cultures were taken every hour to analyse protein over-expression. The 
O.D. A600 of cultures with 1 mM IPTG measured at every time point was similar to 
that of cultures without IPTG (Figure 3.4A), indicating that induction with 1 mM 
IPTG was not toxic to the host strain carrying pnmb1467-pET-15b. Whole cell lysates 
were separated by SDS-PAGE, and proteins were stained with Coomassie blue. Over-
expression of a protein with a molecular mass of approximately 56 kDa appeared in 
samples after incubation with 1 mM IPTG for 1 hour, and the amount of the over-
expressed protein increased over time (Figure 3.4B). Thus, over-expression of 
rNMB1467 was successfully induced with 1 mM IPTG at 37°C for 1 hour, and 
induction for 4 hours was optimal for large scale protein purification.  
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To purify rNMB1467, bacteria were harvested from large scale cultures (500 ml) 4 
hours after induction, then lysed using a French press. The soluble and insoluble 
fractions of the lysates were separated by centrifugation; the over-expressed protein 
appeared in the soluble fraction in the supernatant (Figure 3.4C). Next, the soluble 
fraction was loaded onto a His-Trap column, washed with equilibration buffer and the 
protein was eluted in the presence of 200 mM imidazole (Figure 3.4C). Using 
Western blot analysis, the purified his-tagged rNMB1467 was recognised by an HRP-
conjugated anti-His mAb as a protein with a molecular weight around 56 kDa (Figure 
3.4D). Precipitation was observed when the N-terminal His-tag of rNMB1467 was 
cleaved by thrombin (data not shown), so the His-tag was not removed for all 
subsequent analyses.  
  
 101 
 
 
 
Figure 3.4 Over-expression and purification of rNMB1467 in E. coli 
(A) Growth of E. coli BL21 cells harbouring pnmb1467-pET15-b in the presence (solid line 
with circles) or absence (dashed line with squares) of 1 mM IPTG from early exponential 
phase.  
(B) Analysis of proteins expressed by E. coli BL21 containing pnmb1467-pET15-b. Whole 
cell lysates were prepared from bacteria grown with or without IPTG for 0, 1, 2, 3, 4 hours 
(T0, T1, T2, T3, T4, respectively), and analysed by SDS-PAGE. Proteins were stained with 
Coomassie blue, and the sizes of molecular weight markers (in kDa) are shown. 
(C) Analysis of the purification of rNMB1467 by SDS-PAGE and Coomassie blue staining. 
Bacteria over-expressing rNMB1467 were lysed with a French press. The soluble fraction 
(Lane 1) of whole cell lysates was separated from insoluble pellet (Lane 2) by centrifugation 
and loaded onto a His-trap column. There was no detectable protein with a molecular mass of 
56 kDa in the flow-through (Lane 3) and wash solution (Lane 4), but a protein of this mass 
was eluted from the column in the presence of 200 mM imidazole (Lane 5).  
(D) Western blot analysis of purified rNMB1467 using an HRP-conjugated α-poly-His 
antibody. 
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3.5 Recognition of rNMB1467 by antibodies in convalescent serum  
Purified recombinant NMB1467 (25 µg) was used to generate anti-sera by 
immunising six-eight week old female BALB/c mice on three occasions by the 
subcutaneous route. To confirm the specificity of the immune serum, pre-immune and 
immune (α-rNMB1467) sera were tested by Western blot analysis. First, it was 
confirmed that the immune but not pre-immune serum recognised purified 
recombinant rNMB1467 as a single band of about 56 kDa (Figure 3.5A). Next, whole 
cell extracts from the MC58 and the Δnmb1467 mutant were tested with the α-
rNMB1467 serum. As expected, the 56 kDa band was present in lysates from MC58 
but not in samples of the Δnmb1467 mutant (Figure 3.5B).  
 
To test the hypothesis that the increased resistance of the Δnmb1467 mutant was due 
to the loss of NMB1467 as a target of bactericidal antibodies, the presence of α-
rNMB1467 antibodies in patient H’s serum was examined. By Western blot analysis, 
purified rNMB1467 (detected as a 56 kDa band) was recognised by antibodies in this 
serum at a 1:500 dilution (Figure 3.5C). To confirm this result, ELISAs were 
performed using higher concentrations of patient H’s serum. Recombinant 
rNMB1467 (100 ng) was coated onto the wells of ELISA plates, and dilutions of 
patient’s serum, pre-immune and immune α-rNMB1467 murine serum were added to 
the wells. ELISA readings detecting rNMB1467 with serum from patient H were 
lower than that with α-rNMB1467 serum. These results are consistent with findings 
by Western blot that demonstrated weaker binding was detected when rNMB1467 
was incubated with patient H’s serum compared with α-rNMB1467 immune serum. 
In contrast, results with patient’s H serum were higher than those obtained with pre-
immune murine serum (Figure 3.5D). Taken together, ELISA and Western blot 
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analysis show that α-rNMB1467 antibodies were present in convalescent serum from 
patient H, which was used to select Δnmb1467 mutants by GSI.  
 
 
 
 
Figure 3.5 Recognition of rNMB1467 by antibodies in serum from patient H 
(A) Western blot analysis of binding of anti-rNMB1467 serum (1:5,000 dilution) to the 
recombinant protein rNMB1467. The sizes of a molecular weight marker are indicated in kDa. 
(B) Western blot analysis of the presence of NMB1467 in MC58 but not in the ∆nmb1467 
mutant using a 1:2,000 dilution of anti-rNMB1467serum.  
(C) Western blot analysis of binding to rNMB1467 by patient H’ serum (1:500 diluted).  
(D) ELISA analysis of binding to rNMB1467 of total immunoglobulins in the pre-immune 
serum (dark dashed line with squares), anti-rNMB1467 (grey dashed line with squares) and 
patient H’s serum (dark solid line with circles). 
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3.6 Assessment of the vaccine potential of rNMB1467 
As an effective vaccine, a selected antigen should be present in all N. meningitidis 
serogroup B strains and be able to elicit bactericidal antibodies that are cross-reactive 
with a range of strains. To examine whether nmb1467 is conserved in serogroup B 
strains, genomic DNA was extracted from 21 clinical isolates (Appendix 1) and used 
as template in PCRs to detect the presence of nmb1467. Using a pair of primers 
flanking nmb1467, a 1.5 kb PCR product was amplified from all these 21 strains as 
well as MC58, and 10 of 20 PCR products are shown in Figure 3.6A. The presence of 
homologues of nmb1467 in the serogroup A and C strains was confirmed by PCR and 
BLAST of DNA sequence (data not shown).  
 
To examine whether α-rNMB1467 antibodies have bactericidal activity, standard 
SBAs were performed. In the first assay, the SBA titre of the α-rNMB1467 serum 
against MC58 was 512, whereas, the SBA titre against the Δnmb1467 mutant was < 
64. These results were consistent with the hypothesis that α-rNMB1467 serum has 
bactericidal antibodies which binds to MC58. Similar killing of BZ167 and H44/76, 
which belong to ET-5, by the α-rNMB1467 serum was also found (Figure 3.6B). 
However, these SBA results were not reproducible in the subsequent experiments 
using sera from second and third immunisation experiments (Figure 3.6B).  
 
To establish whether rNMB1467 can confer protective immunity, groups of mice (15 
animals per group) received 25 µg of rNMB1467 by subcutaneous administration on 
days 0, 21, and 28. Control groups were given either medium alone or a previously 
characterized live attenuated N. meningitidis strain, 23A10 (Li et al., 2004). On day 
43, animals were challenged with 5 x 10
6
 CFU or 5 x 10
7
 CFU of live MC58. As 
described previously, animals immunised with the attenuated N. meningitidis strain 
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survived much better than animals that only received medium following challenge 
with the homologous strain (Li et al., 2004). However, vaccination with rNMB1467 
did not provide significant protection to animals against challenged with MC58 
(Figure 3.6D and 3.6E).  
 
To further analyse the vaccine potential of rNMB1467, the localisation of NMB1467 
in MC58 was analysed by FACS. No significant shift to the right was observed when 
fixed bacteria were incubated with α-rNMB1467 (1:10 dilution) compared with 
negative control in which cells were incubated in PBS alone. This result indicates that 
NMB1467 is unlikely to be present on the bacterial surface. Therefore, these series of 
results indicate that rNMB1467 is not a good vaccine candidate against serogroup B 
N .meningitidis. 
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Figure 3.6 Assessment of the vaccine potential of rNMB1467  
(A) Detection of nmb1467 gene by PCR in a range of clinical isolates, MC58 (Lane 1), 
H44/76 (Lane 2), BZ169 (Lane 3), BZ83 (Lane 4), SWZ107 (Lane 5), NGF26 (Lane 6), 
NG6/88 (Lane 7), 860800 (Lane 9), 2996 (Lane 10), A22 (Lane 11) and 2059001 (Lane 12). 
H2O instead of genomic DNA was used as negative control (Lane 8).  
(B) SBA titres against MC58, MC58∆nmb1467, H44/76 and BZ169 using anti-rNMB1467 
sera raised on three independent immunisations. 
(C) and (D) Protection by immunisation of rNMB1467 against live meningococcal challenge. 
Group of 15 mice were vaccinated with 25 µg of rNMB1467 on days 0, 21, and 28 (dark 
solid line with circles). Control animals (15 per group) were immunised with either N. 
meningitidis 23A10 (dark dash line with squares) or PBS alone (grey dash line with squares). 
On day 43, animals were challenged with low dose 5 x 10
6
 CFU of MC58 (C) or 10
7
 CFU 
MC58 (D), and survival was recorded over the following 72 hours. 
(E) FACS analysis of binding of anti-rNMB1467 to MC58. There was no significant binding 
of anti-rNMB1467 serum to MC58 compared to negative control PBS. 
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Chapter 4 Biochemical characterisation of NMB1467 
 
4.1 Homology of NMB1467 to PPX from E. coli 
The ORF of nmb1467 is predicted to encode a protein consisting of 502 amino acids, 
with a predicted molecular weight of 55,921.07 Da and pI of 7.68. BLASTP searches 
showed that NMB1467 belongs to the PPX/GppA Super Family, and shares 35% 
amino acid identity with the biochemically characterised PPX of E. coli (Figure 4.1). 
Examination of the whole genome sequence of N. meningitidis MC58 demonstrated 
that nmb1467 is the only ORF with identity to E. coli ppx (cut off 3.00E-14). A 
BLASTP with E. coli PPX revealed the presence of PPX in many but not all bacterial 
species (Table 4.1).  
 
It has been reported that over-expression of S. cerevisiae PPX in E. coli reduces the 
cellular level of poly P and decreases resistance against heat and oxidative stress 
(Shiba et al., 1997). Therefore, the effect of over-expressing rNMB1467 on the 
resistance of E. coli against heat shock and oxidative stress was examined. Over-
expression of rNMB1467 was performed by inducing exponential phase bacteria with 
1 mM IPTG at 37°C with shaking at 200 r.p.m for 4 hours. For the oxidative stress 
assay, bacteria (10
9
 CFU) were spread over the surface of agar plates and filter disks 
soaked in 8 mM H2O2 were placed in the centre of plates. Zones of growth inhibition 
were observed after an overnight incubation. The zone of inhibition by H2O2 was 
significantly larger on the plates inoculated with a strain over-expressing rNMB1467 
compared with E. coli containing the vector alone, indicating that over-expression of 
rNMB1467 enhances the susceptibility to the oxidative stress (Figure 4.2 A). To 
examine sensitivity to heat, bacteria were incubated at 55°C for 5 minutes and 
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survival was determined by plating aliquots to solid LB media. After an overnight 
incubation, the strain over-expressing rNMB1467 only exhibited about 10% survival 
compared to the strain containing the vector alone. Taken together, these data 
demonstrate that over-expression of rNMB1467 in E coli has similar effects to over-
expression of yeast PPX on resistance against heat and oxidative stress, suggesting 
that nmb1467 may encode a functional exopolyphosphatase.  
 
 
 
NMB1467         ----MTTTPANVLASVDLGSNSFRLQICENNNGQLKVIDSFKQMVRFAAGLDEQKNLSAA 56 
PPX             MPIHDKSPRPQEFAAVDLGSNSFHMVIARVVDGAMQIIGRLKQRVHLADGLGPDNMLSEE 60 
                     .:. .: :*:********:: *..  :* :::*. :** *::* **. :: **   
 
NMB1467         SQEQALDCLAKFGERLRGFRPEQVRAVATNTFRVAKNIADFLPKAEAALGFPIEIIAGRE 116 
PPX             AMTRGLNCLSLFAERLQGFSPASVCIVGTHTLRQALNATDFLKRAEKVIPYPIEIISGNE 120 
                :  :.*:**: *.***:** * .*  *.*:*:* * * :*** :** .: :*****:*.* 
 
NMB1467         EARLIYTGVIHTLPPGGGKMLVIDIGGGSTEFVIGSTLNPDITESLPLGCVTYSLRFFQN 176 
PPX             EARLIFMGVEHTQPEKG-RKLVIDIGGGSTELVIGENFEPILVESRRMGCVSFAQLYFPG 179 
                *****: ** ** *  * : ***********:***..::* :.**  :***:::  :* . 
 
NMB1467         -KITAKDFQSAISAARNEIQRISKNMRREGWDFAVGTSGSAKSIRDVLAAEMPQEADITY 235 
PPX             GVINKENFQRARMAAAQKLETLTWQFRIQGWNVAMGASGTIKAAHEVLMEMGEKDGIITP 239 
                  *. ::** *  ** :::: :: ::* :**:.*:*:**: *: ::**     ::. **  
 
NMB1467         KGMRALAERIIEAGSVKKAKFENLKPERIEVFAGGLAVMMAAFEEMKLDRMTVTEAALRD 295 
PPX             ERLEKLVKEVLRHRNFASLSLPGLSEERKTVFVPGLAILCGVFDALAIRELRLSDGALRE 299 
                : :. *.:.::.  .. . .: .*. **  **. ***:: ..*: : : .: :::.***: 
 
NMB1467         GVFYDLIGRGLNEDMRGQTVAEFQHRYHVSLNQAKRTAETAQTFMDSLCHAKNVTVQELA 355 
PPX             GVLYEMEGRFRHQDVRSRTASSLANQYHIDSEQARRVLDTTMQMYEQWREQQ--PKLAHP 357 
                **:*:: **  ::*:*.:*.:.: ::**:. :**:*. :*:  : :.  . :  .    . 
 
NMB1467         LWQQYLGRAAALHEIGLDIAHTGYHKHSAYILENADMPGFSRKEQTILAQLVIGHRGDMK 415 
PPX             QLEALLRWAAMLHEVGLNINHSGLHRHSAYILQNSDLPGFNQEQQLMMATLVRYHRKAIK 417 
                  :  *  ** ***:**:* *:* *:******:*:*:***.:::* ::* **  **  :* 
 
NMB1467         KMSG---IIGTNEMLWYAVLSLRLAALFCRSRQDLSFPKNMQLRTDTESCGFILRIDREW 472 
PPX             LDDLPRFTLFKKKQFLPLIQLLRLGVLLNNQRQATTTPPTLTLITDDS--HWTLRFPHDW 475 
                  .     : .:: :   :  ***..*: ..**  : * .: * ** .   : **: ::* 
 
NMB1467         LERHPLIADALEYESVQWQKIN-MPFKVEAV------- 502 
PPX             FSQNALVLLDLEKEQEYWEGVAGWRLKIEEESTPEIAA 513 
                 :.::.*:   ** *.  *: :    :*:*          
 
Figure 4.1 Amino acid alignment of NMB1467 with E. coli PPX 
Identical residues are shown with an asterisk, conserved substitutions are shown with two 
dots and semi-conserved substitutions are shown with one dot. The residues shown in grey 
are highly conserved in 20 micro-organisms (Kristensen et al., 2004). 
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Table 4.1 Presence or absence of predicted PPX in microbial genomes 
      Presence        Absence  
Acinetobacter calcoaceticus Archaeoglobus fulgidus 
Aquifex aeolicus Bacillus subtilis 
Bacillus cereus Campylobacter coli 
Bordetella pertussis  Dictyostelium discoideum 
Clostridium acetobutylicum Enterococcus faecalis 
Deinococcus radiodurans Mycobacterium leprae 
Escherichia coli Mycoplasma pneumoniae 
Haemophilus influenzae Mycobacterium tuberculosis 
Helicobacter pylori Myxococcus xanthus 
Klebsiella pneumonia Propionibacterium shermanii 
Neisseria gonorrhoeae Streptomyces coelicolor 
Neisseria meningitidis Thermotoga maritima 
Plasmodium falciparum  
Propionibacterium shermanii  
Pseudomonas aeruginosa  
Saccharomyces cerevisiae  
Salmonella typhi  
Shigella flexneri  
Synechocystis spp.  
Vibrio cholerae  
Yersinia pestis  
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Figure 4.2 Effects of over-expression of rNMB1467 on E. coli  
(A) The effect of over-expression of rNMB1467 on sensitivity to H2O2. Protein over-
expression in E. coli strain BL21 carrying pnmb1467-pET15-b or an empty plasmid (pET15-
b) was induced with 1 mM IPTG for 4 hours, then 10
9
 CFU of each strain spread onto LB 
plates. Filter disks containing 10 µl of 8.8 M H2O2 were added and the plates were incubated 
overnight at 37°C.  
(B) Effect of over-production rNMB1467 on heat sensitivity of E. coli. Bacteria over-
expressing rNMB1467 were incubated at 56°C for 5 minutes. The viability of bacteria was 
determined by plating serial dilutions onto LB agar plates and incubation overnight at 37°C. 
The expected number of bacteria in aliquots (CFU) are indicated above each spot.  
B
A pET15-b pnmb1467-pET15-b
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4.2 NMB1467 is an exopolyphosphatase 
Several approaches have been used to quantify the level of poly P in cells, among 
which the toluidine blue assay is an easy, fast and inexpensive method (Ault-Riche et 
al., 1998; Kornberg, 1999; Mullan et al., 2002). Toluidine blue is a metachromatic 
dye, and the addition of negatively charged poly P to toluidine blue changes the 
colour of the dye from blue to pink, shifting the absorption of the dye from 
approximately 630 nm to 530 nm.  
 
To examine the sensitivity of the toluidine blue assay for quantification of poly P, 
different concentrations of poly P75 were diluted in 10 µl of 10 mM Tris-HCl and 
added to 990 µl of dye solution (6 g/L in 40 mM acetic acid), and the absorbance of 
the solution was measured at 530 and 630 nm. The ratio of O.D. A630 /O.D. A530 was 
approximately 0.15 when 10 µl of 10 mM Tris-HCl alone was used as control. The 
ratio increased with increasing concentrations of poly P75 from 1 mM to 15 mM in 10 
µl of samples, but the relationship was linear only over a narrow range of 
concentrations (approximately 6-12 mM), and did not increase over 15 mM (Figure 
4.3A).  
 
To determine the biochemical function of rNMB1467, different concentrations of the 
protein were incubated with 10 mM of poly P75 in 100 µl of exopolyphosphatase 
reaction buffer, and the concentration of poly P75 was determined at 0, 1, 15, and 30 
minutes using the toluidine blue assay. In the presence of rNMB1467 with a final 
concentration of 50 µg/ml, the level of poly P75 declined to almost 0 mM within 15 
minutes (Figure 4.2B); there was no change in the poly P75 level using the same 
concentration of BSA (data not shown). Lower concentrations of rNMB1467 (5 
µg/ml and 10 µg/ml) decreased the level of poly P75 within 30 minutes at slower rates 
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compared to 50 µg/ml (Figure 4.3B). These results demonstrate that rNMB1467 has 
exopolyphosphatase activity, and the kinetic activity of rNMB1467 is related to the 
concentration of protein. Thus, NMB1467 was designated PPX.  
 
Divalent cations are required for the activity of many phosphatases. It has been 
reported that removal of divalent cations reduces the activity of E. coli PPX to 0.3% 
of the maximum level, and that activity using Ca
2+
 only reaches 12% of that obtained 
with Mg
2+
 (Bolesch and Keasling, 2000). Thus, the effect of divalent cations on the 
activity of rPPX was examined using 1 mM CaCl2. Different final concentrations of 
rPPX (5 µg/ml, 10 µg/ml and 50 µg/ml) were used in reactions with 1 mM CaCl2 
instead of 1 mM MgCl2. rPPX activity was not detected when 5 µg/ml of protein was 
used in the reaction buffer with 1 mM Ca
2+
 (Figure 4.3C). In the presence of 50 
µg/ml of rPPX, the level of poly P75 reduced at a lower rate than obtained with 10 
µg/ml of rPPX and 1 mM Mg
2+
 (Figure 4.3C). These results indicate that Ca
2+
 is able 
to sustain the enzymatic activity of rPPX of N. meningitidis, but it reaches less than 
20% of the activity obtained with Mg
2+
. 
 
The effect of the temperature on rPPX activity was examined by incubating reactions 
containing 5 µg/ml of rPPX and 1mM Mg
2+ 
at different temperatures. The level of 
poly P75 decreased much slower when the reaction was incubated at 20°C or 56°C 
than at 37°C over 30 minutes (figure 4.3D). These results indicate that rPPX is most 
active at 37°C.  
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Figure 4.3 Biochemical characterisation of rNMB1467 
(A) Quantification of poly P75 using the toluidine blue assay. Different concentrations of poly 
P75 in 10 µl of Tris-HCl were added to 990 µl of dye solution, and the absorbance of the 
solution was measured at 530 and 630 nm.  
(B) Biochemical characterisation of rPPX. Different concentrations of purified rNMB1467 
were added to 100 µl of exopolyphosphatase reaction buffer and incubated at 37°C. 
Concentrations of poly P75 were measured at 1, 15 and 30 minutes using the toluidine blue 
assay.  
(C) Activity of rPPX in the presence of Ca
2+
. Reactions containing 1 mM CaCl2 instead of 1 
mM MgCl2 with indicated concentrations of rPPX were incubated at 37°C. The resulting 
levels of poly P75 were measured at 1, 15 and 30 minutes using the toluidine blue assay.  
(D) Effect of temperature on rPPX activity. PPX assay reactions containing 1 mM MgCl2, 50 
mM Tricine/KOH (pH 8.0), 175 mM KCl, and 5 µg/ml rNMB1467 were incubated at 20°C, 
37°C and 56°C, respectively. Levels of poly P75 were determined at 1 min, 15 min and 30 
min using the toluidine blue assay.  
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4.3 Requirement of Glu
147 
for the full catalytic activity of rPPX 
The crystal structure of the A. aeolicus PPX suggests that the Glu
148
 residue is 
involved in binding to a divalent cation (Figure 4.4A) (Kristensen et al., 2004). This 
residue is conserved in most PPX sequences, and corresponds to Glu
147
 in PPX of N. 
meningitidis MC58 (data not shown). To examine the role of the Glu
147
 in the activity 
of rPPX, this residue was replaced with alanine (A) by site-directed mutagenesis. 
rPPX
E147A
 was over-expressed and purified from E. coli using the same method as 
used for rPPX. This protein had the same mobility as the wild-type protein when 
analysed by SDS-PAGE (Figure 4.4B), and was recognised by the anti-rPPX serum 
using Western blot analysis (data not shown). The exopolyphosphatase activity of 
rPPX
E147A 
was measured under identical conditions to those used to measure the 
activity of rPPX. However, in the presence of 5 µg/ml, 10 µg/ml and 50 µg/ml of 
rPPX
E147A
, the level of poly P75 remained constant over 30 minutes. When the 
concentration of rPPX
E147A
 was increased to 500 µg/ml, a slow decrease in the level 
of poly P75 was detected (Figure 4.4C). The level of poly P75 after incubation with 
500 µg/ml rPPX
E147A 
for 30 minutes was about 7 mM, which was close the level 
(about 6 mM) obtained after incubation with 5 µg/ml of rPPX over the same time. 
These results indicate that substitution of Glu with Ala at residue 147 dramatically 
reduces the activity of rPPX to about 1% of the wild-type enzyme, and that Glu
147
 is 
required for the full enzymatic activity of the protein.  
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Figure 4.4 Effect of the rPPX
E147A 
substitution on PPX activity 
(A) Structure of Aquifex aeolicus PPX/GppA phosphatase. Three chloride ions (green spheres) 
and a calcium ion (grey sphere, indicated with an arrow) indicate the position of the putative 
active site (Kristensen et al., 2004). 
(B) Over-expressed rPPXE
147A
 was purified from E. coli and analysed by SDS-PAGE. 
rPPX
E147A
 (Lane 1) and wild-type rPPX (Lane 2) were visualised by Coomassie staining, and 
the sizes of molecular weight markers (in kDa) are indicated.  
(C) rPPX
E147A
 has significantly reduced PPX activity. PPX assays containing 10 mM poly P75, 
1 mM MgCl2, 50 mM Tricine/KOH (pH 8.0), 175 mM KCl, and 500 µg/ml of recombinant 
protein were incubated 37°C, and concentrations of poly P75 were measured at 1, 15, 30 
minutes by the toluidine blue assay. 
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4.4 Mutation of ppx leads to increased cellular poly P levels in N. meningitidis  
To compare the level of poly P in MC58 and the ∆ppx mutant, a Δppk mutant was 
generated as a control. Interruption the ORF of ppk was initially performed using in 
vitro Tn5 transposition (data not shown). A linearised plasmid containing ppk::Tn5 
was introduced into MC58 by transformation. However, there was significant 
heterogeneity in the sizes of Δppk mutant colonies. To examine whether this 
phenotype was caused by the insertion of the Tn5 transposon, another Δppk mutant 
was then constructed by insertion of a cassette containing a tetracycline resistance 
gene at bp 1701 of the ORF, at the location of an EcoRI recognition site (data not 
shown). The resulting Δppk mutants were confirmed by PCR and DNA sequencing, 
but size variation was still observed (data not shown). Thus, large and small single 
colonies were kept separately for the following assays.  
 
Levels of poly P in MC58, MC58∆ppx, MC58∆ppk with large and small colonies 
were initially analysed based on the methods reported by Tinsley (Tinsley et al., 
1993). Poly P was extracted from bacteria (10 x 10
9
 CFU) using NaClO, precipitated 
and dissolved in 100 µl of 10 mM Tris-HCl. The level of poly P was determined 
using the toluidine blue assay as described above. However, poly P was not detected 
in any of these strains. Several attempts were made to improve the sensitivity of the 
assay, by increasing the amount of bacteria and the concentration of toluidine blue 
solution, and by varying the ratio of the poly P sample and toluidine blue dye. 
However, no difference was observed in poly P levels between MC58, MC58Δppx 
and MC58Δppk (data not shown). This result could have been due to contamination 
with other polyanions (such as capsular polysaccharide) during poly P extraction, 
which also could lead to a shift in the wavelength of toluidine blue, and mask any 
differences in poly P levels between the mutants and the parental strain.  
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Thus, a more sensitive and specific method was used to quantify the poly P levels in 
N. meningitidis strains based on the activity of PPK. Poly P was extracted from cells 
with GITC lysis buffer and bound to Glassmilk, while binding of ATP or protein to 
glass was prevented by adding ethanol and SDS (Ault-Riche et al., 1998; Kornberg, 
1999). Poly P was eluted from the Glassmilk with hot low-ionic buffer, and 
quantified by its conversion to ATP by PPK in the presence of a 10-fold excess of 
ADP. The generated ATP was then determined using a luciferase assay (Ault-Riche 
et al., 1998).  
 
To purify rPPK of N. meningitidis from E. coli, the ORF of nmb1900 was amplfied 
by PCR using primers NG591 and NG663, and then cloned into pET-15b. The over-
expression of rPPK of N. meningitidis in E. coli BL21 was induced at 37°C overnight 
to increase the protein level. However, no polyphosphate kinase activity was found 
with purified rPPK. This was probably due to the presence of a poly-His-tag at the N-
terminus instead of the C-terminus (Zhu et al., 2003). Thus, a plasmid with a His-tag 
on the C-terminus of E. coli PPK (generous gift provided by Professor J. Roth) was 
used to produce recombinant protein. The polyphosphate kinase activity of the E. coli 
protein was confirmed by detecting increased levels of poly P75 when incubated with 
rPPK and ATP (Figure 4.5A). In addition, the ability of PPK to generate ATP from 
poly P was examined by incubating poly P75 with rPPK and ADP, and measuring the 
resulting ATP based on luminescence (data not shown). This method is able to detect 
concentrations of poly P75 as low as 0.5 µM, which is 2,000 times more sensitive than 
the toluidine blue assay (Figure 4.5B).  
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Poly P was extracted from different N. meningitidis strains after overnight growth, 
and converted to ATP. The level of poly P in MC58∆ppx was about 750 pmol/109 
CFU, which was about twice as much as the poly P level in MC58. The level of poly 
P extracted from large colonies of MC58∆ppk was similar to that from small colonies, 
and was only approximately 10% of MC58 (p < 0.05, Figure 4.5D), consistent with 
previous reports (Tinsley and Gotschlich, 1995).  
 
To examine the role of the activity of PPX on the levels of cellular poly P, a 
complemented strain MC58∆ppxE147A was constructed by introducing the ppxE147A 
allele as a single chromosomal copy in the intergenic region between nmb102 and 
nmb103 in the ∆ppx mutant. Western blot analysis confirmed the expression of a 56 
kDa protein by MC58∆ppxE147A recognised by the α-rPPX serum (Figure 4.5C). The 
level of poly P in the ∆ppxE147A mutant was similar to levels in the ∆ppx mutant 
which dose not express PPX, and was approximately twice as much as that in strain 
complemented with the wild-type ppx allele (p < 0.05, Figure 4.5D). These results 
demonstrate that modification of Glu
147 
in PPX not only reduces the enzymatic 
activity of rPPX to less than 1% in vitro, but is also necessary for the maintenance of 
the level of poly P in N. meningitidis. 
 
To examine the effect of modification of PPX activity on bacterial resistance against 
complement mediated-killing, different N. meningitidis strains were incubated with 
NHS at a 1:8 dilution for 1 hour. The survival of the ∆ppxE147A mutant was 100% 
more than that of the MC58 and MC58∆ppxcom (p < 0.05, Figure 4.5E), indicating 
that full enzymatic activity of PPX is required for the relatively enhanced resistance 
against complement-mediated killing.  
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Figure 4.5 Quantification of poly P levels in N. meningitidis using rPPK 
(A) Polyphosphate kinase activity of rPPK. Purified rPPK (0.1 mg/ml) was incubated with 
poly P75 at 37°C over 30 minutes, and levels of poly P75 were determined by the toluidine 
blue assay. The same concentration of BSA was used as control.  
(B) Quantification of the concentration of poly P75 by luminescence reaction. Poly P75 was 
converted to ATP in the presence of rPPK and an excess of ADP; the level of resulting ATP 
was measured by luminescence.  
(C) Western blot analysis of the presence of PPX in N. meningitidis strains (indicated above 
each lane) using the α-rPPX serum. The size of a molecular weight maker is shown in kDa.  
(D) Quantification of poly P levels in N. meningitidis. Poly P was extracted from 2 x 10
9
 CFU 
after overnight growth using Glassmilk and converted to ATP, which was measured by 
luminescence. The figure is a representative of three independent experiments performed in 
triplicate, and the error bars show the SEM.  
(E) Increased survival of the ∆ppxE147A mutant. N. meningitidis strains were harvested after 
overnight growth, and exposed to NHS at a 1:4 dilution. The survival of bacteria was 
determined after 1 hour. The results are a representative of three independent experiments 
performed in triplicate, and the error bars show the SEM.  
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4.5 Levels of poly P at different stages of meningococcal growth 
To measure cellular levels of poly P in N. meningitidis at different growth stages, 
bacteria were grown overnight then inoculated into fresh liquid BHI medium and 
incubated at 37°C with shaking at 150 r.p.m. Samples were taken every three hours, 
and poly P was extracted by Glassmilk. Levels of poly P both in MC58 and the ∆ppx 
mutant increased during bacterial growth and reached the maximum at stationary 
phase (Figure 4.6A). The difference in poly P levels between MC58 and the ∆ppx 
mutant became more marked after 12 hours growth (p < 0.05, Figure 4.6A).  
 
It has been reported that the ∆ppx mutant of B. cereus has approximately 10 fold 
more PPK and 1,000 fold more poly P than the wild-type strain (Shi et al., 2004), so 
the increased level poly P in the ∆ppx mutant of B. cereus could be due to increased 
activity of PPK. Western blot analysis of PPX expression of N .meningitidis MC58 
showed that the level of PPX does not significantly change during growth (Figure 
4.6B). This result indicates that the increased level of poly P in MC58 during growth 
is not due to reduced expression of PPX. Thus, it is possible that the increased level 
of poly P in the ∆ppx mutant partly resulted from the increased level of PPK. To test 
this hypothesis, the levels of PPK transcript were analysed at mid-log phase by 
quantitative real-time PCR (qrtRT-PCR). The results were analysed by comparison 
with a control housekeeping gene, gdh. Surprisingly, there was no significant 
difference in PPK transcript level between MC58 and the ∆ppx mutant (Figure 4.6C). 
Taken together, these results demonstrate that the increased level of poly P in the 
∆ppx mutant is caused by loss of PPX and not changes in PPK expression.  
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Figure 4.6 Quantification of cellular poly P of N. meningitidis at different growth 
stages  
(A) Quantification of poly P produced by N. meningitidis strains during different growth 
stages. Bacteria were grown overnight on BHI plates, and sub-cultured to liquid BHI medium 
at an initial O.D. A600 of 0.1. Bacterial cultures were incubated at 37°C with shaking at 150 
r.p.m and samples were taken at 0, 3, 6, 9, 12, 24 hours and assayed for poly P. The figure 
shows representative results of two independent experiments performed in triplicate, and 
error bars show the SEM.  
(B) Quantification of PPX expression by Western blot analysis using the α-rPPX serum. 
Bacteria were grown in liquid medium under identical conditions as described above, and 
samples were taken 0, 2, 4, 6, 8, 10, 24 hours post-subculture 
(C) Quantification of ppk transcription by qrtRT-PCR. Bacteria were grown in liquid BHI at 
37°C with shaking at 150 r.p.m for 4 hours. Total RNA was extracted from bacteria, and the 
transcription of ppk and gdh measured by qrtRT-PCR. The results are representative of three 
independent experiments, and error bars show the SEM of assays performed in triplicate.  
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4.6 Crystallisation of N. meningitidis rPPX 
Crystallisation is a phase transition phenomenon. Crystals grow from an aqueous 
protein solution when the solution is brought into supersaturation (Chayen, 1998). 
The most popular and successful techniques to establish crystallisation conditions 
rapidly and efficiently are based on vapour diffusion, including the hanging drop, 
sitting drop and sandwich drop methods. These techniques utilise the difference in 
precipitant concentration between the protein drop and the mother liquor to drive 
volatile components to evaporate from the drop until the concentration of the 
precipitant in drop equals that of the well solution to achieve the supersaturation state 
of protein macromolecules (Chayen, 1998).  
 
Purified rPPX was stable in buffer consisting of 20 mM Tris-HCl, pH 8.0, 200 mM 
NaCl, 5 mM DTT and 5 mM pentasodium triphosphate at 4°C or -20 °C for about one 
month. The initial screen for PPX crystals was performed using nine commercially 
available 96-well plate screens kits and the Mosquito Nanodrop crystallisation robot. 
Each well of the 96 well plates contains different crystallisation solutions, with a 
chamber of the mother liquor (100 µl) and one drop (200 nl) sitting on a bridge which 
sits over the reservoir. Using the Mosquito Nanodrop crystallisation robot, 200 nl of 
10 mg/ml of PPX was added to each drop in the wells, then, the plates were sealed 
with tape and stored at 20°C. As the crystallisation solution in the drop was mixed 
with an equal volume of protein solution, the solution in the mother liquor had double 
concentration of that in the drop. This allows the water to evaporate from the drop 
gradually. During the first week each drop was viewed by microscopy every day, and 
in the second week the samples were checked every other day. Most crystals appeared 
after 24 hours incubation and positive hits were found in 78 conditions. Different 
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shapes of rPPX crystal were observed under the microscope, and 5 samples of 
conditions are listed in Figure 4.7. 
 
Once the crystals were found, the conditions were optimised in 24-well plates using 1 
ml of mother liquor and 1 µl of protein. Optimising the crystal conditions was 
achieved by varying all crystallisation parameters, including precipitant, salt, protein 
and pH.  
 
  
 124 
 
 
 
 
Figure 4.7 Typical shapes of rPPX crystals under different conditions 
(A) Clustered needle shapes of rPPX were obtained in the conditions of 0.2 M NaCl, 
0.1 M CHES pH, 9.0, and 12% PEG 8,000.  
(B) Small cubic crystals of rPPX were obtained in conditions of 0.07 M NaCl, 0.01 M 
0.05 M sodium citrate and 22% PEG 400.  
(C) Long rod shapes of rPPX crystals were obtained in conditions of 0.225 M 
MES/Bis-Tris pH 6.6, and 6,6% PEG6K.  
(D) Small plate shapes of rPPX crystals were obtained in conditions of 0.02 M CaCl2, 
0.02 M MES pH 6.5, and 7.7% PEG 1,500.  
(E) Big plate shapes of rPPX crystals were obtained in conditions of 0.1 M Li2SO4, 
0.1 M Na citrate pH 5.5, and 12% PEG 4,000. 
A B C
D E
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Chapter 5 Investigation of the contribution of PPX to avoidance of 
complement-mediated killing  
 
5.1 The in vitro growth of the ∆ppx mutant 
The increased survival of the ∆ppx mutant in the presence of NHS could be due to a 
growth advantage of the mutant compared with the wild-type strain. To examine this 
possibility, the growth of both strains was analysed in vitro. The growth of the strains 
in BHI liquid medium was monitored at hourly intervals from the lag phase to 
stationary phase by measuring the O.D. at 600 nm. Given the same starting O.D. A600 
of 0.1, the growth of the ∆ppx mutant at each time point was slightly lower than that 
of the wild-type on three independent experiments (Figure 5.1A), indicating a slower 
replication rate of the ∆ppx mutant. Reducing the agitation of cultures from 200 r.p.m 
to 150 r.p.m during incubation significantly reduced the growth rate of both strains. 
When the bacteria were propagated at 150 r.p.m, the lower growth rate of the ∆ppx 
mutant compared with MC58 was still observed, with the difference between two 
strains becoming more marked (data not shown). Similar results were found when 
bacteria were grown in DMEM that was used to dilute bacteria in the normal human 
serum assays (data not shown).  
 
In addition to the measurement of O.D., the growth of the ∆ppx mutant and the 
parental strain was compared by measuring cell viability expressed as colony forming 
units (CFU). Aliquots of cultures grown at 200 r.p.m were collected at each time 
point, plated to solid media, incubated overnight, and colonies were counted. The 
numbers of the ∆ppx mutant recovered were similar to MC58 over the whole growth 
phase (Figure 5.1B). Therefore, taken together, these results indicate that the ∆ppx 
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mutant does not grow faster than MC58, and therefore the resistance of the ∆ppx 
mutant cannot be explained simply by an increased replication rate of the mutant.  
 
 
 
 
 
 
 
 
Figure 5.1 Growth of MC58 and MC58Δppx in vitro 
(A) Analysis of bacterial growth by measuring the O.D. at 600 nm. Bacteria were inoculated 
into BHI liquid medium at a starting O.D. A600 of 0.1, then incubated at 37°C with shaking at 
200 r.p.m. Growth was monitored by measuring the O.D. A600. The result shows the mean 
from three independent experiments performed in triplicate and error bars represent the SEM.  
(B) Analysis of the viability of MC58 and MC58Δppx during the growth. The initial 
concentration of bacteria was 10
8
 CFU/ml. The number of viable bacteria was determined by 
plating aliquots to solid media and counting the number of colonies after an overnight 
incubation. Results represent the mean of three independent experiments performed in 
triplicate, and the error bars show the SEM. 
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5.2 The resistance of the ∆ppx mutant is independent of the polysaccharide 
capsule 
Expression of a polysaccharide capsule by N. meningitidis is critical for bacterial 
virulence (Vogel et al., 1996). Loss of siaD, which encodes polysialyltransferase, 
leads to loss of capsule, and marked sensitivity to complement-mediated killing 
compared with the parental strain, MC58 (Edwards et al., 1994; Kahler et al., 1998). 
As opposed to N. meningitidis, no capsule has been identified in N. gonorrhoeae. 
However, half of total cellular poly P was found to be loosely attached to the 
gonococcal surface. Thus it has been proposed that poly P on the surface of the 
gonococcus has a role of a pseudocapsule (Kornberg, 1999; Noegel and Gotschlich, 
1983; Tinsley et al., 1993; Tinsley and Gotschlich, 1995). 
 
To examine whether the resistance of the ∆ppx mutant was due to changes in the 
capsule, the levels of capsule expression of MC58 and the ∆ppx mutant were 
determined initially by whole cell ELISA. Strains were coated onto the wells of 
ELISA plates and incubated with serial dilutions of an anti-serogroup B capsule mAb. 
Absorbance readings taken at 492 nm were dependent on the dilutions of the α-
serogroup B capsule mAb used for detection. The O.D. A492 from MC58 incubated 
with a 1:10 dilution of the mAb was higher than that obtained with the ∆ppx mutant, 
but the cut off (O.D. A492 < 0.4) dilution for both strains was the same (Figure 5.2A). 
To determine whether there was a significant difference in the level of capsule 
expression between the ∆ppx mutant and MC58, capsule expression was quantified 
using a more sensitive method, flow cytometry. Bacteria were fixed with 3% PFA 
and incubated with the α-serogroup B capsule mAb at a 1:10 dilution in PBS. An 
increase in fluorescence intensity and thereby capsule expression was detected as a 
shift to the right of the FACS tracing. The amount of capsule was calculated as the 
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mean fluorescence intensity (MFI, calculated as the geometric mean multiplied by the 
percentage of positive cells), and MC58∆siaD was used as a negative control. The 
value obtained from the ∆siaD mutant was less than 1% that of MC58, confirming 
that siaD is essential for capsule production and validating the assay. The MFI of the 
∆ppx mutant was not significantly different from that of MC58 (Figure 5.2B), 
indicating that loss of ppx does not affect capsule expression.  
 
To investigate the role of capsule in the enhanced resistance of the ∆ppx mutant 
against complement-mediated killing, the impact of PPX on survival was examined in 
a capsule-negative background. Due to the inherent susceptibility of capsule-minus 
strains to complement-mediated killing, lower concentrations of NHS were used in 
the serum assays. After a 1 hour incubation with serum at 1:16 dilution in DMEM, 
loss of PPX in MC58∆ppx:siaD, still resulted in significantly enhanced survival, with 
an approximately 100% increased survival compared with the strain expressing PPX, 
MC58∆siaD (p < 0.05, Figure 5.2C). This result indicates that the relative serum 
resistance of bacteria caused by loss of PPX does not require the expression of 
capsule. Overall, these findings indicate that the relative resistance of the ∆ppx 
mutant against complement–mediated killing is capsule independent.  
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Figure 5.2 The increased resistance of the ∆ppx mutant is independent of capsule 
expression 
(A) Detection of capsule expression by ELISA. Heat-inactivated bacteria (10
8
 CFU) were 
coated onto the wells of microtitre plates and capsule expression was detected by incubation 
with serial dilutions of an α-serogroup B capsule mAb.  
(B) Quantification of capsule expression by FACS using an α-serogroup B capsule mAb. 
Fixed bacteria (2 x 10
7
 CFU) were incubated with the α-serogroup B capsule mAb. Capsule 
expression is shown as the mean fluorescence index (MFI, calculated as the geometric mean 
multiplied by the percentage of positive cells). The figure is a representative example of three 
independent experiments with similar results performed in the triplicate, and the error bars 
show the SEM.  
(C) Serum resistance of MC58∆siaD and MC58∆siaD:ppx. The ppx mutation was 
introduced into MC58∆siaD. The survival of bacteria was determined after a 1 hour 
incubation in a 1:16 dilution of NHS. There was a significant increase in the survival of 
MC58∆siaD:ppx compared with MC58∆siaD (p < 0.05). The figure shows the representative 
results of three independent experiments performed in the triplicate, and the error bars show 
the SEM.  
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5.3 The resistance of the ∆ppx mutant is independent of LPS sialylation 
In N. gonorrhoeae, sialylated LPS and PorB have been proposed to bind to fH, which 
enhances cleavage and inactivation of C3 by factor I, leading to serum resistance of 
bacteria (Ram et al., 1998). In contrast, the role of LPS sialylation in serum resistance 
of N. meningitidis remains controversial (Ram et al., 1999). To investigate the impact 
of inactivation of ppx on LPS sialylation, the extent of sialylation of LPS in MC58 
and the ∆ppx mutant was analysed. First, total LPS of MC58 and the ∆ppx mutant 
were extracted, analysed on Tricine-SDS gels, and visualised by silver staining. The 
migration of the LPS of the ∆ppx mutant was indistinguishable from the wild-type 
strain (Figure 5.3A), indicating it is unlikely that there is a significant difference in 
LPS sialylation of the ∆ppx mutant.  
 
To quantify the levels of LPS sialylation in the different strains, total LPS and 
unsialylated LPS were measured by flow cytometry. Initially, FACS analysis was 
performed with the immunotyping antibody against L3,7,9 LPS. The results showed 
that the total amount of L3,7,9 immunotype LPS produced by MC58 and the ∆ppx 
mutant were similar (Figure 5.3B). Next, the extent of LPS sialylation was assessed 
using mAb 3F11, which recognises the terminal Gal1-4GlcNAc epitope on the α-
chain of meningococcal LPS, and therefore detects unsialylated LPS (Mandrell et al., 
1991). An ∆lst mutant, which is unable to sialylate LPS, was used as a control (Exley 
et al., 2005). The level of MFI showed that binding of 3F11 to the ∆ppx mutant was 
similar to that of the wild-type strain; the result for both strains was significantly 
lower than MC58∆lst (Figure 5.3C). The results of FACS indicate that the 
unsialylated LPS expressed by MC58∆ppx is similar to that expressed by MC58. 
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Taken together, the results demonstrate that loss of ppx does not change the level of 
LPS sialylation. 
 
To exclude the role of LPS sialylation in the serum resistance of the ∆ppx mutant, the 
effect of PPX was evaluated in an lst-negative background. Normal human serum 
assays were performed with MC58∆lst:ppx and MC58∆lst. Increased survival of 
MC58∆lst:ppx was observed compared with MC58∆lst (p < 0.05) in the presence of 
NHS diluted in DMEM. Therefore, sialylation of LPS was not required for the 
increased resistance of the ∆ppx mutant against complement-mediated killing. 
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Figure 5.3 The relative resistance of the ∆ppx mutant is independent LPS 
sialylation 
(A) Silver staining of the LPS from MC58 (Lane 1), the ∆ppx mutant (Lane 2) and the 
complemented strain ∆ppxcom (Lane 3), separated by Tricine-SDS-PAGE. The size of 
molecular weight maker (in kDa) is shown. 
(B) Quantification of LPS expression by FACS using an α-L,3,7,9 mAb. The results show the 
MFI from one representative experiment performed on three independent occasions in 
triplicate, and error bars represent the SEM. 
(C) Quantification of the expression of unsialylated LPS by FACS using mAb 3F11, which 
recognises unsialylated LPS. Binding of 3F11 to the ∆lst mutant was significantly higher than 
to parental strain MC58 (p < 0.05), but there was no significant difference in binding of 3F11 
to MC58 and MC58∆ppx. The figure shows representative results from three independent 
experiments performed in triplicate, and error bars represent the SEM. 
(D) Increased resistance of the ∆lst:ppx mutant. The survival of ∆lst:ppx in the presence of 
1:4 diluted NHS for 1 hour was significantly increased compared with the ∆lst mutant (p < 
0.05). The figure shows one representative experiment performed on three independent 
occasions in triplicate, and error bars represent the SEM. 
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5.4 Examination of the deposition of complement factors on N. meningitidis 
To further understand the basis of the enhanced resistance against complement-
mediated killing of strains lacking PPX, the deposition of different complement 
components on bacteria after incubation with NHS was analysed. The formation of 
the MAC, a high molecular weight protein complex which inserts into cell 
membranes, is required for complement-mediated lysis of bacteria (Walport, 2001). 
Increased survival of bacteria is likely to be associated with less deposition of MAC 
on the resistant strains (Uria et al., 2008). To test this hypothesis, binding of the MAC 
to the bacterial surface was determined by flow cytometry using a pAb recognising 
the C5b-9 complex. As expected, there was significantly less MAC deposition on the 
∆ppx mutant compared with MC58 after incubation in NHS (p < 0.05, Figure 5.4A).  
 
The complement factor C3, the site of convergence of the CP, the AP and the LP, is 
one of most important components of the complement cascade. Deposition of C3 on 
bacterial surfaces has been studied in several pathogens, including Staphylococcus 
aureus and N. meningitidis (Vogel et al., 1997). C3 activation is essential for the 
assembly of the MAC and bacteriolysis, demonstrated by the finding that animals 
lacking C3 have no complement-mediated bactericidal activity (Densen et al., 1988). 
Therefore, the level of C3 deposition on the bacterial surface after incubation in NHS 
was compared by flow cytometry. There was a significant decrease in the amount of 
C3 binding to the strain lacking PPX compared with MC58, with approximately 60% 
more C3 present on the ∆ppx mutant than MC58 (p < 0.05, Figure 5.4B).  
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Figure 5.4 Loss of ppx affects C3 and MAC deposition on the bacterial surface 
(A) Quantification of MAC deposition on the bacterial surface by FACS analysis. Fixed 
bacteria (2 x 10
7
 CFU) were incubated with NHS at 37°C for 30 minutes and MAC 
deposition detected by an α-human C5-9 pAb. The deposition of MAC to the ∆ppx mutant 
surface was significantly less than to wild-type MC58 (p < 0.05). The figure shows 
representative results from three independent experiments performed in triplicate, and error 
bars give the SEM.  
(B) Quantification of C3 deposition on the bacterial surface by FACS after incubation with 
NHS. Binding of C3 to bacteria was detected using a FITC-conjugated, α-human C3 mAb 
and shown as the MFI. There was significantly less binding of C3 to the ∆ppx mutant than to 
MC58 (p < 0.05). The figure shows representative results from three independent 
experiments performed in triplicate, and error bars represent the SEM. 
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5.5 Reduced activity of the AP contributes to the relative resistance of 
MC58∆ppx 
Antibody recognition and binding to antigens are the initial steps in the activation of 
the CP. As mentioned above, Western blot analysis using the α-23A10 showed there 
is no clear change in surface antigen expression upon loss of PPX. It is unlikely that 
reduction of C3 on bacterial surface and increased survival of bacteria in NHS were 
due to loss of PPX as an antigen from the surface of bacteria. However, to exclude 
this possibility, the presence of α-PPX antibodies in the NHS was examined. By 
Western blot analysis, no antibody binding to purified rPPX could be detected in 
NHS using a 1:500 dilution of serum. Subsequently the concentration of NHS was 
increased during incubation with the immunoblots, but this led to extensive 
background staining. To overcome this problem and to exclude the possibility that the 
undetectable signal was due to inadequate levels of NHS, ELISAs were performed 
using higher concentrations of NHS; pre-immune serum from mice was used as a 
control. The level of fluorescence detected at A492, representing binding antibodies in 
NHS to rPPX, was similar to results obtained when bacteria were incubated with pre-
immune serum, even when the concentration of NHS was as high as 1:16. As a 
control, binding of rPPX recognised by α-PPX serum led to a much higher O.D. A492 
(Figure 5.5A). These data suggest that α-PPX antibodies are undetectable in NHS, 
and indicate that there is no difference in the initial antibody-antigen binding to the 
∆ppx mutant compared with MC58.  
 
The AP serves to amplify the amount of complement activation on pathogen surfaces 
(Walport, 2001). To address the role of the AP in the increased resistance of the ∆ppx 
mutant, the CP and the LP were blocked by the addition of 10 mM EGTA-MgCl2 
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when bacteria were incubated with NHS during killing assays. Both MC58 and the 
∆ppx mutant were recovered at higher levels in serum without the activation of the 
CP and the LP compared with NHS. Despite this, there was at least 50% more 
survival of the ∆ppx mutant compared with MC58 after a 1 hour incubation. This 
result indicates that the AP contributes to the relatively increased resistance of the 
∆ppx mutant against complement-mediated killing (Figure 5.5B).  
 
To examine the difference in the extent of the AP activity, C3 and MAC levels on the 
bacterial surface were determined after incubation with NHS without the CP and the 
LP. As expected, inhibition of the CP and the LP resulted in significantly reduced 
total levels of C3 and MAC present on bacterial surface. However, amounts of C3 
and MAC on the ∆ppx mutant were about 60% lower than of those on MC58, 
demonstrating that loss of PPX resulted in reduced activity of the AP on their surface.  
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Figure 5.5 Reduced activity of the AP on the ∆ppx mutant 
(A) Quantification of binding of antibodies in different sera to rPPX ELISA. Binding of rPPX 
(100 ng) to NHS was similar to that detected with the pre-immune serum from mice. Both 
were significantly less than binding of murine α-rPPX serum.  
(B) and (C) FACS analysis of binding of MAC and C3 to bacteria in the absence of the CP 
and the LP. Fixed bacteria were incubated in NHS with 10 mM EGTA-MgCl2 to block the 
CP and the LP (-CP/LP). Binding of MAC (B) and C3 (C) to the bacterial surface was 
quantified by FACS using an α-C3 mAb and an α-human C5b-9 pAb, respectively. There was 
significantly less activity of the AP on bacterial surface of the ∆ppx mutant compared with 
the wild-type MC58 (p < 0.05). Both figures are representative for at least three independents 
experiments that gave similar results, and the error bars show the SEM.  
(D) Increased survival of the ∆ppx mutant in the absence of the CP and the LP. MC58 and 
MC58∆ppx were incubated with NHS with 10 mM EGTA-MgCl2 for 1 hour, and more 
survival of the ∆ppx mutant was found compared with MC58 (p < 0.05). NHS was used as a 
control. The figure shows representative results of three independent experiments performed 
in the triplicate, and error bars show the SEM.  
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5.6 Increased binding of fH to the ∆ppx mutant 
fH is the major negative regulator of the AP and is the second most abundant 
complement factor present in serum (Walport, 2001). fH is recruited by many bacteria 
pathogens to evade killing by the complement system. It has been demonstrated by 
our group that fH binds to N. meningitidis MC58, and recruitment of fH to the 
bacterial surface protects the meningococcus against complement-mediated killing 
(Schneider et al., 2006). The reduced activity of the AP on the ∆ppx mutant could be 
due to increased fH deposition. To test this hypothesis, the effect of loss of ppx on fH 
binding to the bacterial surface was initially examined by flow cytometry. Fixed 
bacteria were incubated in a 1:4 dilution of NHS and deposition of fH to the bacterial 
surface was detected using a α-human fH pAb. Incubation of bacteria with PBS was 
used as a control, and the MFI representing the level of fH was determined by 
subtracting the MFI obtained when bacteria were incubated with PBS from the MFI 
using NHS. Deposition of fH was detected on both strains, but the level of fH binding 
to the ∆ppx mutant was about 100% more than that to the parental strain MC58 (p < 
0.05, Figure 5.6A). Similar results were observed in a capsule–minus background, 
with significantly increased binding of fH to the ∆siaD:ppx mutant compared with 
the ∆siaD mutant (p < 0.05, Figure 5.6B). Taken together, these results indicate that 
inactivation of ppx leads to increased binding of fH to the bacterial surface, 
irrespective of capsule expression.  
 
To exclude the possibility that the increased binding of fH to the ∆ppx mutant was 
due to changes as a result of fixation, live N. meningitidis stains were incubated with 
serum from C7-deficient patient, which is unable to form terminal MACs to lyse 
bacteria. The level of fH deposition was significantly increased on the surface of the 
live ∆ppx mutant compared with MC58 (p < 0.05, Figure 5.6C). Consistent results, 
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with increased binding of fH to the ∆ppx mutant, were observed when bacteria were 
incubated with purified 440 μg/ml fH instead of NHS as the source of fH (p < 0.05, 
Figure 5.6D).  
 
To examine whether the increased fH binding was physiologically relevant, the 
survival of strains was examined in fH-depleted plasma (kind gift from Professor R. 
B. Sim, University of Oxford). Although depletion of fH leads to a decreased level of 
C3, fH depleted plasma still retains about 50% of its bactericidal activity (Schneider 
et al., 2006). The relatively increased resistance of the ∆ppx mutant was abolished in 
the serum without fH, indicating the requirement of fH for the increased resistance of 
the ∆ppx mutant against complement-mediated killing (Figure 5.7).  
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Figure 5.6 Increased binding of fH to the ∆ppx mutant using different sources of fH.  
(A) and (B) FACS analysis of binding of fixed bacteria to fH in NHS. Bacteria (2 x 10
9
 CFU) 
were incubated with NHS at 37°C for 30 minutes, and the deposition of fH to bacterial 
surface was detected by FACS using an α-human fH pAb, and shown as the MFI. Binding of 
fH to the surface of the ∆ppx mutant and ∆siaD:ppx was significantly increased compared 
with the parental strain MC58 (A) and ∆siaD (B), respectively (p < 0.05). Figures show 
representative results of three independent experiments performed in the triplicate, and error 
bars show the SEM.  
(C) and (D) Quantification of binding of live bacteria to different sources of fH by FACS. 
Live bacteria (2 x 10
9
 CFU) were incubated with C7-deficient serum (C) or with 440 µg/ml 
purified fH (D), and deposition of fH to bacterial surface was quantified by FACS. There was 
significantly increased binding of fH to the live ∆ppx mutant compared with MC58 (p < 0.05). 
Figures are representative results of at least three independents experiment performed in 
triplicate, and error bars show the SEM.  
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Figure 5.7 Reduction of the relative resistance of the ∆ppx mutant in the fH-
depleted serum. MC58 and MC58∆ppx were incubated with fH-depleted serum or NHS, and 
the survival of each strain was determined after a 1 hour incubation. The ∆ppx mutant had 
similar recovery number as MC58 in the presence of fH-depleted serum. As control, 
there was significantly increased survival of the ∆ppx mutant compared with MC58 in the 
presence of NHS (p < 0.05). The figure shows representative results of three independent 
experiments performed in the triplicate, and error bars show the SEM.  
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5.7 Increased binding of fH to the ∆ppx mutant is independent of the fH 
receptor NMB1870 
Lipoprotein GNA1870 has been identified as a fH receptor in N. meningitidis 
serogroup B strain H44/76 (Madico et al., 2006). The sequence of GNA1870 in 
H44/76 is identical to NMB1870 in N. meningitidis MC58 (data not shown). Previous 
work in our group has demonstrated that an isogenic mutant of MC58 with a kan
R
 
cassette in nmb1870 has significantly less fH deposition on its surface compared with 
the parental strain, MC58. To examine whether the increased binding of fH to the 
∆ppx mutant was due to alterations in NMB1870, the expression of NMB1870 was 
examined by Western blot. Equal amounts of whole cell lysates of MC58 and 
MC58∆ppx were separated by SDS-PAGE and verified by immunobloting with an α-
RecA mAb. A single band of around of 33 kDa with similar intensity was recognised 
by α-rNMB1870 serum (kind gift from Dr. YW.Li) in both strains, indicating 
mutation of ppx does not affect NMB1870 expression levels (Figure 5.8A). 
 
To confirm that the increased binding of fH to the ∆ppx mutant is independent of 
expression NMB1870, the effect of loss of PPX on fH deposition was compared in 
strains lacking nmb1870. As there was already a kan
R
 cassette in ppx, a new 
∆nmb1870 mutant was constructed by inserting a tetracycline resistance gene into 
nmb1870 to allow construction of the double mutant, MC58∆ppx:nmb1870. The 
upstream and downstream regions of nmb1870 were amplified by PCR using primers 
NG1347 and NG1348, and NG1349 and NG1350, respectively. PCR products were 
ligated to a tetracycline resistance gene; the resulting construction was used to 
transform MC58 (Figure 5.6A). The successful construction of ∆nmb1870 mutants 
was verified by PCR with primers flanking nmb1870, which generated products of 
2.3 kb from mutants compared with a product of 0.9 kb from MC58 (Figure 5.6B). 
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The loss of NMB1870 in the ∆nmb1870 mutants was also confirmed by Western blot 
analysis using the α-rNMB1870 serum; no band of around 33 kDa was detected in 
the mutants (Figure 5.8C). In addition, significantly reduced binding of fH to the 
∆nmb1870 mutant was confirmed by flow cytometry using the α-human fH pAb 
(data not shown). Genomic DNA from the ∆nmb1870 mutants was extracted and 
used to transform the ∆ppx mutant to generate an isogenic ∆nmb1870:ppx mutant. 
The resulting transformants were verified by PCR and Western blot analysis (Figure 
5.8B and 5.8D).  
 
Fixed ∆nmb1870 and ∆nmb1870:ppx mutants were incubated with NHS then with α-
human fH pAbs to detect fH binding. About 100% more binding of fH to 
∆nmb1870:ppx compared with the parental strain ∆nmb1870, indicating that 
nmb1870 is dispensable for the increased binding of fH to the mutant lacking ppx 
(Figure 5.9C and 5.9D). Serum assays showed significantly increased survival of 
∆nmb1870:ppx compared with ∆nmb1870 (Figure 5.9B), demonstrating nmb1870 is 
not involved in increased binding of fH, which contributes to the decreased activity 
of the AP and serum resistance of the ∆ppx mutant.  
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Figure 5.8 Construction of MC58∆nmb1870 
(A) Strategy to generate the ∆nmb1870 mutant. The upstream (5’) and downstream (3’) 
region of nmb1870 with additional EcoRI sites were amplified and cloned to pTrcHis vector. 
The resulting plasmid was digested with EcoRI and ligated to tetracycline resistance gene 
flanked by EcoRI.  
(B) Verification of the presence of the tetracycline resistance gene in ∆nmb1870 by PCR 
using primers flanking nmb1870. The size of PCR products amplified from genomic DNA of 
four ∆nmb1870 mutants and four ∆nmb1870:ppx mutants was about 2.4 kb bigger than that 
from MC58.  
(C) Western blot analysis of ∆nmb1870 mutants using an α-rNMB1870 serum. A band of 
about 33 kDa was recognised by the α-rNMB1870 serum (1:1,000 dilution in PBS) in the 
whole cell lysates of MC58 but not in the ∆nmb1870 mutants. 
(D) Western blot analysis of ∆nmb1870:ppx mutants using an α-rNMB1870 serum. A band 
of about 33 kDa recognised by the α-rNMB1870 serum (1:1,000 diluted in PBS) was present 
in the whole cell lysates of the ∆ppx mutant but not in the ∆nmb1870:ppx mutants.  
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Figure 5.9 Increased fH binding to the ∆ppx mutant is independent of the fH 
receptor NMB1870 
(A) Western blot analysis of NMB1870 expression in whole cell lysates. The strains are 
indicated above each lane, and the protein detected with the α-rNMB1870 serum was about 
33 kDa. An α-RecA serum was used as the loading control. There was no significant 
difference in expression of NMB1870 between MC58 and the ∆ppx mutant. 
(B) The percent survival of ∆nmb1870:ppx and ∆nmb1870 after a 1 hour incubation with 
NHS. There was increased survival of the ∆nmb1870:ppx mutant compared with the 
∆nmb1870 mutant (p < 0.05). The results are representative of three independent experiments 
performed in triplicate, and error bars show the SEM. 
(C) FACS analysis of binding of fH to the ∆nmb1870:ppx mutant and the ∆nmb1870 mutant. 
Fixed bacteria were incubated in NHS, and fH deposition was detected using an α-human fH 
pAb. A shift to the right was seen with the ∆nmb1870:ppx mutant compared with the 
∆nmb1870 mutant.  
(D) Deposition of fH on bacterial surface was quantified by FACS analysis and expressed as 
MFI. The increased fH binding on the surface of ∆nmb1870:ppx compared with ∆nmb1870 
was significant (p < 0.05), and the increased fH binding on the surface of MC58∆ppx 
compared to the MC58 was used as control.  
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Chapter 6 Discussion 
 
This thesis describes the isolation of a mutant with a transposon insertion in the gene 
nmb1467 (referred to as ppx from now on), the characterisation of the gene product as 
an exopolyphosphatase (designated PPX), and investigation into the role of this 
enzyme in interactions between N. meningitidis and the complement system.   
 
The complement system is essential for immunity against meningococcal infection. 
This is demonstrated by the exquisite susceptibility to meningococcal disease of 
individuals lacking components of the MAC (C5-C9 inclusive), who are at 1,000-
10,000 increased lifetime risk of disease compared to immunocompetent people 
(Figueroa et al., 1993). It also highlights the importance of bacteriolytic activity of 
complement as the MAC is required for this effector function. The ppx mutant was 
originally identified through an approach called Genetic Screening for Immunogens 
(GSI). This method attempted to take advantage of the power of bacterial genetics to 
identify vaccine candidates, by performing an unbiased screen for transposon mutants 
that have increased resistance to complement-mediated killing in the presence of 
bactericidal antibodies. The rationale was that a mutant that had lost an important 
surface antigen, would have a survival advantage under immune selection, and could 
be identified by positive selection.  
 
The major advantage of GSI was the ability to use human sera to isolate potential 
immunogens for inclusion in vaccines. Most strategies to identify vaccine candidates 
rely on analysing immune responses generated in animals such as mice or rabbits 
(Rappuoli, 2001). This has proved to be a significant stumbling block as several 
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promising meningococcal surface molecules, including NspA and N-propionylated 
polysaccharide capsule of serogroup B N. meningitidis, have provided encouraging 
results in murine models, but have failed to elicit bactericidal antibodies in humans 
(Bruge et al., 2004; Moe et al., 2001; Pon et al., 1997). In contrast, GSI was designed 
to identify vaccine candidates through the use of bactericidal antibodies in sera from 
convalescent patients. In our screening, we included baby rabbit complement in the 
assays because of the lack of availability of a reliable source of human complement 
which lacked bactericidal activity in large supply. In the future, it would be possible 
to repeat the screening with a human complement source.   
 
The library of mutants was constructed by in vitro mutagenesis. This approach has 
been described previously with mariner and Tn10; both transposons have generated a 
wide range of insertions in N. meningitidis (Pelicic et al., 2000; Sun et al., 2000). 
Here, a modified version of Tn5 was employed which contained a pACYC origin of 
replication that is functional in E. coli (but not N. meningitidis) to facilitate the 
identification of transposon insertion sites. The transposase included in the in vitro 
reactions was commercially available (Epicenter), and has been shown to have less 
target site specificity than wild-type Tn5 transposase (Goryshin et al., 1998; Muller et 
al., 1999; Naumann and Reznikoff, 2002). Southern analysis demonstrated that in 
vitro Tn5 mutagenesis successfully provided a diverse series of mutants in the library, 
and could be used for GSI.  
 
The original GSI screen required considerable initial optimisation. The ideal situation 
was to be able to screen the entire library of over 40,000 individual mutants in a 
single assay in which there was no survival of the wild-type strain, while a few 
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resistant mutants were recovered when the library was screened. The main constraints 
were the amounts of available human immune serum (which was in limited supply), 
and the complement source. The use of a human complement source would have been 
preferable, but there were only small amounts of serum from a C7 deficient individual 
available, so this was not possible. Instead, baby rabbit complement was included in 
the screens. This source of complement was considered to be a suitable alternative as 
it is routinely used in SBAs as recommended by the Centers for Disease Control 
(CDC).  
 
Several other parameters had to be adjusted before screening was undertaken. These 
included the total volume of assays, the number of bacteria, the duration of incubation, 
and the concentration of the complement source. Additionally, it would have been 
possible to adjust the growth conditions of bacteria as these are known to affect gene 
expression. In particular, it would have been interesting to propagate the bacterium in 
iron-restricted conditions prior to screening as this is relevant to the environment in 
vivo and affects the profile of surface antigens (Brener et al., 1981).  
 
Independent ppx mutants (with distinct transposon insertion sites) were isolated from 
separate screens performed with different immune sera, highlighting the role of this 
gene for survival in the presence of an active complement system. Both insertions 
were in the initial portion of the open reading frame and would be expected to result 
in a null phenotype. However, a recurrent issue with performing genetic screens is the 
issue of polar effects on downstream genes (resulting from the insertion of the 
transposon) and of second site mutations. The latter is a particular issue with N. 
meningitidis, in which there are multiple phase variable genes which can give rise to 
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phenotypic variants at high frequency (Richardson and Stojiljkovic, 2001). Phase 
variation is a particular feature of surface expressed molecules (e.g. capsule, LPS, 
PorA), and variants are likely to emerge under immune selection (Hammerschmidt et 
al., 1996; Jennings et al., 1999; van der Ende et al., 2000). Therefore to demonstrate 
that loss of PPX was responsible for the observed relative resistance to complement, 
the mutation was reconstructed in the wild-type background, and was complemented 
by introducing a single copy of the gene at an ectopic chromosomal site. The results 
from these experiments validated the isolation of ppx mutants as the resistant 
phenotype was seen in the newly-constructed mutant and was lost upon 
complementation. To exclude the possibility that the effect of PPX was restricted to 
interactions between the meningococcus and rabbit complement, the sensitivity of the 
strains was examined in human serum assays.  
 
Initial experiments on PPX were designed to examine its candidacy as an antigen in 
vaccines against meningococcal disease. The criteria for an attractive immunogen 
include: i) it should be expressed by a wide-range of strains, ii) it should expressed on 
the surface of the bacterium and be accessible to antibodies, iii) immunisation should 
elicit protection against live challenge, and iv) preferably the antigen should elicit 
bactericidal antibody responses. Furthermore it would be predicted that the sera that 
was used to select the ppx mutants would contain antibodies against the recombinant 
protein.  
 
Therefore, recombinant PPX was expressed in E. coli and purified to >95% 
homogeneity. This was achieved using available vectors with standard E. coli strains 
and expression conditions. The protein was produced with an N terminal poly-His tag 
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to allow purification using a nickel column. Interestingly, removal of the tag by 
digestion with thrombin led to precipitation of the protein. Therefore all subsequent 
experiments were performed with the recombinant protein containing the His tag. 
This was not thought to affect the results of the immunogenicity, function or 
crystallisation of the protein, but if this were the case, an alternative tag or placing the 
tag at another site could have been attempted. Western blot analysis demonstrated the 
presence of antibodies in sera that recognised recombinant PPX, and this was also 
confirmed by ELISA. Furthermore PCR demonstrated that the ppx gene was present 
in all 22 meningococcal strains examined. However this did not address the issue of 
whether the strains expressed the protein. Western analysis could have been 
performed with the anti-PPX sera to confirm the expression of the protein by the 
strains. 
  
Whole cell ELISA has been used to determine the surface localisation of antigens. 
However, this method can be misleading and provide false-positive results if there is 
lysis of bacteria before proteins are coated onto the wells of ELISA plates. Instead, 
FACS analysis was performed using specific anti-sera raised in mice, although there 
was no detectable surface PPX with this method. There are several potential 
explanations for this negative result. It could have been due to the lack of PPX 
expression under the growth conditions used. However this is unlikely as the bacteria 
were grown in the identical way for serum assays in which a clear phenotype of the 
∆ppx mutant was observed. Alternatively, fixation of cells destroyed the epitopes 
recognised by the anti-PPX sera. Again, this explanation is unlikely as the 
experiments were also performed in which the anti-sera was incubated with live 
bacteria before fixation (not shown). Electron microscopy with immunogold labelling 
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of anti-PPX sera could have been used, but in the light of other negative results, this 
was not attempted.  
 
The ability of an antigen to elicit bactericidal antibodies is highly desirable for any 
candidate vaccine against N. meningitidis. The presence of SBA is a proven correlate 
of protection against serogroup C disease (Goldschneider et al., 1969a), and has been 
used as a surrogate marker of immunity in studies on polysaccharide and protein: 
polysaccharide conjugate vaccines (Borrow et al., 2001). However, the validity of 
SBA for non-capsular antigens and for protection against serogroup B meningococcal 
disease remains unproven. The advantage of measuring SBA is that is can be done 
with stored serum samples, and is technically straightforward, although there are 
concerns about reproducibility of the assay between reference laboratories. We used 
the CDC recommended protocol to measure the SBA which includes baby rabbit 
complement. On a single occasion, immunisation with recombinant PPX was found 
to elicit bactericidal antibodies that killed the wild-type strain but not the mutant in 
dilutions of serum of up to 1 in 512. Unfortunately, this result was not reproducible 
when new batches of sera were raised by immunisation of further groups of mice. 
Overall, it was concluded that PPX failed to elicit SBA with Freund’s incomplete 
adjuvant. It would have been possible to use alternative adjuvants to elicit immune 
responses, or to combine PPX with other antigens. However, given the lack of 
evidence of surface expression and lack of protection in animal challenge models, 
these experiments were not performed, and were not considered to be worthwhile.  
 
It has been suggested that antibodies that mediate opsonophagocytosis can also be 
protective against meningococcal disease. Again given the lack of other supportive 
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data, opsonophagocytosis assays were not performed, and it was concluded that PPX 
would not be an effective vaccine candidate.  
 
Therefore, GSI not only identifies gene products that are the targets of bactericidal 
antibodies, but also strains that have inherent resistance against complement-mediated 
lysis, such as the ∆ppx mutants, To further understand the interaction between the 
meningococcus and complement, experiments were undertaken to define the function 
of PPX at the biochemical level. During the initial analysis, advantage was taken of 
the available E. coli strains that had been constructed to express recombinant PPX as 
a heterologous protein. These strains were examined for their sensitivity to heat and 
for resistance against oxidative stress, as E. coli expressing a biochemically 
characterised PPX from yeast had increased resistance against these stresses (Shiba et 
al., 1997). The results obtained with E. coli expressing N. meningitidis PPX were 
entirely consistent with those for the yeast enzyme.  
 
Over the past 10 years, only a few laboratories have been consistently working on 
enzymes involved in the metabolism of poly P. Therefore assays for determining the 
function of PPX and measuring cellular poly P levels had to be developed. The 
standard assay to measure the activity of exopolyphosphatases includes toluidine blue. 
This cheap metachromatic dye can be simply included in reactions with recombinant 
protein along with a defined source of poly P to measure decreases in a poly P over 
time. However this assay has several disadvantages. Toluidine blue is not specific for 
poly P but recognises polyanions, so is not very useful for analysing total cellular 
poly P. For the meningococcus, the capsule and LPS are abundant surface polyanions 
that could be recognised by toluidine blue. Furthermore, the assay is less sensitive 
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than radioactive methods. Indeed, the assay was unable to detect poly P at 
concentrations of less than 1 mM; the concentration of poly P in cells has been 
estimated as 0.1~50 mM and 120 mM in prokaryotic and eukaryotic cells respectively 
(Kornberg, 1999).  
 
In spite of these shortcomings, the toluidine assay proved sufficiently robust for 
demonstrating the biochemical activity of PPX and its dependence on divalent cations. 
To date, no active sites have been determine for prokaryotic exopolyphosphatases, 
although point mutations of yeast PPX have been shown to lead to a loss of activity. 
Active site residues in the meningococcal PPX were predicted through sequence 
alignments and the available crystal structures of the E. coli and A. aeolicus enzymes. 
Glu147 is a residue in the highly conserved putative ATP binding region of PPX, and 
is expected to bind divalent cations (Kristensen et al., 2004; Rangarajan et al., 2006). 
In the A aeolicus structure, a calcium ion is in close proximity with this residue 
(Kristensen et al., 2004). This amino acid was replaced with alanine, and the resulting 
enzyme was found to have dramatically reduced, but not entirely absent activity. 
Attempts were made to construct other point mutants in PPX but these proved to be 
unsuccessful.  
 
The modification of a single amino acid is frequently used to identify critical residues 
that are necessary for enzymatic function. However, it is entirely possible that 
alteration of a single amino acid, especially if the change is not conservative, could 
disrupt the overall structure of a protein, with loss of function not necessarily 
indicating that the change is restricted to the active site. Therefore PPX
E147A
 change 
may affect the structure of the protein. Studies are underway to determine the 
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structure of this modified enzyme to exclude this possibility. The modified ppx allele 
did prove valuable in experiments as it was included as an enzymatically inactive 
control that could be used for complementation of the N. meningitidis ppx mutant. 
The results demonstrated that the enzymatic activity of PPX is required for 
interactions with the complement system, providing further evidence that PPX is not 
an important surface antigen.  
 
Having demonstrated that PPX is indeed a functional exopolyphosphatase, I next 
sought to determine the effect of this enzyme on cellular poly P levels in the 
meningococcus. No other exopolyphosphatases were identified in the MC58 genome 
using bioinformatic analysis by performing BLASTP searches with the sequences of 
the characterised polyphosphates from E. coli and S. cerevisiae. However there can 
be compensatory changes in the expression of PPK in response to loss of PPX that 
maintain wild-type levels of poly P. Therefore a ppk mutant was constructed as a 
strain that was predicted to have decreased or undetectable levels of cellular poly P. 
Interestingly two heritable colony phenotypes were observed in ppk mutants 
constructed both with the kanamycin and the tetracycline resistance cassettes. 
Therefore, these morphotypes are likely to result from compensatory second site 
mutations. Both large and small colonies were sensitive to complement-mediated 
lysis as described previously (Tinsley and Gotschlich, 1995), and gave identical 
results for quantification of cellular poly P, so size of colonies did not the utility of 
the ppk mutants in these experiments.  
 
Initial studies to quantify total cellular poly P were performed using the toluidine blue 
assay. However despite modifying this assay, no significant differences were detected 
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in poly P levels in the wild-type strain and the ppx or ppk mutants. Therefore it is 
likely that the dye was detecting molecules other than poly P in the bacteria, and/or 
the assay was insufficiently sensitive. It would have been possible to examine the 
effect of these mutations in strains specifically lacking polyanions such as capsule 
and LPS. However this was not undertaken it would still not have excluded the 
possibility that further molecules were being detected by the toluidine blue assay. 
Furthermore, loss of LPS or capsule could inadvertently affect poly P metabolism. 
Instead, a more sensitive and specific method was performed based on the reversible 
activity of PPK to generate ATP from poly P in an excess of ADP. First poly P was 
extracted from cells and bound to Glassmilk beads. This approach has proven 
effective for purifying poly P from organisms such as E. coli, P. aeruginosa, B. 
cereus and S. enterica (Ault-Riche et al., 1998; Price-Carter et al., 2005; Rashid and 
Kornberg, 2000; Shi et al., 2004). In early experiment recombinant N. meningitidis 
ppk was cloned, expressed and purified but was found to be enzymatically inactive, 
possibly due to the N terminal poly-His tag include to facilitate purification; the 
sequence of the plasmid used for expressed confirmed the wild-type allele had been 
successfully ligated into expression vector. Instead, purified E coli PPK was obtained 
and a method developed that detected poly P down to a concentration of 500 nM; this 
is over three orders of magnitude more sensitive than achieved with the toluidine blue 
assay. The PPK assay demonstrated significant differences in the level of poly P 
between the strains, with the ppx mutant having approximately twice the level of total 
poly P than the wild-type strain. Of interest, this was not associated with any change 
in expression of ppk as determined by qrtRT-PCR; therefore there was no evidence 
for a compensatory change in expression of this gene in response to loss of PPX 
unlike in B. cereus (Shi et al., 2004). As expected complementation with a fully 
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functional PPX enzyme, but not with the Glu
E147A
 allele, restored poly P levels back 
to wild-type levels in the ppx mutant. 
  
It has been reported that expression of PPX and poly P levels vary during different 
growth stages in bacteria (Shi et al., 2004). However I was unable to detect any major 
alteration in PPX in N meningitidis between early log to stationary phase cultures by 
Western blot analysis, even though there was a ten-fold increase in poly P levels 
between these phases. qrtRT-PCR could be performed to confirm that there was no 
changes in expression of ppx or ppk during growth phase.  
 
The determination of the atomic level structure of proteins can provide key insights 
into their function. Despite the availability of two structures for prokaryotic PPXs, it 
was decided to attempt to crystallise the N. meningitidis PPX during the course of this 
thesis as it might have provided essential information about the role of the enzyme in 
this organism that could not have been predicted from sequence alignments alone. 
Furthermore recombinant PPX was already available and there are close links 
between the CMMI and the Centre for Structural Biology at Imperial College. The 
crystallisation studies were performed in collaboration with Professor Paul 
Freemont’s group. I performed all the trials of crystallisation, and screened the trays 
for potential crystals. The diffraction obtained with crystals was undertaken at the 
Synchrotron by Dr. Duo Lu. After several attempts, several distinct conditions 
supported the growth of PPX crystals which diffracted adequately to provide an 
overall structure of PPX at a 1.8 A resolution. Unfortunately, there were excessive 
differences in the structure at the active site, so this portion of the structure could not 
be solved during the course of my thesis. This variation in structure may have been 
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caused by examining crystals both with and without a divalent cation bound at the 
active site. Therefore further attempts are ongoing to crystallise the Glu
E147A
 variant 
of PPX, and to try and stabilise the active site by crystallising wild-type PPX with its 
substrate, poly P. The latter could be particularly revealing as it should demonstrate 
not only the active site residues but also show how the enzyme binds its substrate.  
 
In the final chapter, experiments were directed at understanding the underlying basis 
of the change in interactions with the complement system mediated by PPX and poly 
P. There were two simple explanations for the enhanced recovery of the ppx mutant 
in the presence of human complement. First the mutant may have an increased growth 
rate compared with the wild-type strain. This was a distinct possibility as ppx mutants 
have pleiotropic effects in other organisms. Several conditions of growth were 
examined, but under no circumstances was there increased survival of the mutant. 
The conditions included growth in rich medium (BHI) and survival in heat treated 
serum (Figure 5.1 and Figure 3.3). Therefore, this trivial explanation could be 
discounted. Secondly, extracellular poly P has been proposed to have a capsule like 
function in the gonococcus. However, extensive attempts to identify extracellular 
poly P from the meningococcus were unsuccessful. Overnight grown bacteria were 
re-suspended in the 10 mM Tris-HCl, pH 7.4 by pipetting 20 times. The supernatant 
collected after centrifuge was filtered with 0.22 μm pore, and used to detect the 
presence of poly P in the N. meningitidis surface. Using the toluidine blue assay poly 
P was detected in the supernatant from 4 x10
10
 CFU/ml of N. gonorrhoeae but not in 
the supernatant from 4 x10
10
 CFU/ml or 1 x10
11
 CFU/ml of N. meningitidis. Using 
the more sensitive poly P assay based on the rPPK, the luminance generated from the 
supernatant in the presence of rPPK was lower than that from the supernatant in the 
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absence of PPK, from all N. meningitidis strains we tested. There are a few 
explanations for the failure of detecting extracellular poly P. Firstly, poly P might 
attach more tightly to the N. meningitidis surface compared to the N. gonorrhoeae, it 
could not be collected by washing with Tris-HCl. Secondly, the chain of extracellular 
poly P on N. meningitidis might composed of about 3-20 residues, which can not be 
detected by the enzymatic poly P based on the rPPK (Kornberg, 1999). Future work 
can be carried on using i) prior 
32
P labelling and polyacrylamide gel analysis, ii) 
High-performance liquid chromatography, and iii) electronic microscopy and direct 
labelling of polyphosphate at the ultrastructural level by using the affinity of the 
polyphosphate binding domain of PPX (Kornberg, 1999; Saito et al., 2005).  
 
The major structures on the surface of N. meningitidis that mediate resistance against 
complement killing are the polysaccharide capsule and LPS. Therefore, experiments 
were performed to determine whether the change in resistance of the ppx mutant was 
caused by alterations in these molecules. However no change in the level of capsule 
or LPS sialylation could be detected following loss of PPX, using FACS or ELISA 
analysis. Furthermore the impact of ppx on serum resistance was still evident in 
mutants lacking either a capsule or which were unable to sialylate their LPS, which 
can affect interactions with the complement system.  
 
To gain further insights into the basis of the enhance complement resistance of the 
ppx mutant, the deposition of complement factors on fixed bacterial strains was 
examined after incubation in immune sera. Strains were fixed in initial experiments as 
live bacteria are lysed in the presence of human immune sera. The deposition of the 
MAC was reduced on the ppx mutant compared with the wild-type strain, as would be 
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predicted for a strain that is less sensitive to complement-mediated lysis. However the 
amount of C3 on the surface of the ppx mutant was also reduced. This could not be 
accounted for by reduced activity of the classical pathway through the loss of PPX as 
a surface antigen, and thence reduced antibody binding. Experiments in preceding 
chapters provided no evidence that PPX is expressed on the surface of N. meningitidis, 
and there were no detectable anti-PPX antibodies in the serum in which bacteria were 
incubated to estimate the binding of complement factors. Therefore, we examined 
complement deposition in the absence of the CP and the LP, which were inhibited by 
the addition of Mg and EGTA (Uria et al., 2008). There were still significant 
differences in the level of C3 binding with only the AP active, consistent with the 
difference in resistance of strains lacking PPX being caused by changes in this 
pathway of complement activation. This was supported by the finding of increased 
survival of the ppx mutant in the presence of human immune sera which only retained 
activity of the AP. Clearly these results do not entirely exclude the possibility that 
changes in other complement pathways are involved. Furthermore, it would be 
preferable to measure the deposition of C3b rather than total C3 on bacteria. C3b is 
the cleavage product of complement that covalently binds to pathogen surfaces, 
through the formation of thioester bonds, and which initiates the formation of the 
MAC. However there are few antibodies available that can differentiate between C3b 
and C3. 
 
As fH is the major regulator of the AP and is recruited by the meningococcus 
(Schneider et al., 2006), the deposition of this complement factor was examined. 
Strikingly, the binding of fH to the ppx mutant was significantly increased regardless 
of whether fH was provided as a purified protein or in heat-inactivated human serum. 
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These assays were initially performed with fixed bacteria, however identical results 
were obtained using live bacteria incubated with either purified fH or with serum 
from a patient with C7 deficient (which lacks bactericidal activity).  
 
fH binds to the surface lipoprotein and lead vaccine candidate variously named 
GNA1870, rLP2086, LP2086 or more recently factor H binding protein (fhbp) 
(Fletcher et al., 2004); (Madico et al., 2006). Of note loss of PPX did not affect the 
expression of GNA1870 by FACS or Western blot analysis (FACS analysis, not 
shown). Instead, PPX apparently affects the expression of other targets of factor H on 
the surface of N. meningitidis, as introduction of a ppx mutation into strains lacking 
GNA1870 still led to an increased of factor H binding. The targets of fH binding to 
structures on the meningococcus other than GNA1870 have not been defined as yet. It 
is possible that fH binds to poly P directly on the exterior of the bacterium; fH binds 
polyanions such as heparin and glucosaminoglycans (Schneider et al., 2006). The 
latter charged carbohydrates are the cognate receptor for fH on the endothelial cells 
along with sialic acid. However against this hypothesis was the inability to detect 
poly P on the surface of N. meningitidis. Furthermore, there was no concomitant 
reduction in fH binding to the ppk mutant (not shown) which has diminished total 
cellular poly P levels. Other groups have identified putative fH receptors on the 
meningococcus (M. Pizza, unpublished data), so these are candidates for being altered 
in response to PPX.  
 
Changes in poly P levels can have pleiotropic effects in bacteria. In E. coli, many 
changes resulting from changes in poly P are mediated by the alternative sigma factor, 
RpoS (Shiba et al., 1997). Interestingly we observed relatively few differences in the 
 161 
phenotype of the ∆ppx mutant aside from survival in the presence of complement. For 
example, growth, and expression of capsule, LPS sialylation, and GNA1870 were not 
affected by the presence/absence of PPX Therefore it might be that poly P affects 
much more limited repertoire of phenotypes in the meningococcus than found in other 
bacteria. The reason for this could be that the meningococcus does not have RpoS. To 
establish whether this is indeed the case, microarray analysis could be undertaken of 
the ppx mutant and compared with the wild-type to determine changes in patterns of 
genes expression. This might also provide clues to the basis of the increased fH 
deposition on the surface of the ppx mutant that would form the basis of future work.  
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Appendix 
 
Table A.1 Strains analysed by PCR for the presence of NMB1467 homologue 
No. Strain Serogroup  Clonal complex Disease 
1 Z2491 A ST-4/subgroup IV Invasive 
2 2059001 A ST-4/subgroup IV Invasive  
3 FAM18 C ST-11/ET-37 Invasive 
4 BZ133 C ST-1/subgroup I/II Invasive 
5 A22 W-135 ST-22 Carrier 
6 860800 Y Unassigned Invasive 
7 MC58 B ST-32/ET-5 Invasive 
8 BZ169 B ET-5 Invasive 
9 BZ83 B ST-32/ET-5 Invasive 
10 SWZ107 B ST-35 Invasive 
11 NGF26 B ST-269 Invasive 
12 2996 B Unassigned Unspecified 
13 NG6/88 B ST-269 complex Invasive 
14 2996 B Unassigned Carrier 
15 NG3/88 B Unassigned Invasive 
16 BZ147 B ST-41/44 Invasive 
17 1000 B ST-18 Invasive 
18 BZ198 B ST-41/44 lineage3 Invasve 
19 NGH36 B ST-41/44 lineage3 Invasive 
20 NGP165 B ST-11/ET-37 Unspecified 
21 C311 B Unassigned Invasive  
22 NGH38 B Unassigned Carrier  
 
 
